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GENERAL INTRODUCTION AND THESIS OUTLINE
1
Introduction 
Stroke and motor impairments
Stroke in numbers
In 2018, in the Netherlands, an estimated 40.000 persons sustained their first stroke. 
In the same year, approximately 496.300 people in the Netherlands had a history 
of stroke, including transient ischemic attacks [1]. The prevalence of stroke increases 
with age and, given the aging of the population, it is expected that it will further 
increase with an extra 54% towards 2040 [2]. Stroke poses a huge burden on the 
patients, families, and society. In the top 10 of the burden of disease, stroke is listed 
2nd mainly because of the impairments and disabilities due to stroke and the 
number of years that people live with these consequences [3]. Annual health care 
costs related to stroke are an estimated € 1.5 billion in the Netherlands [4]. 
Stroke consequences: motor impairment
One of the prominent consequences of stroke is motor impairment, making stroke 
a leading cause of persistent physical disability across the globe [5]. Fine motor skills 
are mostly controlled through the descending motor pathways of the corticospinal 
tract [6]. After a stroke these descending pathways are often damaged, which leads 
to a contralesional loss of motor selectivity and muscle force. Since motor control 
of the distal extremity muscles is heavily dependent on corticospinal control, 
contralateral leg motor impairment after supratentorial (cerebral hemisphere) stroke 
is usually most profound around the ankle and foot. Paresis of ankle dorsiflexors 
and evertors is frequently accompanied by weakness and spasticity of ankle 
plantarflexors and invertors, leading to so-called ‘pes equinovarus’. This ankle-foot 
deformity prevents proper loading of the foot during the stance phase of gait as 
well as proper foot elevation at the ankle during the swing phase. When pes 
equinovarus is predominantly caused by weakness of the ankle dorsiflexors rather 
than spasticity of the plantarflexors, it is commonly referred to as ‘drop foot’, which 
manifests itself mainly during the swing phase and early stance phase (‘loading 
response’). Despite substantial motor recovery in the subacute phase after stroke, 
an estimated 20% of the people with stroke suffer from a persistent contralesional 





Drop foot is usually part of a more generalized stereotypical movement pattern 
after stroke. Patients with a drop foot tend to overload the forefoot and lateral foot 
edge during the (early) stance phase of gait, causing problems with weight acceptance 
on the paretic leg and with postural stability [8]. Due to concomitant loss of ankle 
plantarflexor strength, the push-off during the late stance phase of gait may be 
reduced as well, causing lack of forward propulsion of the body and a poor initiation 
of the swing phase [9]. The subsequent inability to lift the foot in the ankle, accompanied 
by a lack of knee and hip flexion, then causes the foot of the swinging leg to drag 
across the floor. In addition, loading of the foot at the end of the swing phase is 
often compromised by ineffective foot elevation and varus deviation at the ankle.
 To prevent foot drag, most patients tend to compensate by abducting the paretic 
hip and lifting the pelvis on the paretic side, a phenomenon called ‘circumduction’. 
However, this compensation is energetically inefficient and inherently unsafe due 
to the fact that circumduction further affects a proper loading of the foot. Hence, 
despite this compensation strategy many people with stroke are not able to 
maintain a normal stable gait pattern. As a result, people with stroke are generally 
less active [10] and their gait pattern is characterized by reduced walking speed, 
spatiotemporal asymmetry, and increased metabolic cost [11, 12]. 
Gait adaptability 
Daily life ambulation entails much more than walking in a straight line on a perfectly 
paved floor. Community walkers engage in traffic, which requires speeding up, 
stopping and turning, and interaction with others. Community walkers also need to 
be able to walk on uneven terrain. Unfortunately, much more than steady state 
walking, the capacity to walk in complex conditions has been found to be reduced 
in patients after stroke based on a variety of functional tests such as the “Timed Up & 
Go” test [13], Emory functional ambulation profile [14], and walking with concurrent 
cognitive tasking [15]. 
 Adaptation of the gait pattern to environmental demands relies heavily on 
dynamic balance control [16, 17]. An important prerequisite for dynamic balance is 
free joint mobility and good motor control at the ankle for adequate foot placement, 
weight bearing, single-leg balance corrections, and push off [18-20]. As people with 
‘drop foot’ after stroke are typically unable to properly load the foot and control 
the paretic ankle, balance perturbations may easily result in postural instability, 
particularly when weight is being carried on the paretic leg [21]. Furthermore, gait 
pattern adaptations to environmental challenges may be impaired or delayed [22]. 
The inability to quickly adapt to postural perturbations and environmental demands 
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during standing and walking puts people with drop foot after stroke at risk of 
tripping and falling. Indeed, fall incidence reported for people with stroke is high, 
ranging from 1.4 to 5.0 falls per person per year [23]. Most falls reported after a 
stroke happen whilst walking, which heavily impacts on independence and quality 
of life [23].  
Orthotic intervention to improve gait after stroke
Ankle-foot orthoses
Drop foot after stroke is usually treated with an ankle-foot orthosis (AFO). A variety 
of AFOs are available, but most AFOs are designed to offer stability to the paretic 
ankle during the stance phase and to prevent foot drop during the swing phase by 
maintaining the ankle in a more or less neutral position. Dynamic AFOs typically 
offer a certain degree of plantar- and/or dorsiflexion at the ankle, for which reason 
they are often provided with a dorsiflexion spring. AFOs successfully prevent foot 
drop, improve gait parameters such as speed and spatiotemporal symmetry, and 
reduce metabolic costs in people with stroke [24, 25]. However, AFOs may also be 
unpleasant to wear and be cumbersome during other daily activities such as stair 
walking, squatting, cycling, car driving et cetera [26]. Dependent on their stiffness, 
they may limit passive ankle mobility and prevent the use of residual ankle function 
for controlling balance and gait [27, 28]. As a result, many people after stroke use 
their AFO less than prescribed or even refrain from using it at all [29]. 
Peroneal functional electrical stimulation
History
In stroke survivors with proper knee control and sufficient medio-lateral ankle stability 
during the mid- and late- stance phase of gait, functional electrical stimulation 
(FES) of the common peroneal nerve can serve as an alternative method to prevent 
foot drop. By electrically activating the paretic ankle dorsiflexor and evertor muscles, 
the foot is actively lifted at the ankle joint during the swing phase and early stance 
phase (‘loading response’) of gait. This technique of peroneal FES in people with 
stroke dates back to 1961, to the work of Liberson et al. [30]. After their pioneering 
work, it took several decades before technological advances allowed to provide 
easily usable and commercially available peroneal FES devices. These wearable 
systems use in-shoe heel sensors or tilt sensors attached to the leg in order to 
determine the onset and offset of the electrical stimulation, which is conveyed 
through adhesive electrodes placed on the paretic leg. These surface electrodes 
need to be placed precisely over the common peroneal nerve and over the proximal 
part of the tibialis anterior muscle for proper ankle dorsiflexion. Adequate positioning 
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is often problematic for patients with impaired hand motor function [26]. In addition, 
the degree of activation of the peroneal muscles needs to be controlled, as too 
much activation may lead to excessive foot eversion. A more important disadvantage 
of surface-based peroneal FES is that intensive use may lead to skin irritation under 
the electrodes due to hyperreactivity or even allergy [31]. To avoid problems with 
electrode placement and/or skin irritation, implantable peroneal FES systems have 
been developed during the past two decades. In one of the newest systems 
(Actigait®), four separately controllable micro-electrodes are placed directly over 
the common peroneal nerve embedded in an implantable cuff, allowing direct, 
consistent and precise stimulation of this nerve without the risk of skin irritation [32]. 
The cuff is placed just above the knee joint and through a lead wire it is connected 
to an implanted stimulator body higher up in the lateral thigh region. The stimulator 
is controlled by an external antenna, control unit, and heel sensor (see figure 1). 
Orthotic effects of peroneal FES
The potential of peroneal FES as a treatment for drop foot after stroke has been 
investigated in a number of studies [33-35]. With FES, foot drop is successfully 
prevented, which results in higher gait speed and lower physiological costs 
compared to walking without FES. The most important clinical question, however, 
is whether peroneal FES has added value over an AFO. Indeed, AFOs are relatively 
low cost and readily available, which is why they are considered standard care for 
the management of drop foot after stroke. A number of studies have investigated 
differences between peroneal FES and AFO with regard to gait in people with drop 
foot after stroke [36-42]. Recently, data of five randomized controlled studies were 
pooled in a meta-analysis by Prenton et al. [43]. They concluded that AFO and FES 
are equally effective in improving walking speed and endurance (3 or 6 minutes 
walking test)[43]. A fundamental difference, however, between AFO and FES is the 
freedom of ankle motion during the stance phase of gait. Particularly rigid AFOs 
may interfere with normal foot roll-off during the stance phase, possibly interfering 
with the loading response (1st rocker), with tibial rotation at the ankle (indirectly 
affecting knee stability) (2nd rocker), and with push-off (3rd rocker). In contrast, FES 
allows normal ankle motion rocker throughout the entire stance phase. Nonetheless, 
detailed gait analysis and assessment of gait in challenging environmental conditions is 
needed to prove whether this theoretical advantage indeed leads to biomechanical 
and functional benefits of FES over AFO. One RCT-study has reported kinematic 
benefits of FES during the early stance phase of gait [36], but whether FES has 
added value over AFO in the mid- and late-stance phase of gait (in terms of 
kinematics and/or kinetics) is still unclear. If there would be kinematic and/or kinetic 
benefit of peroneal FES compared to AFO, it may well be that these advantages 
particularly surface during challenging walking tasks requiring significant gait 
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adaptation. It has already been reported that the ability to avoid an obstacle under 
time pressure is better with surface-based peroneal FES compared to AFO in people 
with chronic stroke [44]. Such functional advantages of FES may explain the 
relatively high level of patient satisfaction with FES compared to AFO [26, 31].
Pathophysiological changes of muscle and nerve after stroke
Stroke is primarily an upper motor neuron (UMN) disorder. However, it is well known 
that secondary changes of peripheral nerves may occur after UMN lesions. 
Reduced input from UMNs is believed to cause transsynaptic degeneration of 
lower motor neurons (LMNs), resulting in partial muscle denervation. Indications 
for this phenomenon have been found through electromyography (EMG) in a 
variety of muscles. Weeks to months after stroke onset, a rapid drop in functional 
motor units within paretic muscles has been observed as well as spontaneous 
muscle activity suggesting LMN dysfunction [45-48]. Muscle fibers of dysfunctional 
motor units may eventually be reinnervated by remaining motor nerve fibers, 
Figure 1  The ActiGait® system. The implanted part of the ActiGait® consists of a stimulator 
body (A) and an electrode cuff (B), the latter placed around the common peroneal nerve. 
The implant is controlled by a control unit (C), which activates the implant through an antenna 
placed on the thigh (D). The timing of activation is determined by a heel switch (E), which 
communicates wirelessly with the control unit.
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typically favoring type I fiber clusters [49]. Type I muscle fibers show a relatively high 
intramuscular fat content. Besides, it is well known that denervation of muscles 
results in infiltration of fibrous tissue and fat. Indeed, increased intramuscular fat has 
been found in hemiparetic muscles of patients after stroke [50-52]. Next to changes 
in muscle architecture, atrophy of paretic muscle has been extensively reported 
after stroke [53, 54]. Usually, in people with stroke, these changes in muscle 
architecture are attributed to ‘disuse’, but transsynaptic degeneration may well be a 
different explanation.
 Secondary changes of muscles and peripheral nerves may further impair 
functional capacities of people with stroke [55]. Thus far, assessment of paretic-side 
muscle structure after stroke has been done using the non-paretic side as a control. 
However, it can be questioned whether the non-paretic side after stroke is truly 
unaffected and, thus, may serve as a valid reference for the paretic side. Furthermore, 
little is known about the reversibility of the reported secondary effects on peripheral 
nerves and muscles. A potential way to reverse these effects may be through the 
use of FES. As FES can be seen as an ‘active orthosis’, inducing phasic muscle 
activity based on peripheral motor nerve stimulation, FES may be able to induce 
plastic mechanisms both at the level of the muscle and at the level of the central 
nervous system (e.g. the spinal cord or the brain) [56-58]. 
Aims and outline of this thesis
This thesis consists of two parts. In part 1 the surplus value of implanted peroneal 
FES over AFO is investigated with regard to steady state walking and gait adaptability 
in people with chronic supratentorial stroke. In part 2, pathophysiological changes 
of muscle and nerve are assessed in people with chronic supratentorial stroke. 
In addition, the effects on these changes due to the use of long-term implanted 
peroneal FES are evaluated.
Part 1: Surplus value of implanted peroneal FES over AFO 
Indications for implanted peroneal FES use in people with drop foot after stroke 
are discussed in chapter 2. In chapter 3 the surplus value of implanted peroneal FES 
over AFO is explored with regard to energy expenditure, gait quality, and patient 
satisfaction. Kinematic and kinetic differences between implanted FES and AFO are 
discussed in more detail in chapter 4. Because potential benefits of implanted peroneal 
FES may become particularly apparent in challenging environmental conditions, 
gait adaptability was compared between peroneal FES and AFO using a reactive 
obstacle avoidance task in chapter 5. In chapter 6, gait adaptability with implanted 
peroneal FES was tested during a task requiring continuous gait adaptation.
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Part 2: Pathophysiological changes of muscle and nerve and  
the effects of long-term implanted peroneal FES use
Until now, changes in muscle architecture after stroke have been studied by comparison 
of the paretic with the non-paretic side. In chapter 7 we examine bilateral changes 
in muscle architecture in people with stroke, compared to reference values obtained 
from healthy controls. In chapter 8, we investigate whether the observed changes 
in muscle architecture and motor nerve function can be reversed by long-term 
implanted peroneal FES use.

Surplus value of implanted 
peroneal FES over AFO
PART 1

Indications and results of 
implantable functional electrical 
stimulation of the peroneal nerve
Published as: 
Michaela M. Pinter, Frank Berenpas, Alexander C. Geurts. 
Indications and results of implantable functional electrical stimulation of the peroneal nerve. 
In: Sandrini G., Homberg V., Saltuari L., Smania N., Pedrocchi A. 
(eds) Advanced Technologies for the Rehabilitation of Gait and Balance Disorders. 





Drop foot is a common problem following neurological conditions such as stroke, 
multiple sclerosis, brain injury and incomplete spinal cord injury and consists of the 
inability to lift the foot in the swing phase of the gait cycle. Drop foot is frequently 
associated with spasticity and complex movement problems affecting the whole 
body and can easily result in tripping and falling while moving around. 
Functional Electrical Stimulation (FES) devices are designed to improve gait and 
reduce fall risk in patients with a drop foot by their orthotic effect. Typically, the 
peroneal nerve is stimulated using surface electrodes at its most superficial point, 
where it passes over the head of the fibular bone. The peroneal nerve stimulation 
induces activity of the tibialis anterior muscle, the toe extensors, and the peroneal 
muscles, causing dorsiflexion and eversion of the ankle and foot. The stimulation is 
synchronised to the gait usually by a pressure sensitive heel switch. When weight is 
taken from the switch, electrical stimulation is given. In this way, peroneal FES 
results in an improvement of the walking pattern, speed, and distance, and also 
reduces the risk of tripping and falling. 
More recently, an implantable 4-channel drop foot stimulator (ActiGait®) was 
officially approved in 2007 for hemiplegia following stroke. FES by means of the 
ActiGait® system allows independent electrode adjustment and is capable of a 
more specific stimulation of the various branches of the peroneal nerve. Its 
application has shown an improvement of walking speed and a restoration of the 
gait pattern in patients with stroke. In addition, the therapeutic effect of peroneal 
FES using the ActiGait® system was found to be improved compared to 
surface-based stimulation. 
In the future, an extension of the indication spectrum of ActiGait® stimulation 
should be targeted directed at all patients with drop foot due to upper motor 
neuron syndrome, independent of the aetiology.
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Principles of FES
Drop foot is a common problem following neurological conditions such as stroke, 
multiple sclerosis (MS), traumatic brain injury (TBI), incomplete spinal cord injury 
(iSCI) and cerebral palsy (CP). Between 20%-30% of the patients entering 
neurological rehabilitation suffer from drop foot [59]. Typically, drop foot is caused 
by weakness of the ankle dorsiflexors leading to a lack of foot elevation during the 
swing phase of gait, which is often accompanied by a tendency towards varus 
deviation at the ankle due to muscular imbalance. In addition, spasticity of the ankle 
plantarflexors may worsen equinovarus deviation as a result of muscle stiffness, 
contracture and pathological co-contraction. Drop foot leads to an abnormal gait 
pattern, decreased walking speed, limited endurance walking and increased fall 
risk. All these factors can limit mobility, independency and social participation 
leading to reduced quality of life.
 The principle of Functional Electrical Stimulation (FES) applied to the common 
peroneal nerve during the swing phase of the gait cycle to treat drop foot was 
introduced in 1961 by Liberson et al. [30]. Peroneal nerve FES works by activating 
the ankle dorsiflexors and evertors to support foot elevation. Furthermore, peroneal 
nerve FES may reduce, through reciprocal inhibition, mild spasticity of the calf 
muscle, which facilitates dorsiflexion in the ankle joint [60]. 
 In order to harmonize the gait pattern by FES, it is essential to adapt the stimulation 
parameters (rising ramp, plateau phase, extension time and falling ramp) to the 
individual walking characteristics of the patient (figure 1). Rising ramp is the time 
taken for the pulse width to go from zero to the set pulse width after heel rise. 
A longer rising ramp means a slower ankle movement and slower stretch of the calf 
muscles, reducing the risk of evoking a stretch reflex or ankle clonus. The rising 
ramp typically coincides with the late stance phase of gait. After the swing phase 
(plateau phase), a period of extended stimulation can be added following heel 
strike (extension time), which provides an eccentric contraction of the tibialis 
anterior, lowering the foot to the ground and preventing foot slap. In this way, 
extension of the stimulation followed by the falling ramp (the time taken for the 
stimulation pulse width to reach zero) together stabilize the ankle during the loading 
phase of gait. The rising edge ramp and extension time are critical for adequate 
foot elevation, whereas the falling edge ramp is less critical. The faster the patient 
walks, the shorter the rising ramp and extension time must be.
24
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FES with surface electrodes
Since Liberson et al. [30] first applied peroneal nerve FES, several studies have 
noted that subjects who used electrical stimulation improved their walking 
performance, even after the stimulation was turned off. This phenomenon received 
the name ‘carryover effect’, because it was initially reported as a short-lasting 
(minutes) effect of the electrical stimulation. Subsequent studies have shown that 
the so-called carryover effect may increase over time with long-term and repeated 
use [34, 61, 62]. In more recent studies, the change in walking performance over 
time, measured while FES is off, has been referred to as a ‘therapeutic’ effect [63-65], 
a term that seems more appropriate for the changes associated with long-term FES 
use. The therapeutic effect of FES may occur independent of the ‘orthotic’ effect 
that occurs during the electrical stimulation.
 The long-term orthotic and therapeutic effects of peroneal nerve FES on 
walking performance of subjects with progressive (e.g. MS) and non-progressive 
(e.g. stroke, TBI, iSCI) neurological disorders have been compared in the following 
study [29]. Forty-one subjects with non-progressive and thirty-two subjects with 
progressive conditions used a drop foot stimulator for 3 to 12 months while walking 
in the community. The primary outcome parameters were a 10m walk test (walking 
speed), a 4-minute figure-of-8 test (walking agility) and the physiological cost index 
(PCI), which is commonly used to measure walking effort. Subjects with progressive 
and non-progressive disorders had an orthotic benefit from FES up to 11 months. 
Figure 1  This graph represents the general operation of FES devices. Along the bottom of the 
graph is time. Along the vertical axis is stimulation intensity (pulse width). Stimulation begins 
when the heel is lifted from the ground and continues until the heel strikes the ground. 
However, the stimulation is not stopped straight away, but continues for a short period called 
















Heel rise Heel strike
Falling rampRising ramp
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The therapeutic effect increased for 11 months in non-progressive disorders, but 
only for 3 months in progressive disorders. The combined effect remained 
significant and clinically relevant. Moreover, peroneal nerve FES has been shown to 
reduce fall incidence [66], to have a positive impact on activities of daily living,[26, 
66, 67] and on quality of life [67, 68], regardless of the underlying pathology. 
 The long-term effect of FES use on the correction of drop foot due to upper 
motor neuron syndrome of different etiology was shown in a recent study [69]. 
One hundred and twenty-six people with spastic drop foot (62 stroke, 39 MS, 7 iSCI, 
3 CP, 15 others) were analyzed retrospectively. The median time of FES use was 3.6 
years (mean 4.9, standard deviation (SD) 4.1, 95%CI 4.2–5.6). Thirty-three people 
still used FES after on average 11.1 years. Since there was insufficient report of data 
for the other neurological conditions, only walking speed for 62 subjects with 
stroke and 39 subjects with MS was analyzed. People with stroke walked 0.08m/s 
faster with FES (p<0,001; 17% continuing orthotic effect) and also increased their 
walking speed without FES by 0,11m/s (p<0,001; 24% training effect), resulting in an 
overall increase in speed of 0.18m/s (p<0.001; 45% total effect), when compared to 
the start of treatment without FES. People with MS walked 0.09m/s faster throughout 
a 100 days onwards period with FES (p<0.001; 29% continuing orthotic effect), but 
did not show an overall training effect. Interestingly, approximately 10% of all 
patients – regardless whether the condition was progressive or non-progressive – 
discontinued FES each year. Notably, stroke and MS patients showed similar patterns 
of drop out, but more people with MS dropped out because of deteriorating 
mobility, whereas people with stroke dropped out mainly because of co-morbidity 
or death[69].
 The main drawbacks of a surface-based drop foot stimulator are the awkwardness 
in handling the external parts when putting it on, finding the right electrode position 
on the leg, and skin irritation due to stimulation.4 In a study of 26 stroke patients, 
skin problems (n=4), muscle soreness (n=5) and discomfort below the knee (n=7) 
were relatively common.16 Nevertheless, participants were largely satisfied with 
the benefits of surface-based FES as compared to an ankle-foot orthosis (AFO) with 
regard to their gait quality, walking distance, and the stability and effort of walking. 
Because in this study the electrodes were embedded in an orthosis (Bioness L300®), 
ease of donning and doffing, ease of use and comfort to wear also scored better 
than AFO use. 
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Implantable 1-channel and 2-channel FES systems
Already in the nineties implantable systems have been tested to solve the above- 
mentioned problems. However, the first 1-channel-systems were not suited to 
provide a selective and balanced stimulation of the foot dorsiflexors and induced in 
some cases excessive inversion or eversion of the ankle joint [70]. Based on this 
experience, implantable 2-channel-systems were developed to provide a more 
selective stimulation of the peroneal nerve, resulting in a nearly normalized single 
stance and double support phase of the paretic limb [65].
 In a randomized controlled trial, a 2-channel system (StimuStep®) was implanted 
in 29 patients with drop foot after stroke. The StimuStep® system was compared to 
a control group who continued using an AFO, orthopedic shoes or no device. FES 
resulted in a 23% improvement of walking speed measured with the 6-min Walk 
Test, whereas the improvement in the control group was only 3% (p=.010) [71]. 
In addition, FES was more effective to provide ankle dorsiflexion during the swing 
phase and normalized single stance and double support time of the paretic limb as 
well as single support time of the non-paretic limb in comparison to the control 
group[36]. A study evaluating the effects of StimuStep® in a group of 23 patients 
with MS also provided promising results. Improvement of gait performance was 
similar to using a surface-based stimulation system, while patients reported that 
they used the StimuStep® more days a week. The method of fixation, however, 
whereby the electrode was embedded within the epineurium, resulted in considerable 
adverse effects, with implant failure in four cases and pain in response to stimulation 
in two subjects. Pain was likely due to neuropraxia in one case and due to external 
pressure on the nerve from the external controller in another patient [72].
Indications for implantable 4-channel drop foot stimulator
More recently, an implantable 4-channel drop foot stimulator (ActiGait®), with the 
possibility of independent electrode adjustment resulting in a more specific nerve 
stimulation, was officially approved in 2007 for hemiplegia following stroke (see 
table 1 for comparison with the approved indications for surface-based FES) (see 
figure 2)
 In recent studies on the clinical effects of ActiGait® all patients were over the 
age of 18 years and had a drop foot following a stroke at least 6 months prior to 
recruitment. All participants had at least 30° of passive ankle movement and were 
able to stand upright with their heels touching the floor when the hip and knee 
were in a neutral position. Walking capacity was defined either as the ability to walk 
20 meter in less than 2 minutes or the independent capacity to walk for 10 minutes 
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Figure 2  Illustration of the ActiGait® implantable 4-channel drop foot stimulator, copyright 
Otto Bock Group. The implanted part of the system consists of a stimulator body and a 
electrode cuff connected by a leadwire. The electrode cuff, with 12 electrodes equally divided 
over 4-channels, is placed directly around the common peroneal nerve allowing differentiated 
and well balanced activation of the tibialis anterior muscle, the toe extensors, and the 
peroneal muscles. The external parts consist of a heel switch (placed under the heel in a sock 
or shoe) and a control unit worn at the pelvis and connected to a antenna directly on the skin 
over the stimulator body.
Table 1  Indications for functional electrical stimulation (FES)






Drop foot by other UMNS
FES Functional electrical stimulation; UMNS Upper motor neuron syndrome
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without walking aids. Only patients with a positive response to surface-based 
electrical stimulation of the peroneal nerve resulting in muscle contraction leading 
to ankle dorsiflexion during the swing phase were eligible (see table 2) [32, 73, 74].
Interestingly, uncontrolled epilepsy, the presence of other implanted devices such 
as a cardiac pacemaker, unstable diagnosed psychological conditions, and pregnancy 
were reported as exclusion criteria in almost all studies. Only in the study by Burridge 
et al., persons with limited walking capacity were detained (see table 3) [32]. Contra-
indications such as peripheral nerve damage, polyneuropathy, and a thickness of 
subcutaneous fat exceeding 3.5cm in the region of the implant were only mentioned 
by Ernst et al. [74]. 
























































6 months post-stroke onset x x x x
Weakness of ankle dorsiflexors (MRC-Scale <5) x x x x
Passive range of ankle motion ≥30°, with ≥0° ankle 
dorsiflexion while standing 
x x x
Ability to stand upright, both heels touching the floor, 
hip and knee extended
x x
Muscle tone of ankle plantar flexors Modified Ashworth 
Scale ≤3
x
Independent walking capacity for 10 minutes without 
walking aids (except an AFO)
x x x
Ability to walk 20m in less than 2 minutes x
Over the age of 18 years x x x
Age between 18 and 65 years x
Positive response to surface-based peroneal nerve 
stimulation
x x x x
MRC-Scale (Medical Research Council Scale), AFO (Ankle-foot orthosis)
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Clinical results of FES with ActiGait®
Four studies reported clinical outcomes of ActiGait® use. All four studies presented 
gait speed and walking endurance (defined as the covered distance in a preset 
time) as outcomes. Compared to walking without stimulation, gait speed with 
ActiGait® was found to be increased by 19-47% [32, 73-75]. No differences in gait 
speed were found between ActiGait® and AFO in two studies [74, 75], but Martin et 
al. did find a significant improvement of gait speed with ActiGait® compared to 
AFO as well as to surface-based FES [73]. Walking endurance was tested either in a 
four-minute [32] or six-minute [73-75] walking test. With stimulation, the covered 
distance was reported to be generally higher (8-105%) compared to walking without 
stimulation [32, 73, 74]. However, compared to walking with an AFO, the covered 
distance with ActiGait® was not found to be improved nor was the energy 
expenditure as defined by the oxygen consumption during the six-minute walking 
test [75]. Martin et al. were the only group investigating the performance of 
additional functional gait tasks [73]. They found a significant decrease in the timed-
























































Uncontrolled epilepsy x x
Presence of other implanted devices such as a cardiac 
pacemaker
x x x
Peripheral nerve damage or polyneuropathy x




A thickness of subcutaneous fat exceeding 3.5cm in  
the region of implant
x
Unable to walk 100m without stopping prior to their 
stroke
x x x
Walking faster than 1.2 meter per second x
Severe cognitive deficits that might hamper informed 
consent
x x
Psychiatric disorders that might hamper informed consent x x
Pregnancy x x x
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up-and-go test resulting in a transition of the impairment classification from ‘functionally 
relevant mobility impairment’ without stimulation to ‘mild mobility impairment’ 
with ActiGait® stimulation.
 It has been suggested that the improvements in clinical outcomes with ActiGait® 
are due to restoration of ankle movements during gait. The groups of Ernst et al.[74] 
and Schiemanck et al.[75] performed a more thorough investigation of the effects 
of ActiGait® on the quality of walking. Using 3D-gait analysis, both groups presented 
improvements in paretic leg ankle kinematics with ActiGait®. Ernst et al. reported a 
general normalization of the ankle angle with FES, with significantly improved initial 
dorsiflexion (9°) at heel strike and a significantly improved initial plantarflexion (7°) 
after heel strike compared to walking without stimulation [74]. In contrast to Ernst 
et al.[74], who reported no statistically differences in ankle kinematics between 
ActiGait® and AFO, Schiemanck et al. did find ActiGait® use to be statistically superior 
over AFO use [75]. The latter study showed that during late stance, maximum 
plantar flexion was 5° larger with FES than with AFO. Importantly, this gain in late 
stance plantarflexion was believed to be utilized by residual calf muscle capacity as 
the peak plantarflexion power during late stance was also found to be improved 
(49%) with FES compared to AFO. This normalization of ankle kinematics and 
kinetics resulted in a reduction of step length asymmetry from 21% with AFO to 15% 
with ActiGait®.
 Patient satisfaction with ActiGait® is generally good, favouring implanted FES over 
AFO and surface-based FES systems. Martin et al. reported that after implantation a 
majority of patients reported a complete return to normal mobility (78%), normal 
social participation (67%) and normal quality of life (74%) [73]. Comparing ActiGait® 
with AFO, Schiemanck et al. showed a significant benefit of ActiGait® in terms of 
‘comfort of wearing’, ‘appearance’ and ‘going up and down the stairs’ [75]. Finally, 
Burridge et al. discussed that an advantage of ActiGait® over surface-based FES is 
that the time needed for donning and doffing is less [76]. 
Extended indications for ActiGait®
Since the ActiGait® system was officially approved in 2007 for hemiplegia following 
ischaemic or hemorrhagic stroke, implantations for other conditions have been 
rare. The first report of successful implementation of FES applied directly to the 
peroneal nerve via an implanted 4-channel cuff electrode to aid dorsiflexion in two 
patients with MS was provided recently by Hausmann et al. [77]. Walking distance 
increased from 517 to 1884 m in one patient and from 52 to 506 m in another 
patient while gait velocity changed significantly only in the latter patient from 0,6 to 
0,8 m/s. Moreover, after 3 months of stimulation, maximum deviations of center of 
31
INDICATIONS AND RESULTS OF IMPLANTABLE FES
2
mass from the midline to each side while walking changed significantly compared 
to baseline, decreasing from 15 to 12 mm in the first patient and from 47 to 37 mm 
in the latter patient. Both patients experienced reduced pain and fatigue and benefits 
to quality of life. Adverse events did not occur during the observation period [77].
 The long-term effect of the surface-based FES on the correction of drop foot 
due to upper motor neuron syndrome of different etiology was shown in a recent 
study [69]. Since no clinical differences were found between progressive and 
non-progressive neurological disorders, it is unlikely that the effects of implantable 
FES with the 4-channel drop foot stimulator will be different for conditions other 
than stroke. As for MS, only primary or secondary progressive MS patients with a 
maximum EDSS score [78] of 6 (EDSS 6 = ability to walk 100m with intermittent or 
unilateral support) are indicated for treatment with ActiGait®.
Adverse events due to ActiGait® stimulation
Surgical complications by ActiGait® implantation have only rarely been reported, 
such as hematomas at the side of the cuff placement, postoperative wound healing 
deficit (1 of 15 patients), and infections (2 of 15 patients) [32], but injury to the 
peroneal nerve may also occur [73, 75].To avoid possible pitfalls of the surgical 
procedure and the perioperative care recently a technical note was published [79]. 
Conclusion
Altogether, several (yet uncontrolled) studies indicate that implantable FES with a 
4-channel drop foot stimulator (ActiGait®) is most likely superior to surface-based 
FES in patients with drop foot after stroke, since a more precise and selective 
stimulation of the peroneal nerve can be achieved, leading to a well-balanced foot 
elevation [32]. Furthermore, with implantable FES, problems such as skin irritation 
and allergic skin reactions are avoided. In addition, it has been argued that 
implantable systems are technically more reliable than surface-based systems [73, 
76]. Studies using implantable systems have shown evidence for improved gait 
quality, in particular more paretic ankle dorsiflexion during the swing phase and at 
initial contact [74], improved paretic ankle plantarflexion during the loading phase 
[74] and improved ankle power during the push-off phase [75]. Additionally, recent 
reports showed that the implantable device was easier to use than a surface 
stimulator [76]. Lastly, there are indications that long-term FES use may also lead to 




 Given these promising results, more studies are warranted to investigate the 
effects of implantable peroneal nerve FES after stroke, especially RCTs that make a 
direct comparison to surface-based FES and to AFO use. These studies should also 
be extended to other neurological conditions, including mild progressive diseases 
such as MS. Finally, we need more studies to identify the underlying mechanisms 
of any therapeutic (neuroplastic and neuromuscular) effects of long-term FES use, 
particularly in patients with stable neurological conditions such as stroke.
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Purpose: To investigate whether an implantable functional electrical stimulation 
(FES) system of the common peroneal nerve (ActiGait®) improves relevant aspects 
of gait in chronic stroke patients with a drop foot typically using an ankle-foot 
orthosis (AFO).
Methods: Ten community-dwelling patients participated, of whom eight patients 
could be analysed. Gait quality (kinematic, kinetic, and spatiotemporal characteris-
tics) during a 10-meter comfortable walk test, normalised net energy expenditure 
during a 6-minute walk test, participation (physical activity and stroke impact) and 
user satisfaction were tested before implantation and at various moments after 
FES-system activation up to 26 weeks.
Results: Walking with FES yielded increased maximum paretic ankle plantarflexion 
(FES: -0.12; AFO: -4.79°, p<0.01), higher paretic peak ankle power (FES: 1.46; AFO: 
0.98W/kg, p<0.05) and better step length symmetry (FES: 14.90; AFO: 21.45%, 
p<0.05). User satisfaction was higher for FES, but was unrelated to objective gait 
improvements. Energy expenditure and participation did not change. 
Conclusion: Implantable FES improved the use of residual ankle plantarflexion 
motion, ankle power of the paretic leg and step length symmetry compared to 
using an AFO, however, not resulting in decreased energy expenditure or improved 
participation. User satisfaction was highest with FES, but this was not related to the 
observed gait improvements. 
37
EFFECTS ON GAIT QUALITY, ENERGY EXPENDITURE, PARTICIPATION AND SATISFCATION 
3
Introduction
Approximately 75% of the people who survive a cerebral stroke experience irreversible 
physical disabilities [7]. An estimated 20% of the partially recovered population 
suffer from a contralesional ‘drop foot’ primarily due to the inability to selectively 
activate the ankle dorsiflexors [80]. Spasticity of the ankle plantarflexors may add to 
this inability. A drop foot is often part of a more generalized stereotyped movement 
pattern of the paretic leg characterized by insufficient knee and hip flexion during 
the swing phase of gait [81]. As a result, patients with post-stroke drop foot have a 
tendency to drag the paretic foot across the floor, which places them at risk of 
tripping and falling [82]. Most patients tend to compensate for these impairments 
by hip abduction and pelvic tilt on the paretic side [81], but this compensation is 
often insufficient and/or inefficient. In addition, patients with a drop foot tend to 
overload the forefoot and lateral foot edge during the stance phase of gait, which 
impairs weight bearing and postural stability on the paretic leg. Together, these 
problems seriously impact on their walking capacity and quality of life [83].
 The consequences of drop foot in the chronic phase of stroke are commonly 
treated with an ankle-foot orthosis (AFO). AFOs provide both dorsiflexion support 
during the swing phase and ankle stability during the stance phase of gait with 
beneficial effects on walking impairments, walking activity and weight distribution 
[24]. However, depending on their stiffness, most AFOs hamper passive ankle 
motions for dynamic balance and roll off, and limit the use of residual active ankle 
plantarflexion (‘push-off’) during the late stance phase of gait. In addition, AFOs 
may reduce sensory feedback [42] and cause mechanical limitations during other 
activities than walking. They may also be experienced as practically and/or 
cosmetically unappealing leading to limited use or even rejection by patients [29].
 For the above-mentioned reasons, functional electric stimulation (FES) of the 
common peroneal nerve has been introduced as an alternative treatment for drop 
foot [7, 30, 33]. Through electrical stimulation of the ankle dorsiflexors and evertors 
during the swing phase and early stance phase of gait, foot clearance, heel loading 
and roll off are almost normally regulated. The use of FES does not limit passive or 
active ankle movements and, thus, promotes normal sensory feedback, dynamic 
balance (especially on uneven terrain), and push-off [7, 42, 84]. Three recent, large 
randomised controlled trials [38, 40, 85] have shown that surface-based peroneal 
FES is at least as effective as an AFO for improving walking velocity and various other 
aspects of balance and mobility in people with drop foot in the chronic phase of 
stroke. Moreover, several studies have shown that user satisfaction is consistently highest 
with FES [26, 31, 38, 40]. Typically, patients report that they are more satisfied with FES 
than with an AFO with regard to the effort and stability of walking, the quality of the 
gait pattern, walking distance, as well as comfort and appearance of the device [31, 40].
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 Implantable FES might be superior to surface-based FES. With implantable FES 
a more precise stimulation of the peroneal nerve can be achieved, both spatially 
and temporally, than with surface-based systems, leading to a well-balanced foot 
elevation, while problems such as skin irritation and allergic skin reactions [31] are 
avoided. In addition, it has been argued that implantable systems are technically 
more reliable than surface-based systems [33, 76]. Studies using implantable 
systems have shown evidence for improved gait quality, in particular more paretic 
ankle dorsiflexion during the swing phase and at initial contact, and improved 
paretic ankle plantarflexion during the loading phase (compared to walking without 
aid) [74] as well as reduced duration of double support phase (compared to AFO) 
[36]. However, gait kinetics, energy expenditure, participation and user satisfaction 
have never been examined for implanted FES, nor the relationship between these 
outcome measures. Hence, the goal of this exploratory study was to investigate the 
effects of an implantable FES system of the common peroneal nerve (ActiGait®) in 
people with a drop foot in the chronic phase post stroke who typically use an AFO. 
It was expected that peroneal FES would improve their gait quality (kinematic, 
kinetic and spatiotemporal characteristics), energy expenditure, participation, and 
user satisfaction compared to an AFO. Both short-term (after 2 weeks FES 
adaptation) and longer-term (after 8 and 26 weeks FES use) effects were explored. 
In addition, changes in energy expenditure, gait quality and user satisfaction were 
associated with each other to assess their mutual relationships. 
Methods
Subjects
Ten participants were recruited from the outpatients known at the departments of 
Rehabilitation of the Radboud University Medical Centre (Radboudumc) in 
Nijmegen and the Academic Medical Center (AMC) in Amsterdam based on pre-set 
inclusion and exclusion criteria and willingness to participate. Only patients with 
an established clinical diagnosis of supratentorial stroke (either ischemic or 
hemorrhagic) and who were at least 6 months post-stroke onset were eligible. 
Additional inclusion criteria were (1) weakness of ankle dorsiflexors at the paretic 
side (Medical Research Council scale < 5) for which they used an AFO, (2) passive 
range of ankle motion ≥ 30°, with ≥ 0° ankle dorsiflexion while standing with the 
knee extended, (3) muscle tone of ankle plantar flexors Modified Ashworth Scale 
≤ 3, (4) independent walking capacity for 10 minutes without walking aids (except 
an AFO), (5) age between 18 and 65 years, and (6) a positive response to surface-  
based peroneal nerve stimulation (NESS L300, Bioness inc, Valencia, California) 
defined as the ability to make initial heel contact during gait with stimulation. 
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Participants were excluded if they (1) were pregnant, (2) had severe cognitive deficits 
or (3) psychiatric disorders that might hamper informed consent and/or basic 
communication between the research team and the participant. Furthermore, 
subjects who had participated in other studies during the last six months, which 
could possibly interact with the current study, were excluded. At inclusion balance 
capacity (Berg Balance Scale), motor impairment of the paretic leg (Motricity Index 
and Fugl-Meyer Assessment), calf muscle spasticity of the paretic leg (Modified 
Ashworth Scale) and vibration threshold at the affected ankle and forefoot using 
a graduated Rydel-Seiffer tuning fork were obtained. Table 1 summarises the 
demographic and clinical characteristics of all participants at the time of inclusion 
as registered by the treating physician.
Study design
This study used a within-subjects repeated measures design. Figure 1 depicts the 
timeline of the inclusion, intervention, system activation and assessments. Energy 
expenditure (in AMC) and gait quality (in Radboudumc) were assessed at inclusion 
(T0) as well as 2(T1), 8(T2) and 26(T3) weeks after activation of the ActiGait® system 
(at T1 only gait quality). At T0, these gait measures were obtained only with the AFO. 
At later instances, energy expenditure was measured with FES only, as a combined 
assessment with FES and AFO on the same day was considered too much of a 
burden on the patients. From T1, gait quality was always assessed with AFO and FES 
on the same day. At these instances, assessments with AFO and FES were tested 
separately and in a balanced order across participants to neutralize possible time 
effects, e.g. related to fatigue. Patients always used their own AFO and wore the 
same footwear throughout all measurements. Participation and user satisfaction 
were assessed at T0 for the AFO and at T3 for the FES system. 
Intervention
ActiGait system 
The ActiGait® system (Neurodan, Denmark, Otto Bock Group, 2006) is a 4-channel 
peroneal nerve stimulator. The implantable parts consist of a stimulator body at the 
proximal end and a cuff electrode with four separate electrodes at the distal end, 
connected by a lead wire. The stimulator body selectively controls 4 electrodes 
embedded in the cuff to be able to differentially activate nerve fibres to the tibialis 
anterior, peroneus longus/brevis, and toe extensor muscles. The external parts 
consist of a heel switch (placed under the heel and attached to the shoe or a 
special sock) and a control unit worn at the pelvis and connected to an antenna 
on the skin directly over the stimulator body. The control unit enables users to 
switch the stimulation on and off and to make adjustments in stimulation intensity. 
The heel switch wirelessly communicates with the control unit to provide information 
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about heel loading. Special software algorithms warrant insensitivity to environmental 
noise. The ActiGait® system starts peroneal nerve stimulation shortly after the 
detection of heel rise in order to activate the foot dorsiflexors and evertors during 
the entire swing phase. After detection of heel strike, neurostimulation is continued 
during the subsequent loading response to regulate the first rocker. The system is 
inactive during midstance and push-off. The ActiGait® system is rechargeable and 
designed for easy use by hemiparetic patients. Indeed, 92% of the users have shown 
to be able to use the system without help [76]. Implantation of the Actigait® system 
was performed by a neurosurgeon. The system was activated three weeks after 
surgery. Use of the Actigait® system was then built up gradually in a 3-week 
 familiarisation period from 15-60 minutes per day during the first week up to 
minimally 6 hours per day at the end of the third week. From that time, participants 
were free to use either their FES system or their original AFO during the remainder 
of the study. The complete surgical procedure and system activation protocol are 
described in the appendix of this thesis. 
Outcome measures
Gait quality
Instrumented gait analysis was performed to obtain a set of spatiotemporal, kinematic 
and kinetic outcome measures. Subjects walked at a self-selected, comfortable 
speed along a walkway of approximately 15m. A 3D-movement analysis system 
Table 1   Demographic and clinical characteristics of all participants (n=10) 
and those used for analysis (n=8)
n=10 n=8
Age (mean yrs ± SD) 47.4 ± 14.5 49.7 ± 14.3
Body weight (mean kg ± SD) 80.5 ± 19.5 85.2 ± 19.6
Body height (mean cm ± SD) 175.0 ± 7.6 174.9 ± 6.9
Time since stroke (mean months ± SD) 67.7 ± 29.2 65.4 ± 32.2
Gender (male/female) 5/5 4/4
Paretic side (left/right) 6/4 4/4
Type of stroke (ischemic/hemorrhagic) 8/2 6/2
Motricity Index – paretic leg (median (range)) 69 (28-99) 71 (28-99)
Fugl-Meyer Assessment – paretic leg (median % (range)) 64 (25-88) 64 (25-88)
Berg Balance Score (median (range)) 52 (42-56) 52 (42-56)
Modified Ashworth Scale calf (median (range)) 1 (0-3) 1 (0-1)
Vibration threshold paretic forefoot (median (range)) 6 (0-8) 6 (0-8)
Vibration threshold paretic ankle (median (range)) 5 (0-8) 6 (0-8)
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(Vicon Motion Systems, Inc., Lake Forest, CA) was used to measure the trajectories 
of 16 reflective markers placed on key anatomic landmarks at a sampling rate of 
100 Hz. Markers were placed on the pelvis and on both legs: anterior superior iliac 
spine, posterior superior iliac spine, lateral epicondyle of the femur, lateral malleolus 
of the ankle, heel, dorsal head of the second metatarsal bone, and two markers on 
the lateral aspect of the thigh and lower leg, bilaterally. Position and displacement 
of the markers were analysed using the manufacturer’s ‘PlugInGait’ model. 
Simultaneously, ground reaction forces were recorded from two force plates at 
a sampling rate of 1000 Hz (Advanced Mechanical Technology (AMTI), Inc., 
Watertown, MA, USA). A total of five walking trials were captured per condition 
(AFO/FES) for each subject. Ankle kinematics (maximum dorsiflexion at mid-stance 
and maximum plantarflexion during late stance), peak ankle plantarflexion power 
(during late stance) and spatiotemporal gait characteristics (walking speed, step 
length, and single-support phase duration) were calculated using Vicon Nexus 
software, version 1.8.4. Asymmetry of gait was assessed for step length and 
single-support phase duration. For each variable (V), asymmetry was expressed in 
a Symmetry Index (SI) as proposed by Patterson et al. [86]:
Figure 1  Study design. The start of activation of the ActiGait system took place three weeks 
after implantation. Thereafter, the system was increasingly used for an extra 15 minutes per day 
until whole day use. AFO = ankle-foot orthosis; FES = functional electrical stimulation.
T0 T1 T2 T3
























SI(V) = |(Vparetic – Vnon-paretic) / (0.5 * (Vparetic + Vnon-paretic))| *100%
Energy expenditure
Metabolic cost was assessed with a 6-min walk test (6-MWT) at a self-preferred, 
comfortable walking speed on a marked indoor trajectory. The distance (m) and 
the use of aids were recorded. Oxygen consumption (VO2 in ml/min) was measured 
during the 6-MWT with a fully automated, lightweight portable gas analysis system 
(K4b2, Cosmed s.r.l, Rome, Italy). This system is based on breath-by-breath 
technology and measures both oxygen uptake and carbon dioxide production. The 
mean VO2 and VCO2 were determined by averaging all breath-by-breath values for 
the last two steady-state minutes of the test. Respiratory exchange ratios (RERs) 
were calculated as the quotient of VO2 and VCO2. VO2 and RER values were used 
to compute the energy expenditure (J·s–1) for resting and walking:
 
J·s–1 = (VO2 (L·s–1) x RER caloric equivalent (kCal·L O2–1)/4184. 
Net energy expenditure for walking was then calculated by subtracting the resting 
energy cost from the energy cost during walking. Subsequently, the net energy 
expenditure was normalised for body weight and walking speed resulting in net 
energy expenditure per kg body weight per meter walking distance (J·kg–1·m–1). 
Participation
Participants objectively monitored their physical activity, in terms of the number of 
steps per day, with a pedometer (Yamax Digiwalker SW-650, Yamax USA, Inc, San 
Antonio, USA) during a 7-day period. Physical activity was also subjectively assessed 
with the Physical Activity Scale for Individuals with Physical Disabilities questionnaire 
(PASIPD), which was shown to be valid and reliable [87]. In addition, physical 
functioning and social participation were assessed with the Stroke Impact Scale 
(SIS-16 and SIS-Participation) [88]. 
User satisfaction
User satisfaction was tested with the Utility and Satisfaction questionnaire as 
reported in a previous study of our group [31]. The Utility and Satisfaction 
questionnaire contains nine items related to various aspects of gait and system use, 
as shown in figure 3. 
Statistical analysis
Gait quality measures (5 trials) were averaged per individual and tested using a re-
peated-measures ANOVA with Time (T1, T2, T3) and Device (FES vs AFO) as with-
in-subjects factors. To test whether the intervention led to worsening of gait, the 
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spatiotemporal outcomes with AFO were compared between T0 and T1 using 
paired t-tests . Normalised net energy expenditure was tested using a repeat-
ed-measures ANOVA with Time (T0, T2, T3) as a within-subjects factor. Differences 
in PASIPD, step counts , SIS-16, SIS-Participation and user satisfaction were tested 
using Wilcoxon’s signed rank tests. Associations between changes (from T0 with 
AFO to T3 with FES) in ankle kinematics, peak plantarflexion power, comfortable 
walking speed, gait symmetry indices, normalised net energy expenditure and user 
satisfaction were calculated with Pearson (in the case of metric variables) and 
Spearman (in the case of ordinal variables) correlation coefficients. As for user 
satisfaction, we summed the changes in the following gait-related items of the 
Utility and Satisfaction questionnaire: ‘quality of gait pattern’, ‘walking distance’, 
‘effort of walking’ and ‘gait stability’. All statistical analyses were performed in SPSS 
Statistics 17.0, using p<0.05 as a cut-off for statistical significance.
Results
Ten participants were included, but the data of two persons were not used for 
analysis. One participant suffered from a peroneal neuropathy immediately after 
surgery due to excessive tension on the lead wire upon a sudden knee extension 
movement, pulling the cuff in the bifurcation of the common peroneal nerve with 
the lateral sural nerve (post-surgery electromyography (EMG) and magnetic 
resonance imaging (MRI) diagnosis). This patient’s peroneal nerve recovered after 
one-and-a-half year, after which she was able to successfully activate and use the 
ActiGait® system. Another participant did not attend 28% of the assessments due 
to personal reasons unrelated to the intervention. The other subjects (n=8), of 
whom one suffered from a deep venous thrombosis of the operated leg 11 days 
after surgery, participated in all assessments and were used for statistical analysis. 
No other complications occurred. Baseline group characteristics of all participants 
and those used for analysis are presented in table 1. 
Gait quality
Kinematics
Means for kinematic and kinetic parameters are displayed in table 2. From T1, no 
main or interaction effects of time or device were found for any of the kinematic 
parameters, except a main effect of device on maximum paretic ankle plantarflexion. 
Maximum paretic ankle plantarflexion was larger with FES than with AFO (mean 





There were no significant main effects of time or device on any of the kinetic 
parameters, except a main effect of device on peak ankle plantarflexion power, as peak 
ankle plantarflexion power with FES was higher than with AFO (mean difference 
0.5 W/Kg, F(1,7)=5.7, p=0.048) (see table 2 and figure 2). 
Spatiotemporal gait characteristics
No main or interaction effects of time or device were found for any spatiotemporal 
gait parameter, except a significant main effect of device on step length symmetry 
(see table 3). SI (step length) was significantly smaller with FES than with AFO device 
across repeated tests (mean difference 6.6%, F(1,7)=11.7, p<0.011). Spatiotemporal 
outcomes with AFO were not significantly different between T0 and T1.
Energy expenditure
There were no statistically significant effects of time on the normalised net 
metabolic cost of walking. Mean (SD) energy expenditure at T0, T2 and T3 was 4.15 
(±0.89), 4.49 (±1.10) and 4.35 (±0.82) J·kg–1·m–1, respectively. Participants showed 
no significant change in walking distance either. At T0, T2 and T3, the mean 
distance covered (SD) during the 6-MWT was 331.2 (±95.9), 300.6 (±67.7) and 324.9 
(±88.5) m, respectively. 
Table 2  Kinematic and kinetic gait parameters (n=8)
AFO FES Absolute 
difference
Maximum ankle dorsiflexion angle
• Paretic; mean degrees(CI)













Maximum ankle plantarflexion angle
• Paretic; mean degrees (CI)













Peak ankle plantarflexion power 
• Paretic; mean W/kg (CI)













Note: CI = 95% confidence interval; AFO = ankle-foot orthosis; FES = functional electrical stimulation. 
Means were calculated over T1-T3. Joint angles: positive value = dorsiflexion, negative value = plantarflexion
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Participation
There were no significant changes in objective (step counts) or subjective (PASIPD) 
physical activity. The mean (SD) numbers of steps per day were 7724 (±2826) and 
6301 (±2368) at T0 and T3, while the PASIPD scores were 21.7 (±23.5) and 21.1 
Table 3  Spatiotemporal gait parameters (n=8)
AFO FES Absolute 
difference
Walking speed; mean m/s, (CI) 0.86 (0.68-1.04) 0.87 (0.68-1.06) 0.01 (-0.04-0.59)
Step length
• Paretic; mean m (CI)
• Non-Paretic; mean m (CI)









6.55 (2.02 -11.08) 
Single support duration
• Paretic; mean s (CI)
• Non-Paretic; mean s (CI)










Note: CI = 95% confidence interval; SI = symmetry index; AFO = ankle-foot orthosis; FES = functional 
electrical stimulation. Means were calculated over T1-T3.
Figure 2  Mean and SD of paretic side peak ankle plantarflexion power (W/kg). AFO = ankle-foot 
orthosis; FES= functional electrical stimulation.





















(±17.4%) at T0 and T3, respectively. No significant changes in SIS-16 or SIS-Participation 
were found between T0 and T3 either. Mean SIS-16 scores were 74.9 (±10.2) and 
77.5 (8.1%) at T0 and T3, whereas mean SIS-Participation scores were 68.1 (±16.3) 
and 65.5 (±13.9) at T0 and T3, respectively.
User satisfaction
At T0, seven participants indicated that they used their AFO every day. Only one 
participant used the AFO one to three days a week. At T3, six participants used their 
FES system every day, whereas two participants used it four to six days a week. 
Generally, greater user satisfaction was observed for FES (T3) than for AFO (T0) (see 
figure 3). Three of the nine items (33%) showed significantly higher scores for FES; 
1 out of 5 (20%) gait-related items and 2 out of 4 (50%) non gait-related items. With 
AFO, patients scored on average “neutral”, whereas they were “satisfied” with FES. 
Figure 3  Median scores on all components of the Utility and Satisfaction questionnaire. 
1 = very dissatisfied; 2 = dissatisfied; 3 = neutral; 4 = satisfied; 5 = very satisfied, *=p<0.05. 
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Associations among changes in gait parameters and relationship 
with user satisfaction
Change in comfortable walking speed was significantly and negatively correlated 
with change in energy expenditure (r=-0.87, p=0.005) and peak ankle power 
(r=0.71, p=0.050), see figures 4 and 5. In addition, there was a trend towards a 
negative correlation between change in energy expenditure and change in peak 
ankle plantarflexion power (r=-0.69, p=0.061). Change in overground gait-related 
user satisfaction (sum score of the 5 gait-related items minus stair walking) showed 
no significant correlation with change in any of the gait parameters. 
Figure 4  Relationship of change (from T0 to T3) in energy expenditure with change in comfortable 
walking speed. Regression equation: y = -6.98x + 0.64.
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The goal of this exploratory study was to investigate the surplus value of an 
implantable functional electrical stimulation (FES) system of the common peroneal 
nerve (ActiGait®) in people with a drop foot in the chronic phase post stroke who 
were used to wearing an ankle-foot orthosis (AFO). It was hypothesized that 
peroneal FES would improve their gait quality, energy expenditure, participation 
and user satisfaction compared to AFO, mainly because ankle kinematics and 
kinetics would not be hampered by the mechanical constraints imposed by the 
AFO. Our study revealed significant improvements with FES with regard to maximum 
ankle plantarflexion angle, peak ankle plantarflexion power, and step length symmetry. 
Although walking speed and energy expenditure did not show a significant change 
at group level, individual changes in energy expenditure were significantly associated 
with changes in walking speed and ankle power. User satisfaction was generally better 
with FES than with AFO, but there were no significant associations of individual 
change in user satisfaction with change in objective gait parameters.
Figure 5  Relationship of change (from T0 to T3) in comfortable walking speed with change 
in peak ankle plantarflexion power. Regression equation: y = 0.06x + 0.04.
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Gait quality
Ankle plantarflexion power is the main source of forward gait propulsion. As a result, 
in our study, patients with the largest increase in ankle plantarflexion power showed 
the greatest increase in comfortable walking speed. Ankle plantarflexion power 
also induces knee flexion during pre-swing and, indirectly, contributes to hip flexion 
and initiation of the swing phase [89-93]. During the late-stance phase of gait, 
an AFO often restrains normal ankle plantarflexion hampering ‘push-off’ [94-96] 
and, thus, gait propulsion and swing-phase initiation. Our data confirm the notion 
that an AFO impedes late-stance ankle plantarflexion compared to walking with 
peroneal FES. Although ankle plantarflexion improved with FES, there was still a 
difference in peak ankle plantarflexion angle between the paretic and non-paretic 
leg, which might have been due to weakness of ankle plantar flexors in our patients. 
Our results seem to be in contrast with those of Ernst et al. who found no statistical 
differences between AFO and FES in late-stance plantarflexion [74]. Sheffler et al. 
compared ankle kinetics in patients with stroke walking with an AFO versus peroneal 
FES [39]. As in the present study, they found a higher peak ankle plantarflexion 
power with FES compared to AFO, although this result did not reach significance. 
The increase in peak ankle plantarflexion power in our study was larger than 
reported by Sheffler et al., which may be related to the fact that our participants had 
a higher comfortable walking speed. On the one hand, the increase in peak ankle 
plantarflexion power cannot be a direct consequence of FES, as the plantarflexors 
are not electrically stimulated during this phase of the gait cycle. On the other 
hand, it may be questioned whether the improvement in ankle kinetics is simply 
the result of AFO removal, as Yamamoto et al. did not find a similar improvement in 
ankle kinetics by merely taking away an AFO in eight patients with stroke [28]. 
Hence, it is possible that peroneal FES has an indirect beneficial effect on ankle 
plantarflexion power that is not yet completely understood. Interestingly, in a previous 
study, we concluded that improvement of ankle plantarflexion power was the most 
likely cause of a near-normal restoration of the gait pattern in an individual stroke 
patient after Actigait implantation [60]. Future studies should try to shed more light 
on this important issue.
 Several studies found that step length asymmetry is associated with paretic 
ankle plantarflexor impairment in post-stroke hemiparetic subjects [97-99]. Because 
step length is a combination of forward foot placement and trunk progression and 
because trunk progression is caused by gait propulsion [100], step length asymmetry 
can result from asymmetry in ankle plantarflexion power. Thus, the improvement 
in step length symmetry with peroneal FES compared to an AFO may be the result 
of better use of residual paretic ankle plantarflexion power in late stance, enhancing 
trunk progression during the non-paretic step. Nevertheless, step length with FES 
was still asymmetric as the symmetry index was above the 7.6% cut-off point for 
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normal gait [86] due to a difference in peak plantarflexion power between the 
paretic and non-paretic leg in our patients. 
Energy expenditure
No previous study investigated the energy expenditure of walking with peroneal 
FES compared to an AFO, so no comparisons with other studies can be made in 
this respect. As mentioned above, energy expenditure with AFO was assessed only 
at T0 and with FES only at T2 and T3 to prevent excessive fatigue in our participants. 
As we did not even find a tendency towards differences in energy expenditure 
between both devices, we believe that the likelihood of a false negative effect of 
device is very low. The fact that we did not find an improvement in energy expenditure 
at a group level seems to be coherent with the lack of significance for “effort of 
walking” as assessed with the user satisfaction questionnaire. Nevertheless, at the 
individual level, we found that the patients with the greatest increase in comfortable 
walking speed showed the greatest decrease in energy expenditure. It has been 
argued that an improvement in the comfortable walking speed is a prerequisite for 
a reduction of the energy cost of walking after stroke [101]. Walking speed, however, 
did not differ significantly between FES and AFO, which might have been due to a 
ceiling effect as our participants had a relatively high comfortable walking speed 
at baseline. 
Participation and user satisfaction
Physical activity did not increase, neither objectively nor subjectively, with peroneal 
FES compared to AFO. This result is not surprising given the relatively high number 
of steps per day in our participants. Nonetheless, user satisfaction was greater with FES 
than with AFO for five of the nine items of the Utility and Satisfaction questionnaire, 
while the other four items were also better for FES (albeit insignificant). Higher user 
satisfaction compared to AFO has been found by several previous studies using 
surface-based FES [26, 31, 38, 40]. In the present study, all items yielded a median 
score of minimally “satisfied” with FES, whereas the AFO was mostly appreciated 
with “neutral.” This difference in satisfaction scores may be influenced by selection 
bias, as our patients were intrinsically motivated to receive an implantable FES device. 
Interestingly, individual improvements in overground gait-related user satisfaction 
with FES were not associated with individual changes in energy expenditure or gait 
quality, which supports the notion that gait-related user satisfaction is influenced by 
other gait characteristics than measured in this study, such as the automaticity of 
walking or the ability to avoid obstacles. In addition, non-gait related aspects of user 
satisfaction with FES appear to be important and should be further investigated. 
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Study limitations
An obvious limitation of this study was its small sample size and the lack of a parallel 
group design. Yet, the main aim was to explore the surplus value of implantable 
peroneal FES compared to an AFO regarding different gait characteristics, with a 
specific focus on paretic ankle kinematics, kinetics, spatiotemporal symmetry and 
energy expenditure, to aid the design of future comparative studies. Selection bias 
occurred due to the fact that patients needed to be motivated for a surgical 
intervention and had to show a positive response to surface-based peroneal 
stimulation. The fact that our participants were relatively young and had a high level 
of balance capacity and physical activity limits the generalisation of our data to 
more severely disabled stroke survivors.
Conclusion 
The results of this study indicate that the value of implantable peroneal FES, in 
comparison to an AFO, must be sought in a better use of residual ankle plantarflexion 
power of the paretic leg during the push-off phase of gait, better step length 
symmetry and higher user satisfaction. Hence, in order to prove superiority of 
implantable peroneal FES over AFO, it seems sensible to focus on patients with 
sufficient ankle plantarflexion power on the paretic side. In addition, to better 
understand all aspects of user satisfaction with FES, other gait outcomes than 
assessed in this study should be studied, such as obstacle avoidance skills and 
automaticity of gait as well as non-gait related activities of daily life.
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Background: Contralesional ‘drop foot’ after stroke is usually treated with an 
ankle-foot orthosis (AFO). However, AFOs may hamper ankle motion during stance. 
Peroneal functional electrical stimulation (FES) is an alternative treatment that 
provides active dorsiflexion and allows normal ankle motion. Despite this theoretical 
advantage of FES, the kinematic and kinetic differences between AFO and FES have 
been scarcely investigated. 
Aim: To test whether walking with implanted FES leads to improvements in stance 
stability, propulsion, and swing initiation compared to AFO.
Methods: A 4-channel peroneal nerve stimulator (ActiGait®) was implanted in 22 
chronic patients after stroke. Instrumented gait analyses were performed during 
comfortable walking up to 26 weeks (n=10) or 52 weeks (n=12) after FES-system 
activation. Kinematics of knee and ankle (stance and swing phase) and kinetics 
(stance phase) of gait were determined, besides spatiotemporal parameters. Finally, 
we determined whether differences between devices regarding late stance kine(ma)
tics correlated with those regarding the swing phase. 
Results: In mid-stance, knee stability improved as the peak knee extension velocity 
was lower with FES (β=18.1°/s, p=0.007), while peak ankle plantarflexion velocity (β 
=-29.2 °/s, p=0.006) and peak ankle plantarflexion power (β=-0.2 W/kg, p=0.018) 
were higher with FES compared to AFO. With FES, the ground reaction force (GRF) 
vector at peak ankle power (i.e., ‘propulsion’) was oriented more anteriorly (β =-1.1°, 
p=0.001). Similarly, the horizontal GRF (β=-0.8% body mass, p=0.003)  and gait 
speed (β=0.03 m/s, p=0.015) were higher. An increase in peak ankle plantarflexion 
velocity and a more forward oriented GRF angle during late stance were moderately 
associated with an increase in hip flexion velocity during initial swing (rs= 0.502, 
p=0.029 and rs=0.504, p=0.028, respectively).
Conclusions: This study substantiates the evidence that implantable peroneal FES 
as a treatment for post-stroke drop foot may be superior over AFO in terms of knee 
stability, ankle plantarflexion power, and propulsion.
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Introduction
A common gait problem after supratentorial stroke is the occurrence of a hemiparetic 
‘drop foot’ [7]. Paresis of the ankle dorsiflexors, sometimes accompanied by 
plantarflexor spasticity, causes an equinus or equinovarus position of the foot 
during the swing phase and early stance. As a result, patients with drop foot have 
problems with foot clearance and pre-positioning for loading, which makes them 
prone to tripping and falling [23]. An ankle-foot orthosis (AFO) is commonly used to 
compensate post-stroke drop foot. Typically, AFOs provide passive dorsiflexion 
during the swing phase [95], thereby reducing the risk of tripping [102]. However, 
depending on their design and stiffness, most AFOs hamper normal ankle motion 
and push-off during the stance phase [27, 95, 103]. An alternative for AFO is 
functional electrical stimulation (FES) of the common peroneal nerve [30]. Peroneal 
FES provides ‘active’ ankle dorsiflexion during the swing phase and supports a 
gentle foot landing during the first ankle rocker without interfering with ankle 
motion during mid-stance or push-off. However, despite this theoretical advantage 
of FES over AFO, both interventions have been found to be equally effective for 
improving common gait-related outcomes such as gait speed and physical activity 
[43]. Possibly, these outcomes are not sensitive to capture the biomechanical 
benefits of FES over AFO. 
 In line with the theoretical advantage of FES over AFO, several groups have 
shown that ankle kinematics can indeed be improved by replacing AFO with FES 
[36, 39, 74]. In the same vein, we recently reported that late stance ankle plantar 
flexion was enhanced while walking with implantable peroneal FES, which led to a 
substantial increase in peak plantarflexion power during push-off and better 
step-length symmetry [75]. However, in the latter paper we limited our kinematic 
and kinetic analysis to the ankle joint. While late stance ankle plantarflexion power 
is indeed highly important for generating propulsion [104-107], through interjoint 
coupling, it is also a key mechanism for providing knee flexion and initiating leg 
swing [105, 108]. Enabling people with stroke to utilize all of their residual ankle 
plantarflexion power may, therefore, improve propulsion as well as knee and hip 
flexion during (pre-) swing [9, 109]. In our previous single-case report of a successful 
peroneal nerve implantation we have been able to demonstrate improvements 
both in paretic ankle kine(ma)tics and in knee and hip flexion during swing while 
walking with FES compared to AFO [60], but this result has not yet been replicated. 
 Besides a lack of propulsion during late stance and limited knee flexion during 
swing, a subset of stroke patients with drop foot also suffer from a knee (hyper)
extension thrust during mid-stance [110]. In these patients, a lack of knee control 
and/or troublesome ankle plantarflexor spasticity limits the ability to smoothly 
dorsiflex the ankle during mid-stance (i.e., tibial progression during 2nd rocker) [111], 
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which is detrimental for stance phase stability and gait efficiency. Depending on 
the stiffness, AFOs may also hamper normal dorsiflexion during mid-stance and, 
thus, facilitate this knee instability towards extension. Conversely, through replacing 
an AFO by peroneal FES, knee stability may be improved. In a recent case study, 
peroneal FES indeed showed to be a promising tool in management of knee (hyper)
extension during stance [112], but this effect has never been investigated in a group 
of stroke patients using an AFO. 
 With this study, we extend our previous work on the benefits of implantable 
peroneal nerve stimulation [75] by investigating kinematic differences (stance and 
early swing phase) and kinetic differences (stance phase) between FES and AFO in 
a larger sample of patients with chronic drop foot after supratentorial stroke. We 
tested the hypothesis that walking with FES would lead to improvements in the 
kinematics and kinetics of the ankle and knee during the stance phase of the paretic 
leg, thereby improving the knee and hip kinematics of the paretic swing phase as 
well as the spatiotemporal symmetry of gait. In this study, we specifically focus on 
knee stability in mid-stance, propulsion, and swing initiation.
Methods
Participants
Data of two longitudinal observational cohorts were pooled. Our first Actigait 
cohort (Group I) consisted of 10 patients who were followed-up for 26 weeks [75]. 
Our second Actigait cohort (Group II) comprised another 12 patients with a 
follow-up of 52 weeks. All participants were recruited from the outpatient clinic of 
the departments of Rehabilitation at the Radboud University Medical Center in 
Nijmegen and at the Academic Medical Center in Amsterdam. Only patients with 
an established clinical diagnosis of unilateral supratentorial stroke (either ischemic 
or hemorrhagic) and who were at least 6 months post stroke were eligible. Patients 
were included when they used an AFO for the compensation of foot dorsiflexion 
weakness (Medical Research Council scale < 5) and showed a positive response 
to surface-based peroneal nerve stimulation (NESS L300, Bioness inc, Valencia, 
California). All patients needed to be able to walk independently for 10 minutes 
without supervision or walking aid, except an AFO (Functional Ambulation Categories 
4 or 5). For other inclusion and exclusion criteria we refer to our previous publication 
(Chapter 3 in this thesis). At inclusion, balance capacity (Berg Balance Scale), motor 
impairment of the paretic leg (Motricity Index and Fugl-Meyer Assessment), calf muscle 
spasticity of the paretic leg (Modified Ashworth Scale), and vibration threshold at 
the affected ankle and forefoot (graduated Rydel-Seiffer tuning fork) were evaluated 
by the treating physician. 
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Study design
A within-subjects repeated measures design was used for both cohorts. Gait 
analyses were performed at inclusion (T0) as well as 2 weeks (T1), 8 weeks (T2), 26 
weeks (T3), and 52 weeks (T4, Group II only) after activation of the ActiGait® 
system. At T0, these gait measures were obtained only with the AFO. From T1, gait 
was always assessed with AFO and FES on the same day, see figure 1. At these 
instances, walking with AFO and FES was tested separately and in a balanced order 
across participants to neutralize possible order effects, e.g. related to fatigue. 
Patients always used their own AFO and wore the same footwear throughout all 
measurements.
Intervention
The ActiGait® system (Neurodan, Otto Bock, Germany) is a 4-channel peroneal 
nerve stimulator. The implantable parts consist of a stimulator body at the proximal 
end and a cuff electrode with four separate electrodes at the distal end, connected 
by a lead wire. The stimulator body selectively controls 4 electrodes embedded in 
the cuff, which allows differential activation of nerve fibers to the tibialis anterior, 
peroneus longus/brevis, and toe extensor muscles. The system is described in 
more detail in chapter 3 of this thesis, the surgical procedure and system activation 
procedure are presented in the appendix of this thesis. 
Figure 1  Timeline of the two study cohorts. The start of activation of the ActiGait system took 
place three weeks after implantation. Thereafter, the system was increasingly used for an extra 
15 minutes per day until whole day use. AFO = ankle-foot orthosis; FES = implanted functional 
electrical stimulation.
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Instrumented gait analyses were performed to obtain spatiotemporal, kinematic, 
and kinetic outcome measures. Subjects walked at a self-selected, comfortable 
speed along a walkway of approximately 10m. A 3D-movement analysis system 
(Vicon Motion Systems, Inc., Lake Forest, CA,USA) was used to measure the trajectories 
of 16 reflective markers placed on key anatomic landmarks at a sampling rate of 100 
Hz. Markers were bilaterally placed on the pelvis and on both legs: anterior superior 
iliac spine, posterior superior iliac spine, lateral epicondyle of the femur, lateral 
malleolus of the ankle, heel, dorsal head of the second metatarsal bone, and two 
markers on the lateral aspect of the thigh and lower leg. Trajectories of these markers 
were recorded within the measurement volume of the 3D-movement analysis system, 
which was approximately from 2 to 8m on the walkway. Position and displacement 
of the markers were analysed using the manufacturer’s ‘PlugInGait’ model. 
Simultaneously, ground reaction forces were recorded from two force plates at a 
sampling rate of 1000 Hz (Advanced Mechanical Technology (AMTI), Inc., Watertown, 
MA, USA). Five walking trials were captured per condition (AFO/FES) for each subject. 
Data analysis
Raw motion capture data was filtered using a Woltring filtering routine [113]. Gait 
events (heel strike and toe-off), joint kinematics and kinetics were derived from the 
Vicon PlugInGait model and processed with Matlab (The Mathworks Inc. Natick, 
MA, USA). The values of all outcome measures were averaged across the five trials.
Mid-stance knee kinematics (stance stability)
A lack of knee control can cause instability during mid-stance. Such instability 
usually presents as either excessive knee flexion or rapid knee extension (i.e., knee 
(hyper)extension thrust). Excessive knee flexion is often the result of calf muscle 
weakness, whereas knee extension thrust is typically caused by ankle plantarflexor 
spasticity. To quantify the knee extension thrust on the paretic side during mid- 
stance, peak knee extension velocity was determined (in patients without excessive 
knee flexion). Knee angular velocity was computed by taking the first derivative of 
the knee angle. Then the maximum value between each ipsilateral heel strike and 
toe-off was established. For each step, the point where peak extension velocity was 
reached was visually controlled by the primary researcher (FB) to make sure that 1) 
maximum knee flexion was smaller than 15° (to eliminate participants with an 
excessive knee flexion pattern) and 2) the point of peak extension velocity occurred 
during a knee extension motion of minimally 5° (to avoid the identification of very 
small, meaningless extension peaks).
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Late stance ankle kinematics and kinetics (propulsion)
To quantify the push-off during late stance, maximum ankle plantarflexion angle, 
maximum ankle plantarflexion velocity (first derivative of the plantarflexion angles), 
and maximum ankle plantarflexion power were established. Maximum values were 
identified between 30 and 100% of the stance phase (heel strike to ipsilateral 
toe-off) to avoid the identification of ankle plantarflexion during early stance. In 
addition, we determined the orientation of the ground reaction force at the instant 
of maximum plantarflexion power, expressed as the angle relative to the vertical 
(GRF angle), as well as the maximum ground reaction force in the anteroposterior 
direction (AP-GRF). 
Swing hip and knee kinematics (swing initiation)
Maximum knee flexion angle, maximum knee flexion velocity (first derivative of the 
knee flexion angles), maximum hip flexion angle, and maximum hip flexion velocity 
(first derivative of the hip flexion angles) were calculated. Since knee flexion starts during 
pre-swing, these values were identified between 40% and 100% of the gait cycle. 
Spatiotemporal characteristics (speed and symmetry)
We also determined gait speed and step-length asymmetry as basic spatiotemporal 
variables. Gait speed was calculated as the displacement (meters) of the heel 
marker in the anteroposterior direction between the first and last heel strike divided 
by the time from first to last heel strike (seconds). Step length (SL) on one body side 
was determined as the distance from the ipsilateral heel to the contralateral heel. 
Step-length asymmetry was expressed in a symmetry index (SI) [86]
SISL = |(SLparetic – SLnonparetic) / (0.5 * (SLparetic + SLnonparetic))| *100%
Statistics
In previous work maximum ankle plantarflexion angle, peak ankle plantarflexion 
power, step-length asymmetry and gait speed were reported for Group I [75]. For 
the current research report data from Group I was re-analysed, analyses were 
extended, and results were combined with the data from Group II. All outcome 
measures were tested using Generalized Estimated Equations modeling (GEE, 
autoregressive correlation structures). As we were primarily interested in the 
differences between FES and AFO, a model with the (time-integrated) factor Device 
(T1-T4) was tested first (Step 1). Then the factor Time (T1-T3) and its interaction with 
Device were added to the model (Step 2) to assess whether there were any learning 
effects during the study period, and whether time was of influence on the effects 
of Device. For the assessment of Time effects we neglected the final assessment 
(T4) of Group II to avoid finding Time effects attributable to group differences. 
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Finally, we determined whether (time-integrated) Device effects on late stance 
characteristics (maximum ankle plantarflexion velocity and power, AP-GRF, 
GRF- angle) were correlated with those on swing characteristics (maximum knee 
and hip flexion velocity). To this end, differences between FES and AFO (FES-AFO) 
were averaged over time for all subjects. We calculated Spearman’s rank correlation 
coefficients, because we did not expect the differences between FES and AFO to 
be normally distributed. Level of significance was set at p<0.05. All statistical analysis 
were performed in SPSS 22.0 (IBM Corp. Armonk, NY, USA).
Results
Patient inclusion and characteristics
Twenty-two participants were included of whom three were removed from the 
analysis, see table 1. One participant (Group I) suffered peroneal nerve damage 
after surgery (which showed full recovery after one-and-a-half year). One participant 
(Group II) died shortly after activation of the ActiGait system, the cause of death 
being unrelated to the study. No follow-up data of these two participants could be 
collected. The third participant (Group I) had severe calf muscle clonus in reaction 
to FES, which needed to be treated with repeated intramuscular injections with 
botulinum toxin. Because of this additional treatment, this participant deviated too 
much from the study protocol. The ActiGait implant of one participant (Group II) 
failed after 26 weeks, yet sufficient data was collected to include this participant in 
the analysis. Hence, data of 19 participants from the two combined study cohorts 
was analysed. 
Mid stance knee kinematics (stance stability)
Our analysis focused on the difference between AFO and FES on knee instability 
towards extension on the paretic side during mid-stance. Two subjects showed 
instability towards knee flexion, i.e. excessive (> 15°) knee flexion in mid-stance, and 
were thus discarded from this analysis. Peak knee extension velocity was significantly 
different between the two devices and was on average 14% lower with FES 
compared to AFO (Device, β=18.1°/s, p=0.007) (see table 2 and figure 2a). The Time 
effect was also significant (p=0.039). Knee extension velocity was slightly higher at 
26 weeks after system activation compared to 2 weeks. There was no significant 
Device*Time interaction. 
Late stance ankle kinematics and kinetics (propulsion)
There was a trend towards a larger maximum ankle plantarflexion angle with FES 
compared to AFO (Device, β=-1.6°, p=0.07) (see table 2). On average, both devices 
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did not provide true plantarflexion in late stance as can be seen by the negative (i.e., 
dorsiflexion) values for maximum plantarflexion in figure 2b. Yet, there was a 
significant difference between the two devices for both peak ankle plantarflexion 
velocity (Device, β=-29.2 °/s, p=0.006) and peak ankle plantarflexion power (Device, 
β=-0.2 W/kg, p=0.018). With FES, plantarflexion velocity and plantarflexion power 
were on average 22% and 17% higher, respectively (see table 2 and figures 2c and 
2d). GRF angle at the instant of peak ankle power significantly changed towards a 
more forward orientated angle with FES compared to AFO (Device, β =-1.1°, 
p=0.001). In the same vein, maximum AP-GRF was significantly larger with FES 
compared to AFO (Device, β =-0.8 % body weight, p=0.003). On average, GRF 
angle and maximum AP-GRF increased by 14% and 10% with FES, respectively (see 
table 2 and figure 2e). There were no other significant (interaction) effects for 
maximum ankle plantarflexion angle, peak ankle plantarflexion velocity, peak ankle 
plantarflexion power, GRF angle or maximum AP-GRF.
Table 1   Demographic and clinical characteristics of both study cohorts obtained 
at baseline (T0)
N=19
Age (mean yrs ± SD) 54.4 ± 12.3
Body weight (mean kg ± SD) 83.3 ± 15.2
Body height (mean cm ± SD) 177.0 ± 7.2
Time since stroke (mean months ± SD) 59.9 ± 44.0
Sex (men/women) 14/5
Paretic side (left/right) 11/8
Type of stroke (ischemic, hemorrhagic) 14/5
Motricity index – paretic leg (median (range)) 77 (28-99)
Fugl-Meyer Assessment – paretic leg (median % (range)) 71 (25-88)
Berg Balance Scale (median (range)) 53 (42-56)
Modified Ashworth Scale calf (median (range)) 1 (0-2)
Vibration threshold paretic forefoot (median (range)) 4 (0-8)
Vibration threshold paretic ankle (median (range)) 4 (0-8)
Type of AFO used (fixed/hinged) 17/2
Baseline comfortable walking speed using AFO (mean m/s ± SD) 0.94 (0.2)
AFO = ankle-foot orthosis
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Table 2: Estimated marginal means for both study cohorts combined (T1-3) (n=19)
Outcome Time Mean ± SE Statistics




T1 134 ± 18 116 ± 16 p=0.007 p=0.039
T2 133 ± 16 122 ± 14




T1 -4.09 ± 1.32 -1.51 ± 2.06 p=0.07 p=0.125
T2 -3.12 ± 1.34 -1.56 ± 1.73




T1 133 ± 11 171 ± 25 p=0.006 p=0.312
T2 121 ± 8 149 ± 13




T1 1.30 ± 0.15 1.45 ± 0.15 p=0.018 p=0.970
T2 1.22 ± 0.15 1.57± 0.16
T3 1.28 ± 0.15 1.47 ± 0.17
GRF angle
(degrees)
T1 7.25 ± 0.80 8.37 ± 0.97 p=0.001 p=0.887
T2 7.20 ± 0.80 8.77± 0.90




T1 8.80 ± 0.95 9.81 ± 1.01 p=0.003 p=0.740
T2 8.60 ± 0.88 9.65 ± 0.88




T1 40.61 ± 2.98 40.62 ± 2.96 p=0.798 p=0.028
T2 44.59 ± 3.23 43.92 ± 3.48




T1 244 ± 23 247 ± 22 p=0.819 p=0.066
T2 253 ± 23 262 ± 22




T1 32.44 ± 1.22 33.70 ± 1.38 p=0.637 p=0.002
T2 33.89 ± 1.22 34.48 ± 1.05




T1 142 ± 16 137 ± 16 p=0.696 p=0.687
T2 136 ± 11 132 ± 9
T3 140 ± 13 144 ± 18
Gait Speed
(m/s)
T1 0.93 ± 0.05 0.95 ± 0.05 p=0.015 p=0.345
T2 0.91 ± 0.05 0.96 ± 0.05




T1 10.21 ± 2.38 8.78 ± 1.76 p=0.852 p=0.717
T2 9.30 ± 2.37 8.33 ± 2.30
T3 8.91 ± 1.72 9.15 ± 2.02
AFO = ankle-foot orthosis. FES = implanted functional electrical stimulation 
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Swing hip and knee kinematics (swing initiation)
There was no significant difference between AFO and FES for maximum knee 
flexion angle (Device, β =0.4°, p=0.798) or maximum knee flexion angular velocity 
(Device, β =19.0°/s, p=0.819). Likewise, there was no significant difference between 
AFO and FES for maximum hip flexion angle (Device, β =-0.2°, p=0.637) or 
maximum hip flexion angular velocity (Device, β =15.0°/s, p=0.696) (see table 2). 
Time was a significant factor for both peak knee flexion angle (p=0.028) and peak 
hip flexion angle (p=0.002) during swing. Compared to the first follow-up 
measurements (T1), peak knee flexion angles were significantly larger after 8 weeks 
(Timet2, β =4.0°, p=0.006) and peak hip flexion angles were significantly larger after 
26 weeks (Timet3, β =3.2°, p=0.006). 
Spatiotemporal characteristics (speed and symmetry)
There was a significant difference between AFO and FES for comfortable walking 
speed, indicating that participants walked faster with FES (Device, β =-0.03, p= 
0.015). On average subjects walked 3% faster with FES compared to walking with 
their AFO (see table 2). Further analysis revealed no other significant (interaction) 
effects for walking speed. There was no significant difference between AFO and 
FES for step-length asymmetry (Device, p= 0.852). In our previous report [75], 
step-length asymmetry was significantly different between devices. As Group II 
presented with fairly low values of step-length asymmetry, we corrected for possible 
floor effects. To this end, step-length asymmetry at baseline and its interaction with 
Device was added to the model. This additional analysis revealed a trend for a 
significant interaction between Device and baseline step-length asymmetry 
(p= 0.077), indicating that participants with greater step-length asymmetry at baseline 
tended to have more benefit from FES. 
Relationship between device effects on late stance versus swing 
characteristics
Correlations between the (time-integrated) Device effects in late stance and those 
in the swing phase are presented in table 3. An increase in peak ankle plantarflexion 
velocity during late stance with FES was significantly correlated with an increase in 
peak hip flexion velocity during swing (rs= 0.502, p=0.029). A more forward oriented 
GRF angle during late stance with FES was also significantly correlated with an 
increase in peak hip flexion velocity during swing (rs=0.504, p=0.028). An increase 
in ankle plantar flexion power and an increase in AP-GRF during late stance with 
FES tended to correlate with an increase in peak hip flexion velocity (rs= 0.453, 
p=0.052) and knee flexion velocity (rs= 0.440, p=0.059) during swing, respectively.
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With this report we extended our previous work on the benefits of implantable 
peroneal nerve stimulation (FES) compared to ankle-foot orthosis (AFO) including a 
larger sample of patients (n=22) with chronic drop foot after supratentorial stroke. 
We focused on the possible kinematic, kinetic, and spatiotemporal improvements 
with FES throughout the stance and swing phase of walking as well as on possible 
relationships between stance-phase and swing-phase improvements. As such, it is 
currently the largest cohort to investigate the beneficial effects of implantable 
peroneal nerve stimulation compared to AFO on gait characteristics, including 
kinetics. Our results showed that implantable peroneal FES might be superior over 
AFO in terms of knee stability, plantarflexion power, and propulsion, but we found 
no swing-phase related benefits at group level.
Stance-phase kinematics and kinetics and spatiotemporal 
characteristics
The results confirmed our hypothesis that implantable peroneal FES would improve 
knee stability compared to AFO in patients with knee (hyper)extension during 
mid-stance on the paretic side. Many of these patients show a knee (hyper)
extension thrust, which is promoted by an AFO that limits tibial progression during 
the 2nd rocker [114]. Peroneal FES does not promote such a knee (hyper)extension 
Table 3   Relationship between changes in stance-phase characteristics (FES-AFO) 
with changes in swing-phase characteristics (n=19)
Δ Maximum knee flexion 
velocity (degrees/s)




























Δ = individual mean difference between FES and AFO, averaged over time. For example: (GRF angleFEST1 - 
GRF angleAFOT1) + … (GRF angleFESTn - GRF angleAFOTn) / n
AFO = ankle-foot orthosis. FES = implanted functional electrical stimulation. n = number of measurements
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thrust. The average improvement was a 14% lower maximum knee extension 
velocity, which difference may well be clinically relevant. Yet, there is no literature 
on the minimal clinically relevant difference in this outcome for supporting its 
interpretation. Furthermore, no previous study compared maximum knee extension 
velocity between FES and AFO. Generally, maximum knee extension velocity was 
slightly higher at 26 weeks compared to 2 weeks after system activation, which 
may be related to a small increase in walking speed over time. 
 The results also confirm our hypothesis that implantable peroneal FES would 
enhance propulsion compared to AFO, by improving ankle kinematics and kinetics 
during late stance. We found a borderline significant improvement of the maximum 
ankle plantarflexion angle and a significant improvement of peak ankle plantarflexion 
velocity (22%) and power (17%). These findings are in agreement with our previous 
study [75], although the presently reported mean differences in peak plantarflexion 
power between FES and AFO were lower (0.21 W/Kg vs 0.48 W/Kg). This reduction 
in device effect is remarkable as the average scores for the Motricity Index and 
Fugl-Meyer Assessment of the paretic leg were somewhat better for Group II 
compared to Group I (see table 1). Since well recovered participants seem more 
likely to suffer from limitations imposed by AFO, it was expected that the difference 
in peak plantarflexion power between FES and AFO would have increased with the 
addition of this group. Nevertheless, the observed difference in peak plantarflexion 
power between FES and AFO closely matches the values observed by Sheffler 
et al (0.18 W/Kg) [39]. As expected, the observed improvements in peak ankle 
plantarflexion power with FES coincided with improved propulsion, which was 
indicated by a larger maximum anteroposterior component (10%) and more 
anteriorly orientated angle (14%) of the ground reaction force. Overall, these results 
suggest that FES allowed participants to better utilize their residual calf muscle 
strength and ankle power for push-off. Indeed, the calf muscles provide 
approximately 75% of the propulsion power during normal gait. This propulsion can 
be limited by using an AFO, especially in patients with substantial residual calf 
muscle strength. 
 In our previous report, an improvement in step-length asymmetry with FES was 
found [75]. We explained this finding on the basis of an improved peak ankle power 
on the paretic side, leading to a larger step length with the nonparetic leg. In the 
pooled results of Group I and Group II, the improvement in step-length asymmetry 
with FES was no longer significant. Yet, when the presence of step-length 
asymmetry at baseline was considered in the statistical model, we still found a 
borderline significant interaction with Device, indicating that participants with the 
greatest step-length asymmetry at baseline indeed tended to improve their gait 
symmetry with FES. Overall, the pooled data set showed less step-length asymmetry 
at baseline compared to Group I reported in our previous study, allowing less room 
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for improvement, which may well explain the absence of a significant Device effect. 
Consistent with the improved peak ankle power and propulsion, we did find a 
significant Device effect for walking speed, albeit fairly small (3%). This improvement 
in mean comfortable walking speed does not surpass the minimal clinically import 
difference of 0.10 -0.17 m/s [115]. Nevertheless, this is an interesting finding in view 
of a recent meta- analysis by Prenton et al. that did not find significant differences 
between FES and AFO for gait speed in patients after stroke [43].    
Swing-phase kinematics and associations with stance-phase 
characteristics 
In contrast with our hypothesis, the beneficial effects of FES on stance-phase 
 characteristics such as ankle power and propulsion did not coincide with improved 
swing-phase kinematics in the group at large. The use of implantable peroneal FES 
did not lead to a larger or faster knee or hip flexion during the swing phase compared 
to AFO. This finding is in contrast to our previous case study that showed 
normalization of knee and hip kinematics during swing with implanted FES 
compared to AFO [60]. This observation was explained by an improved individual 
capacity to utilize residual calf muscle strength with FES, leading to larger knee and 
hip angles during swing through inter-joint coupling. Yet, the presently observed 
lack of differences in knee and hip kinematics with FES is in line with previous 
studies on both implantable [36] and surface-based FES [39]. Collectively, these 
results indicate that a translation of stance-phase benefits into swing-phase benefits 
may not be expected for the majority of patients. It is possible that the observed 
moderate average increase in paretic peak ankle power (17%) from AFO to FES was 
generally insufficient to improve swing-phase kinematics. Nevertheless, the fact 
that FES-induced improvements of ankle plantarflexion velocity, ankle plantarflexion 
power, and orientation angle of the ground reaction forces during the stance phase 
were moderately associated (R2 = 25%) with improvements in hip flexion velocity 
during the swing phase may point towards some type of functional coupling 
between these phenomena as a result of peroneal stimulation, but this needs to be 
corroborated by further research. The observed small increase across time in peak 
knee and hip flexion angles during the swing phase, irrespective of Device, may 
well be related to the parallel (modest) increase in walking speed.
Study limitations
Despite the combination of two study cohorts, this study is still limited by a small 
sample size, which is inherent in our focus on implantable peroneal FES and in the 
complexity of the instrumented gait assessments. Patients were compared to 
themselves instead of a control group using an AFO and not receiving implanted 
FES, yet the applied within-subjects design was considered a better option to 
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identify FES-induced improvements than a parallel group design with larger (be-
tween-subjects) variability. The latter option would also have required many more 
participants. Selection bias has probably occurred due to the fact that patients 
needed to be motivated for a surgical intervention and had to show a positive 
response to surface-based peroneal stimulation, which limits the generalizability of 
our data. Blinding of participants and investigators was not possible due to the 
visibility of the devices. To minimize assessor bias, the approach by the investigators 
(e.g., instructions, encouragement) was kept constant during all data collection. 
Each patient used his own AFO during the course of the study, which may not 
necessarily have been the optimal device, but it does reflect regular clinical practice. 
Most participants preferred the use of FES over AFO during the follow-up, which 
might have led to an ‘unlearning’ effect. However, we did not find any evidence for 
worsening of walking with AFO over time.
Conclusions
This study substantiates the scientific evidence that implantable peroneal FES as a 
treatment for post-stroke drop foot may have kinematic and kinetic advantages 
compared to AFO. In particular, by allowing full freedom of motion at the ankle 
joint, patients are able to optimally use any residual calf muscle strength for 
generating ankle plantarflexion power and propulsion during push-off, which may 
optimize step-length symmetry in asymmetric patients. In addition, knee instability 
(towards extension) during mid-stance may be less with FES compared to AFO due 
to optimal tibial progression at the ankle. Whether these stance-phase benefits 
translate into improved swing-phase characteristics remains questionable. Changes 
in swing-phase kinematics are probably strongly dependent on individual patient 
characteristics such as the timing and strength of the push-off and compensation 
strategies used. Future research should focus on more complex gait tasks in which 
stance-phase stability and push-off regulation are challenged in order to fully 
understand the potential benefits of (implantable) peroneal FES compared to AFO 
in patients with post-stroke drop foot.
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Background: Implanted peroneal functional electrical stimulation (FES) is an effective 
alternative treatment to ankle-foot orthosis (AFO) in people with drop foot after stroke. 
With FES no constraints on ankle mobility are imposed which might particularly be 
exploited in challenging walking environments that require adaptations of the gait 
pattern to environmental disturbances.
Research Question: Is gait adaptability, by means of the capacity to avoid sudden 
obstacles while walking on a treadmill, superior with implanted FES compared to 
AFO in people with drop foot after stroke?
Methods: A 4-channel peroneal nerve stimulator (ActiGait®) was implanted in 22 
persons with stroke (>6 months) who regularly used an AFO. Gait adaptability was 
tested with an obstacle avoidance task on an instrumented treadmill up to 26 weeks 
(n=10) or 52 weeks (n=12) after FES-system activation. At assessments, 30 trials, in 
which obstacles were suddenly dropped onto the treadmill in front of the paretic 
leg, were recorded with each device (FES / AFO). Trials were grouped by available 
response times (ART) and success rates were calculated. The effect of device, 
ART and follow up time on success rates was tested using generalized estimated 
equations. Nonparametric correlations were calculated to associate changes in 
success rates with clinimetrics. 
Results: Success rates of obstacle avoidance were higher when participants used 
their FES system compared to AFO (Δ4.7%, p=0.03), which effect was largest for 
longest ARTs (Δ15%, p=0.03). Participants with greater motor impairment of the 
paretic leg showed greater benefit from FES (rs=-0.49, p=0.04). 
Significance: FES has been found equally effective as AFO in improving walking speed 
of people with drop foot after stroke. We now present superior walking performance 
in a complex walking environment for implanted peroneal FES compared to AFO. 
These findings underline the importance of using gait assessments that require 
interplay with the environment, besides assessment of stationary walking, in community 
ambulators.
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Introduction
Hemiparetic drop foot is one of the most common gait impairments in people with 
stroke [7]. Ankle-foot orthosis (AFOs) are generally prescribed as a treatment for 
drop foot, keeping the ankle and foot in a neutral position during the swing phase 
and loading phase of gait[24]. Functional electrical stimulation of the peroneal 
nerve is an alternative for AFO as it can provide an active ankle dorsiflexion moment 
during swing and loading[30]. In contrast to AFO, no mechanical constraints are 
imposed by FES enabling normal ankle range of motion and allowing optimal use 
of residual plantarflexor activity. Indeed, we recently reported that late stance 
plantarflexion was enhanced with peroneal FES, resulting in increased peak 
plantarflexion power and gait propulsion [75, 116]. 
 In spite of this theoretical advantage of FES over AFO, scientific evidence for a 
surplus value of FES on functional outcome is limited. A meta-analysis showed that 
gait speed and functional capacity were not significantly different between AFO 
and FES [43]. Since most FES users included in this meta-analysis were community 
walkers (comfortable walking speed > 0.4 m/s), more complex gait skills than 
normal level walking are also relevant to this population. Indeed, walking in daily life 
demands continual adaptations to environmental challenges, such as inclination 
angles, uneven terrain or traffic. It may be that the advantages of unrestricted ankle 
motion and control with FES particularly surface in more complex walking 
environments where adaptation of gait is required. Perhaps these advantages may 
explain the fact that patient satisfaction has been shown to be consistently higher 
for FES compared to AFO [117]. 
 Studies that compared FES with AFO in challenging conditions are yet scarce. 
Sheffler et al. did not find a significant difference between FES and AFO in the time 
it took to complete an obstacle course after only one day of FES use [118]. In 
contrast, in an RCT with a 12-month follow-up, others found that for the FES group 
the time to complete an obstacle course gradually decreased, whereas it did not for 
people using AFO [37]. In line with this finding, our previous work demonstrated 
that the capacity to avoid sudden obstacles on a treadmill was better with FES 
compared to AFO [44]. Interestingly, this superiority of FES over AFO seemed to be 
particularly present in patients with greater motor impairment (Motricity Index 
<64%). 
 These previous studies on walking adaptability were all limited to surface-based 
peroneal FES systems, whereas (partially) implantable systems are now available 
that allow for direct electrical stimulation of the common peroneal nerve with 
potentially greater spatial and temporal precision [32, 119]. Therefore, in this study 
we aimed to investigate the capacity of avoiding sudden obstacles while walking 
on a treadmill with an implanted FES system (Actigait®) compared to AFO in people 
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in the chronic phase after stroke. We expected to observe higher avoidance success 
rates with implanted FES than with AFO, similar to our previous findings on the use 
of surface-based FES [44]. In addition, we aimed to study the benefit from implanted 
FES in relation to the available response time for obstacle avoidance.
Methods
Participants
Gait adaptability data were collected in two longitudinal observational cohorts. In the 
first cohort, 10 persons with stroke were included and followed-up for 26 weeks. 
In the second cohort, another 12 persons with stroke were included and followed-up 
for 52 weeks. Participants were recruited from the outpatient rehabilitation clinics 
Figure 1  The ActiGait® system. The implantable parts consist of a stimulator body (A) at the 
proximal end and a cuff electrode with four separate controllable electrodes at the distal end 
(B), connected by a lead wire. External parts (i.e. a control unit (C), antenna (D) and heel switch 
(E)) are used to activate and control the level of intensity of the stimulation. The ActiGait® system 
starts peroneal nerve stimulation shortly after the detection of heel rise in order to activate 
the foot dorsiflexors and evertors during the entire swing phase. After detection of heel strike, 
neurostimulation is continued during the subsequent loading response to regulate the first 
rocker. The system is inactive during midstance and push-off.
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of two University Medical Centers in the Netherlands. Eligible participants had 
sustained a clinically established supratentorial stroke (ischemic or hemorrhagic) at 
least 6 months prior to inclusion. They needed to have impaired paretic side ankle 
dorsiflexion (Medical Research Council scale ankle dorsiflexion force < 5) for which 
they used an AFO, a muscle tone of ankle plantar flexors Modified Ashworth Scale ≤ 3, 
and they needed to show a positive functional response to surface-based peroneal 
nerve stimulation (NESS L300, Bioness inc, Valencia, California). Furthermore, they 
had to have a functional walking capacity of at least 10 minutes without the use of 
walking aids. For additional inclusion and exclusion criteria, we refer to Schiemanck 
et al. [75]. At inclusion the treating physician obtained clinical scores as listed in 
table 1. Both studies received approval from the local medical-ethical committee 
and all participants gave their written informed consent before participation. 
Intervention
The ActiGait® system (Neurodan, Denmark, Otto Bock Group, 2006) is a 4-channel 
common peroneal nerve stimulator (figure 1). A neurosurgeon performed the 
implantation of the Actigait® system at each study site. Three weeks after surgery 
the system was activated and stimulation settings were determined. Use of the 
Actigait® system was then built up incrementally from 15-60 minutes per day in the 
first week up to minimally 6 hours per day after three weeks. From three weeks on 
participants were free to use their FES system or AFO as they pleased. The FES 
system is described in more detail in chapter 3 of this thesis, the surgical procedure 
and system activation procedure are presented in the appendix of this thesis.
Figure 2  Timeline of the two studies. 
T0 T1 T2 T3 T4





















Both longitudinal studies used a within-subjects repeated measures design. The time- 
line of inclusion, system implantation, system activation, and gait adaptability 
assessments of both cohorts is presented in figure 2. Gait adaptability was tested 
at inclusion (T0) as well as 2 weeks (T1), 8 weeks (T2) ,26 weeks (T3), and 52 weeks 
(T4; second study group only) after activation of the ActiGait® system. At T0, gait 
adaptability was assessed only with AFO. At follow up assessments, gait adaptability 
was tested both with AFO and with FES; the order was balanced across participants 
to neutralize possible time (e.g. fatigue) effects. Subjects used their own AFO and 
wore the same footwear during all measurements.
Gait adaptability measurement
Gait adaptability was tested with an obstacle avoidance task on an instrumented 
treadmill[44, 120, 121]. At baseline (T0), treadmill speed was set at either 2 or 3 km/h 
(depending on the participant’s ability to walk safely on the treadmill) and kept 
constant across the entire follow-up period. Participants were requested to walk 
without the use of handrail support, but they were allowed to grab the handrail 
when needed in the case of fall risk. To protect participants against falling, they 
wore a safety harness that was attached to a rail fixated onto the ceiling. A wooden 
obstacle (length 40 cm, width 30 cm, and height 1.5 cm) with a magnet in its centre 
was held by an electromagnet just above the treadmill and was placed in front of 
the paretic leg. Participants were instructed to maintain a distance of about 10 cm 
from the toe of the affected foot to the hanging obstacle at the moment of foot 
strike (see figure 3).
 Positions of both feet and the obstacle were collected with a 6-camera, 
3D-movement analysis system (Vicon Motion Systems, Vicon- UK, Oxford, United 
Kingdom) at a sampling rate of 100 Hz. To this aim, a reflective marker was placed 
on the front edge of the obstacle and three markers were placed bilaterally at the 
lateral malleolus of the ankle, heel, and the dorsal head of the second metatarsal 
bone. Marker data of the paretic foot were processed online to determine the 
instant of foot strike and the step cycle duration. Based on this information, the 
obstacle was released in either the mid stance, late stance / early swing, or mid 
swing phase of gait in order to introduce distinct levels of difficulty. Obstacles 
dropped during mid swing were most difficult, because the available response time 
(ART) to adjust the ongoing step was very short. In contrast, ARTs were long for 
obstacles released during mid stance, which were relatively easy to avoid. In total, 
30 trials were recorded with each device (FES / AFO). The instants of obstacle 
release were randomly distributed over the trials. Participants were instructed to 
avoid the obstacle once it was dropped onto the treadmill by either lengthening or 
shortening their paretic step. Contact of the foot with the obstacle and paretic 
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steps parallel to the obstacle were classified as failures. Two assessors judged the 
success of the avoidance maneuver both online (during the assessment) and offline 
(based on video and marker recordings). At the beginning of each session, the 
participants performed five practice trials to familiarize themselves with the 
experimental setup. 
Data processing and statistical analysis
ART was quantified as the time between obstacle release and the moment that the 
toe of the paretic foot would have crossed the front edge of the obstacle in 
the case of an unaltered step [121]. The trials were then stratified into three ART 
categories corresponding to the phases of the gait cycle in which the obstacle 
was dropped: 450-600 ms (mid stance), 300-450 ms (late stance/early swing), 
and 150-300 ms (mid swing). For each participant and for both devices, success 
rates were calculated by dividing the number of successful trials by the total number 
of trials in each ART category. 
 Differences in success rates between FES and AFO were assessed using 
generalized estimated equation modeling (GEE with autocorrelated structure). 
Time (T1-4), device (AFO, FES), and ART (450-600, 300-450, 150-300 ms) were 
used as within-subject factors. Similar to van Swigchem et al., the variance in the 
Figure 3  Experimental setup. Image adapted from van Swigchem et al. (2012). 
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success rates was stabilized by subjecting the data to angular transformation before 
conducting the GEE [44]. To minimize the number of factors in the model, factors 
that were non-significant and showed no significant interaction effect with device 
were removed from the model. 
 To investigate whether the expected benefits of FES depended on clinical 
 characteristics of the participants, bivariate nonparametric (Spearman) correlations 
were calculated between the change in success rates with FES (compared with 
AFO) at week 26 and each of the following clinical scores: Modified Ashworth Scale 
(for ankle plantarflexors), vibration threshold (from the lateral malleolus), lower- 
extremity Motricity Index, lower-extremity Fugl-Meyer Assessment, Berg Balance 
Scale, and comfortable walking speed with the AFO at baseline. We used SPSS version 
15.0 (SPSS Inc, Chicago, Illinois) for all statistical analyses. The level of significance 
was set at p<05.
Results
Participants
The characteristics of the participants included in both cohorts are presented in 
table 1. Three participants were removed from the analysis. One participant (group 
I) dropped out of the study because of peroneal nerve damage after surgery, which 
had fully recovered after one-and-a-half year. One participant (group II) died prior 
to the first follow-up measurement, the cause of death being unrelated to the 
study. A third participant (group I) had severe calf muscle clonus in reaction to FES 
after the system activation. This clonus needed to be treated with botulinum toxin 
injections, which resulted in substantial protocol deviations with several missing 
follow-up measurements. In one participant (group II) the ActiGait implant failed 
after 26 weeks. Since sufficient follow-up data was obtained, this latter participant 
was included in the final analysis. Hence, a total of 19 participants from the two 
combined cohorts was analyzed. 
Obstacle avoidance success rates
There was no significant change in success rates over time and no significant inter - 
action between time and device (see table 2). Therefore, the factor time was removed 
from the model. Note that statistics were performed on angular transformed success 
rates, yet for clarity untransformed values are reported below and in the figures. 
 The GEE model revealed that success rates were on average 4.7% higher with 
FES than with AFO (55.4% vs. 50.7%, p=0.03). However, this device effect was not 
uniform across the three ARTs, as indicated by a significant interaction between 
device and ART (see figure 4). Post-hoc analysis showed a significant difference of 
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15% in favor of FES for ART 450-600 ms (p=0.03), a non-significant difference of 
10% for ART 300-450 ms (p=0.059), whereas no significant difference was observed 
for ART 150-300 ms (p=0.193). Success rates differed significantly between ARTs 
(p<0.001), indicating higher success rates for trials with longer ARTs (figure 4).
 The participants showed a wide range of individual differences in success rates 
between FES and AFO. At 26 weeks after system activation, differences between 
the devices ranged from -29% to 85%. Both Motricity Index (rs=-0.49, p=0.04) and 
Fugl-Meyer Assessment (rs=-0.47, p=0.05) scores of the paretic leg showed a 
moderately strong, negative correlation with the difference in success rate, 
indicating that participants with greater motor impairment had more benefits from 
FES (figure 5). Berg Balance Scale, Modified Ashworth Scale of plantar flexors, 
vibration threshold from the lateral malleolus,  and comfortable walking speed did 
not significantly correlate with individual differences in success rates between FES 
and AFO (respectively p=0.26, p=0.51 and p=0.67).
Table 1   Demographic and clinical characteristics of all participants (n=22) and 








Age (mean yrs ± SD) 47.4 ± 14.5 57.4 ± 9.6 54.4 ± 12.3
Body weight (mean kg ± SD) 80.5 ± 19.5 80.6 ± 12.2 83.3 ± 15.2
Body height (mean cm ± SD) 175.0 ± 7.6 177.3 ± 8.3 177.0 ± 7.2
Time since stroke (mean months ± SD) 67.7 ± 29.2 55.0 ± 49.8 59.9 ± 44.0
Sex (men/women) 5/5 8/4 14/5
Paretic side (left/right) 6/4 8/4 11/8
Type of stroke (ischemic, hemorrhagic) 8/2 9/3 14/5
Motricity index – paretic leg (median (range)) 69 (28-99) 78.5 (42-91) 77 (28-99)
Fugl-Meyer Assessment – paretic leg  
(median % (range))
64 (25-88) 72.1 (53-88) 71 (25-88)
Berg Balance Scale (median (range)) 52 (42-56) 54 (42-56) 53 (42-56)
Modified Ashworth Scale calf 
(median (range))
1 (0-3) 1 (0-2) 1 (0-2)
Vibration threshold paretic forefoot  
(median (range))
6 (0-8) 3.5 (0-8) 4 (0-8)
Vibration threshold paretic ankle 
(median (range))
5 (0-8) 3 (1-8) 4 (0-8)
Type of AFO used (fixed/hinged) 9/1 11/1 17/2
Baseline comfortable walking speed using 
AFO (mean m/s ± SD)




Figure 4 Obstacle avoidance success rates (percentages) with FES and AFO for different 
available response times (ARTs)
Figure 5 Relationship between Motricity Index of the paretic leg (x-axis) and difference in 
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Discussion
The aim of this study was to investigate the surplus value of an implanted peroneal 
FES system (Actigait®) regarding the capacity to avoid sudden obstacles while 
walking on a treadmill in people in with drop foot after stroke. As hypothesized, 
success rates of obstacle avoidance were higher when participants used their FES 
system compared to AFO, which effect was larger with longer available response 
times. There was not a significant (interaction) effect for assessment time indicating 
that differences in success rates could not be attributed to task-specific learning 
effects. In addition, participants with greater motor impairment of the paretic leg 
showed the greatest benefit from FES. 
 Since implanted FES is applied directly onto the peroneal motor nerve we 
expected it to provide a more precise, and therefore functionally better, stimulation 
of the foot dorsiflexors compared to surface-based systems with adhesive 
electrodes. However, the mean difference in obstacle avoidance success rates 
between implanted FES and AFO reported in this study (4.7%) did not exceed the 
effect size obtained using a surface-based FES system in a previous study (7.9%, van 
Swigchem et al. [44]). Both reports revealed modest but significant device effects 
on success rates in favour of FES, albeit somewhat smaller in the current report. 
Hence, this indirect comparison of effect sizes provides no indication that implanted 
FES might be superior to surface-based FES systems with regard to obstacle 
avoidance.
 In addition to the two studies mentioned above, demonstrating the surplus 
value of FES over AFO on gait adaptability under time pressure, other studies have 
compared the time to complete an overground obstacle course between peroneal 
FES and AFO. Our results are in line with those from a previous RCT that yielded 
faster obstacle course completion times with FES than AFO at long-term follow-up, 
indicating better functional capacity with FES [37]. In contrast, the lack of immediate 
Table 2   Estimated marginal means (standard error) in obstacle avoidance success 
rates (percentages) for Device and Time.
Group I (n=8) Group II (n=11) Total (n=19)
AFO FES AFO FES AFO FES
2 weeks 35.8 (8.2) 36.5 (7.6) 59.1 (9.1) 55.3 (7.0) 49.2 (6.9) 46.9 (5.7)
8 weeks 42.1 (5.7) 50.1 (7.0) 63.3 (6.6) 64.5 (5.6) 54.1 (5.2) 58.2 (4.7)
26 weeks 41.8 (6.7) 48.4 (6.7) 56.7 (6.1) 59.8 (7.6) 50.3 (4.9) 55.2 (5.4)
52 weeks 56.1 (4.3) 62.1 (6.2)
Overall 39.9 (4.8) 45.0 (6.4) 58.8 (5.5) 60.4 (4.9)
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surplus effects of FES on completion time as reported by Sheffler et al.[118]suggests 
that people with stroke need some time to adapt to walking with FES before they 
may experience its benefits on their gait adaptability. Taken together, there is 
growing evidence that people with stroke-related drop foot may particularly benefit 
from FES when performing challenging walking tasks that require adaptation of the 
gait pattern, whereas such benefits are less apparent during simple overground 
walking [43]. 
 The better avoidance success rates with FES than AFO were most evident in 
trials with longer ARTs (450-600ms). At short ARTs, people usually attempt to place 
the foot in front of the obstacle by quickly shortening their pre-crossing stride. This 
response greatly depends on the central nervous system’s processing time for 
making the visuomotor transformation, and on the degree of recruitment of 
upper-leg muscles [22, 122]. These processes are probably not impacted on by 
peroneal FES, which may explain the lack of differences between FES and AFO at 
ARTs of 150-300 ms. At longer ARTs, however, people commonly lengthen their 
crossing stride to land the foot behind the obstacle. Better success of enlarging the 
paretic crossing step with FES may indicate a more selective leg control during 
swing. However, in overground walking such benefits during swing phase have not 
been found for peroneal FES [36, 39, 116]. Alternatively, this movement of stride 
lengthening may have been facilitated by the increased ability for paretic ankle 
push-off, that we have previously reported with FES compared to AFO in the same 
group of participants [75, 116]. which also may explain the greater benefits of FES 
on avoidance success rates at longer ARTs. Yet, the exact mechanisms underlying 
the ART-dependent effects of FES need to be addressed in future research. 
 So far there is no consensus on which patients are most likely to benefit from 
peroneal FES [7]. In the present study, participants showed a wide range of 
differences in success rates between FES and AFO (i.e. -29% to 85%). Interestingly, 
and similar to our previous findings regarding surface-based FES[44], we found that 
people who had greater leg motor impairment (both reduced motor selectivity and 
muscle weakness) showed more benefit from implanted FES on their gait 
adaptability. Although the associations found in both studies were moderate, the 
consistency of these findings imparts confidence in their clinical significance.
 Despite pooling of the two study cohorts, obvious limitations of the current 
report are the limited sample size and the lack of a control group. Conducting 
larger (multicenter) controlled studies in this area is (almost) unfeasible given the 
type of intervention, the complexity of the experimental setup and data analysis, 
and the considerable costs. Under the given circumstances, we believe that our 
within-subjects design using repeated obstacle-avoidance assessments was the 
most optimal strategy for investigating differences between peroneal FES and AFO. 
We designed the experimental task as to mimic adaptations to the environmental 
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context during daily life walking, yet walking on a treadmill at a fixed speed does not 
allow natural adaptive behavior such as speeding up or slowing down. In future 
studies, gait adaptability under time pressure may be tested in a setup that resembles 
daily life more closely, which should also include dual tasking. Finally, it was not 
clinically verified whether the AFO worn throughout the study was optimal for each 
participant, but no participant expressed any AFO complaints.
 In conclusion, this report supports the idea that walking performance in a 
more complex walking environment, demanding quick gait adaptations, shows 
superiority of implanted peroneal FES over AFO. These findings also underline the 
importance of using gait assessments that require interaction with the environment, 
besides assessment of stationary walking, in community ambulators.
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Background: Benefits of peroneal functional electrical stimulation (pFES) over 
conventional care (CONV) in people with post-stroke drop foot may particularly 
emerge in environments that require continual gait adaptation. Such adaption is 
known to increase the attentional demands of gait.
Research questions: Is performance of a target stepping task more accurate and 
less attention demanding with pFES compared to CONV in people with post-stroke 
drop foot?
Methods: Thirteen people with an implanted pFES device participated in this 
observational study. Participants performed a continual stepping task with irregularly 
spaced targets on a self-paced treadmill, both as a single task and combined with 
an auditory Stroop task. Participants performed each task with pFES and CONV. 
The effects of Device (pFES, CONV), Task (single, dual) and Side (paretic, non-paretic) 
on stepping performance in the frontal and sagittal plane were tested based on the 
total error (E) of foot placement relative to the targets, using repeated measurements 
ANOVA. Differences between pFES and CONV on auditory Stroop task accuracy 
were assessed using a non-parametric Wilcoxon signed-rank test. Non-parametric 
correlations were calculated to associate changes in stepping performance with 
paretic leg motor function (Fugl-Meyer Assessment – leg score).
Results: Frontal-plane E was smaller with pFES compared to CONV (Δ=1.0cm, 
p=0.011) and tended to be generally larger in the dual-task condition (p=0.056). 
There was no effect of Side. In the sagittal plane, no effects of Device or Task were 
found, but E was generally larger on the paretic side compared to the non-paretic 
side (Δ=2.3cm, p=0.028). There were no interaction effects in either plane. E changes 
(pFES compared to CONV) were not significantly associated with leg motor function. 
Stroop task accuracy was not statistically different between pFES and CONV.
Significance: Implanted pFES may have benefits over CONV with regard to frontal- 
plane accuracy of a continual target stepping task, although the effect size is relatively 
small. This benefit seems to be independent of the performance of a concurrent 
attention-demanding task and may reflect better gait stability in the frontal plane, 
which is known to be a problem in people with stroke.
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Introduction
One of the most common gait impairments in people with chronic stroke is the 
inability to selectively activate the contralesional ankle dorsiflexors during the swing 
phase and early stance phase of the gait cycle. Particularly when calf muscle 
spasticity is low, this inability is often referred to as ‘drop foot’, requiring compensatory 
muscle activation at a more proximal level (e.g. increased hip flexion, circumduction). 
This compensatory gait pattern is inefficient, inflexible, and puts people with 
chronic stroke at risk of falling [23]. Conventional methods designed to reduce this 
‘drop foot’ (e.g. ankle-foot orthosis) do not prevent foot drop effectively or often 
restrict normal ankle motion, leaving many people with a drop foot unsatisfied [29]. 
An alternative for conventional treatment is peroneal functional electrical 
stimulation (pFES). With pFES, ankle dorsiflexors are electrically activated during the 
swing phase and early stance phase of the gait cycle, providing an almost normal 
foot elevation and loading [30]. Technological developments opened the door for 
implantable pFES systems, which offer precise muscle activation with minimal 
inconvenience to the user [32, 123]. User satisfaction with pFES is consistently high 
and several studies showed that people with stroke-related drop foot prefer pFES 
over their conventional device [26, 31, 75]. 
 Despite the subjective appreciation of pFES by many people with drop foot due 
to chronic stroke, objective evidence for the superiority of pFES over conventional 
treatment is still lacking. For instance, two recent meta-analyses showed that gross 
walking performance, in terms of walking speed and distance walked in 3 or 6 
minutes, was not significantly different between ankle-foot orthosis and pFES [43, 
124]. Yet, the test conditions in these assessments of walking speed and endurance 
(i.e. walking on perfectly even terrain without distraction) do not capture the 
intricacies of walking in daily life, and may thus lack sensitivity to demonstrate 
potential benefits of pFES for walking capacity. 
 Real-life walking typically involves adapting the gait pattern to the physical 
environment, while often attending to concurrent attention demanding tasks as 
well (e.g. having a conversation while walking in the forest). Previous studies have 
demonstrated profound gait adaptability impairments in people with stroke-related 
drop foot, such as delayed reaction times and poorer obstacle avoidance success 
rates [22, 125]. In addition, these individuals needed more time to regain their 
steady-state walking pattern following an obstacle avoidance maneuver [126]. 
Avoiding the obstacle also imposed a considerable attentional demand, as shown 
by substantial dual task costs when a secondary cognitive task was performed 
concurrently [120]. Interestingly, two previous studies by our group demonstrated 
better obstacle avoidance performance with external [44] and implanted [127] pFES 
compared to a conventional ankle-foot orthosis. These findings may point at a 
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potential surplus value of pFES during adaptive gait, yet the reported effects sizes 
were rather modest and beneficial effects of pFES were limited to those with 
relatively low lower-extremity motor function.
 In this study, we aimed to provide further insight into the potential benefits of 
pFES for gait adaptability in a group of people with drop foot after a stroke who 
were using an implanted pFES system. We used a task that involved continual 
gait adjustments to irregularly spaced stepping targets while walking on a treadmill, 
as imposing multiple stepping constraints (cf. a single constraint, as used in our 
previous work) is known to enhance contrasts in performance [128]. We hypothesized 
that the participants would perform the task more accurately while walking with 
pFES than with their conventional aid. In addition, we investigated whether walking 
with pFES could reduce the attentional demands of adaptive gait. The participants 
therefore performed the task both with and without a concurrent cognitive task. 
We hypothesized that performing both tasks simultaneously would result in lower 




Participants were recruited from a group of 24 people with a drop foot after chronic 
stroke who had been treated with the ActiGait® implantable pFES system (Neurodan, 
Denmark, Otto Bock Group, 2006) at the Radboud University Medical Center in 
Nijmegen. Inclusion criteria for the current study were (1) independent walking 
capacity for 10 minutes without a walking aid (e.g. stick, crutch, walker) and (2) a 
functioning ActiGait implant. 
 The primary researcher (FB) screened all patient files and contacted eligible 
people to ask if they were willing to participate. One person had died within a year 
after system implantation. Five candidates had too limited walking capacity to 
participate. In four people, the pFES system was no longer being used because 
of system failure (n=1), peroneal nerve damage (n=2), or dissatisfaction with the 
system (n=1). In three of those four cases, the pFES system had been explanted. 
One person was unwilling to participate. Hence, a total of 13 participants were 
invited for this study. At inclusion, the primary researcher (FB) obtained clinical 
scores as listed in table 1. The study was approved by the local medical-ethical 
committee and all participants gave their written informed consent before 
participation. 
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In this single visit observational study, each participant was tested using a continual 
stepping task with irregularly spaced targets on a self-paced treadmill, both as a 
single task and in combination with a secondary cognitive task (auditory Stroop task 
[129]). The order of the single-task and dual-task conditions was randomized. Each 
participant performed the two tasks both with peroneal FES (pFES) and with their 
conventional aid (CONV); the order of pFES and CONV assessments was balanced 
across participants to neutralize possible time (e.g. fatigue) effects.
Experimental protocol
Target stepping task 
Assessments were performed using the Gait Real-time Analysis Interactive Lab, or 
GRAIL (Motekforce Link Amsterdam, the Netherlands). The GRAIL is an instrumented 
dual-belt treadmill with a self-paced option and a synchronized Virtual Reality (VR) 
environment projected on a 180° semi-cylindrical screen and on the treadmill (see 
figure 1). A set of 25 reflective markers was placed on the subjects according to the 
manufacturers Human body model [130]. Positions of these reflective markers 
were collected with a 10-camera, 3D-movement analysis system (VICON, Oxford, 
United Kingdom) at a sampling rate of 100 Hz. Four reflective markers placed on 
the pelvis were used to trace the participant’s position on the treadmill, which the 
Table 1  Demographic and clinical characteristics of included participants
 (n=12)
Age (mean yrs ± SD) 62.8 ± 10.0
Time since stroke (mean yrs ± SD) 12.6 ± 7.8
Time since pFES implantation (mean yrs ± SD) 4.9 ± 1.5
Sex (men/women) 10/2
Paretic side (left/right) 7/5
Type of stroke (ischemic, hemorrhagic) 7/5
Conventional device (AFO/(high) sturdy shoes) 8/4
Fugl-Meyer Assessment – paretic leg score (0-28) (median (range)) 18 (16 - 27)
Berg Balance Scale (0-56) (median (range)) 54 (47 - 56)
Vibration threshold paretic forefoot (0-8) (median (range)) 3 (0 - 7)
Vibration threshold paretic ankle (0-8) (median (range)) 5 (0 - 8)
Passive ankle dorsiflexion with knee extended (°) (median (range)) -5 (-30 - 20)
Walking speed on 10-meter walk test (m/s) (mean ± SD) 1.02 ± 0.2
pFES= peroneal functional electrical stimulation; CONV= conventional; AFO= ankle-foot orthosis
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GRAIL system used to adjust the treadmill speed in the self-paced mode [131]. 
Maximum acceleration and deceleration of the treadmill were set at 0.25 m/s2.
 Before the start of the actual experiment, the participants performed a set of 
practice trials in which they learned to safely speed up and slow down on the 
self-paced treadmill and got familiar with the target stepping task. Only when 
participants were confidently able to walk on the self-paced treadmill, the actual 
experiment began. During the experiment, each trial was always preceded by a 
minute of familiarization to allow participants to get used to the treadmill and reach 
their comfortable walking speed. During this familiarization phase no stepping 
targets were projected and no auditory Stroop stimuli were presented. Trials ended 
after 150 strides. 
 We used a stepping task with irregularly spaced targets to impose continual 
adaptations in step length and/or width. Stepping stones were projected on the 
treadmill and served as targets for the participant to step on. Size of the targets 
were set to be 5 cm larger and 5 cm wider than the participants shoes. Target 
positions were based on spatiotemporal gait characteristics obtained during the 
last 15 seconds of the 1-minute familiarization phase (the reference stepping 
pattern). The distances between targets were varied randomly, with respect to the 
reference stepping pattern, in the mediolateral (max 5 cm) and anteroposterior 
(max 10% of participant’s step length) directions. Participants were instructed to 
place their feet as accurately as possible in the center of the targets. The sequence 
Figure 1  Experimental setup of the target stepping task. Targets were projected on the self- 
paced treadmill and presented in a synchronized Virtual Reality (VR) environment projected 
on a 180° semi-cylindrical screen.
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of targets were projected ahead on the cylindrical screen and the treadmill, allowing 
participants to anticipate upcoming steps. Participants wore a safety harness that 
was attached to a rail fixated onto the ceiling and they were allowed to grab the 
handrail if needed. 
Auditory Stroop task 
Subjects listened to the words “high” or “low” spoken in Dutch at a high or low pitch, 
presented in random order through headphones (Sennheiser, Wedemark, Germany) 
with an interstimulus-interval of 1.5 s. Subjects were instructed to respond as fast as 
possible by verbally indicating the pitch of the stimulus. For instance, the word 
“high” was presented at a high (congruent, correct response is ‘high’) or a low pitch 
(incongruent, correct response is ‘low’). Responses of the subjects were collected 
by the microphone attached to the headphone and recorded on a computer 
through an external audio interface (Creative Sound Blaster E5, Singapore). Prior to 
the actual experiment, the participants were allowed to practice the auditory Stroop 
task for three minutes, while seated.
Data analysis 
Foot placement was obtained from the reflective markers on the foot during 
midstance. Average walking speed over the trial was calculated by dividing the 
distance walked during a trial divided by the time to complete the trial. 
 Performance on the target stepping task was assessed for the frontal and 
sagittal planes separately by calculation of the total error (E), i.e. a combined 
measure of constant error (CE) and variable error (VE), of foot placement [132]. 
Stepping precision, or constant error (CE), was expressed as the distance between 
the mean foot position (averaged over all steps) and the target, and therefore 
represents overall bias (see left figure in figure 2). Stepping consistency, or variable 
error (VE), was expressed as the average deviation of all steps relative to the mean 
foot position, representing step variability (see right figure in figure 2). Total error (E), 
represents an overall measure of how successful the participant was in performing 
the target stepping task: 
E =   (VE2 + CE2)
Recorded responses to the auditory Stroop task stimuli were checked and scored 
offline. Responses that were not within 1.5 s of the stimuli were scored as false. 
Stroop task accuracy was expressed as the percentage of correctly given answers 




Total error was tested using a three-way repeated-measurements ANOVA with 
Device (pFES, CONV), Task (single, dual) and Side (paretic, non-paretic) as within- 
subject factors. Differences between pFES and CONV on auditory Stroop task 
accuracy were assessed using a non-parametric Wilcoxon signed-rank test. 
 In our previous work on obstacle avoidance, participants with greater motor 
impairment showed the greatest benefit from pFES [44, 127]. To investigate whether 
the expected benefits of pFES on target stepping performance depended on lower- 
xtremity motor function, bivariate non-parametric (Spearman) correlations were 
calculated between the E changes (pFES compared to CONV, averaged over both 
Side and Task) and lower-extremity Fugl-Meyer Assessment (FMA) scores of the 
paretic leg. We used SPSS version 15.0 (SPSS Inc, Chicago, Illinois) for all statistical 
analyses. The level of significance was set at p<0.05.
Figure 2  Explanation of the calculated errors, using artificial data: black circles represent the 
target center. Red open circles represent midfoot positions of individual steps. Red filled circles 
represent the mean position of midfoot over all individual steps. Constant error is expressed 
as the distance between the mean foot position (red filled circle) and the target (black circle), 
and represents overall bias. Variable error is expressed as the average absolute deviation of all 
steps (red open circles) relative to the mean foot position (red filled circle), representing step 
variability.
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Results
For one participant the dual task condition was not available due to technical issues; 
data from this participant were discarded from the analyses. At inclusion, participants 
were between three years and eight years after implantation of their pFES system. 
Ten out of the remaining twelve participants preferred to use their implanted pFES 
system (almost) every day. One participant preferred to use a conventional device 
in daily life, whereas another participant indicated to use both a conventional device 
and pFES in an equal manner. Eight out of the twelve participants used an AFO as 
conventional device. The remaining four participants did not use anything other 
than (high) sturdy footwear as a form of conventional care to reduce foot drop. The 
characteristics of the participants are presented in table 1. 
Target stepping task
All participants were able to safely complete the target stepping task trials. Walking 
speed did not differ between devices or between single- and dual-task conditions 
(see table 2). Because gait speed remained constant across all conditions, any 
significant change in total error was considered not to be the result from a 
speed-accuracy trade-off. 
Frontal-plane E was, 1 cm significantly (Device; F(1,11)=9.225, p=.011) smaller with 
pFES (E=4.4 ± 1.8 cm) than with CONV (E=5.4 ± 2.2 cm). Frontal-plane E tended to 
be larger in the dual-task condition, however, this difference did not reach 
significance (Task: F(1,11)=4.566, p=0.056). There was no main effect of Side, nor 
were there any interaction effects for frontal-plane E (figure 3). 
Table 2  Gait speed for different task conditions and devices (n=12)
Single task Dual task Statistics












pFES = implanted peroneal functional electrical stimulation; CONV= conventional device; Statistics 




Sagittal-plane E was not significantly different between pFES (E=10.1 ± 5.8 cm) and 
CONV (E=11.4 ± 6.4 cm) (Device; F(1,11)=1.917, p=0.194) and was not affected by 
dual-task performance (Task: F(1,11)=1.495, p=0.247). Sagittal-plane E was 2.3 cm 
larger on the paretic side (E=11.9 ± 6.6 cm) compared to the non-paretic side 
(E=9.6 ± 5.5 cm), which difference was significant (Side; F(1,11)=6.404, p=0.028). 
No interaction effects were found for sagittal-plane E (figure 4).
 FMA scores of the paretic leg did not significantly correlate with E changes 
(pFES compared to CONV) in the frontal plane (rs=-0.05, p=0.89) or the sagittal 
plane (rs=-0.07, p=0.83). 
Stroop task accuracy
For one participant the responses on the auditory Stroop tasks were inaudible due 
to speech problems (i.e. dysarthria) and could not be scored. For the remaining 11 
participants response accuracy varied between 16% and 98%. Two participants had 
accuracy scores lower than 50%, because they were unable to respond, in time or 
at all, to the auditory stimulus for more than half of the provided stimuli. Median 
accuracy scores were 88.2% with pFES and 73.6% with CONV (p =0.424).
Figure 3  Total error in the frontal plane (mean ± SD) (n=12). Significant difference between 
CONV and pFES, p=0.011.
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In this study we evaluated the potential surplus value of implanted peroneal 
functional electrical stimulation (pFES) compared to conventional care (CONV) for 
gait adaptability in people with drop foot after chronic stroke. We used a target 
stepping task that required continual adaptations of the gait pattern, which was 
performed both as a single task and while concurrently performing a secondary 
cognitive task. Regardless of the task condition, the participants positioned their 
steps more accurately with pFES than with CONV, albeit only significantly in the 
frontal plane. Moreover, mediolateral foot placement tended to be less accurate in 
the dual-task compared to the single-task condition, but this was independent of 
device. Poorer paretic than non-paretic step accuracy was only observed in the 
sagittal plane (anteroposterior direction) and was independent of both device and 
task condition.
Effects of pFES on gait adaptability
This study supports the idea that the capacity to adapt the gait pattern to environmental 
constraints may benefit from pFES compared to CONV in people with stroke-related 
drop foot. The current findings are in line with previous studies from our group in which 
pFES was compared with an ankle-foot orthosis (AFO) using an obstacle avoidance 
Figure 4  Total error in the sagittal plane (mean ± SD) (n=12). Significant difference between 
paretic and non-paretic side, p=0.028.
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task. These previous studies demonstrated a moderately better capacity with pFES 
when avoiding a sudden obstacle. However, these benefits were mainly attributable to 
people with relatively low motor function of the paretic leg [44, 127]. Compared to 
the good responders in our previous study [127] who had FMA scores of the paretic 
leg between 7 and 17, our present sample consisted of people with relatively good 
leg motor function (FMA scores between 16 -27 out of a maximum 28 points). 
Within the current study there was no significant association between changes in 
step accuracy and paretic leg motor function. Hence, our present findings indicate 
that the benefits of pFES for gait adaptability may also pertain to those with relatively 
good paretic leg motor function. Possibly, gait adaptability needed to be challenged 
by applying continual stepping constraints, as opposed to the single constraint 
used in our previous work (i.e. discrete obstacle avoidance task), in order to reveal 
all benefits of pFES. Indeed, it is known that applying multiple (vs. single) stepping 
constraints can enhance contrasts in gait adaptability performance [128]. Importantly, 
such conditions mimic the kind of challenge that people are faced with in their 
daily lives when walking outdoors over uneven or cluttered terrain. 
 Step adaptations were performed more accurately with pFES than with CONV, 
however only significantly in the frontal plane. During walking, step-by-step medio - 
lateral control of foot placement is pivotal for maintaining frontal-plane balance 
[16]. Hence, any mediolateral deviation between actual and optimal foot placement 
may jeopardize the control of lateral center-of-mass movements and, thus, dynamic 
postural stability. This is even more true for people with stroke, who often have 
impaired dynamic balance particularly in the frontal plane [133]. Indeed, a previous 
study found that people with stroke with relatively good paretic leg motor function 
were well capable of adjusting their steps in the mediolateral direction when their 
balance was supported, but that these stepping adjustments were aborted in the 
absence of balance support, presumably in anticipation of a potential balance loss 
[17]. As pFES does not restrict stabilizing ankle movements during the stance phase 
(in contrast to an AFO), it may have permitted our participants to more accurately 
follow the mediolateral target shifts by enabling better dynamic balance control. 
Indeed, in our previous work we found that walking with pFES was perceived as 
more stable than walking with an AFO [31]. It must be mentioned, though, that 25% 
of the participants in the present study did not use an AFO. Regrettably, our sample 
was too small to determine whether the results differed between subjects with and 
without an AFO. Hence, further research should focus on the question if (and how) 
pFES improves dynamic postural stability during gait, and whether such effects may 
explain the observed gains in gait adaptability.
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Attentional demands of target stepping 
Congruent with our hypothesis, mediolateral target stepping became less accurate 
when a secondary cognitive task had to be performed simultaneously (albeit only 
bordering significance). This is in line with previous work showing that people with 
stroke presented with considerably greater dual-task costs during obstacle crossing 
compared with healthy controls and compared with non-obstructed steps [120, 
134], which suggests that the cognitive cost of walking is particularly high during 
step adjustments. Yet, in contrast to our hypothesis, we found no evidence that 
dual-task costs were relatively low when making continual step adjustments with 
implanted pFES compared to CONV. Despite the benefits of pFES for target stepping 
performance per se, the addition of a cognitive task neither enlarged the difference 
in step accuracy between devices, nor did it induce differences in Stroop task 
performance. Apparently, pFES does not have a clear advantage over CONV in 
terms of the attentional demands of step-by-step adjustments. 
Study limitations and recommendations
The surplus value of pFES for gait adaptability reported in this study was found – on 
average –several years after system implantation. At inclusion, the vast majority of 
the participants were still satisfied with their implanted pFES system and used it 
(nearly) every day. The fact that most participants hardly used their conventional 
device in daily life could potentially have biased our results. Yet, it is believed that 
conventional devices such as an AFO have an immediate orthotic effect on gait and 
that functional outcomes with a conventional device do not deteriorate over a 
period where the device is not (or less) used [44, 116, 127]. 
 Another limitation of this study is the small sample size, yielding low statistical 
power. The small sample size follows directly from the limited number of people 
known at our center (24 in total) and in general (approximately 200, with the largest 
cohort reported n=45 [135]) who use this unique implanted pFES system. 
 We believe that the presently used tasks reflect important abilities of daily-life 
walking, but it is unknown whether the observed modest difference between pFES 
and CONV truly represents a clinically meaningful gain. Yet, the present findings, 
as well as those from earlier studies, advocate the inclusion of challenging walking 
tasks in future (controlled) trials on the effects of pFES in people with drop foot after 
stroke.
Conclusions
This study supports the notion that implanted pFES may have functional benefits 
over CONV in people with drop foot after chronic stroke in complex environments 
that require continual gait adaptations. Our results show more accurate mediolateral 
foot placement with pFES, which could be indicative of better dynamic balance 
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control. With the continual stepping constraints imposed in our study, we now show 
that surplus value of pFES over CONV may also pertain to people with relatively 
good paretic leg motor function. Despite the benefits in target stepping performance, 
pFES did not have a clear advantage over CONV in terms of the attentional demands 
of step-by-step adjustments. The findings of this study generally underline the 
importance of using gait assessments that require (multiple) stepping constraints in 
community ambulators.
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Objective: Changes in muscle architecture after stroke are usually assessed by 
investigating inter-limb differences. As a result bilateral changes of muscle architecture 
might be missed. Our aim was to investigate whether bilateral architectural changes 
in skeletal muscle can be detected in chronic, physically active stroke patients using 
quantitative muscle ultrasound (QMUS).
Methods: Twenty-eight patients (mean time since stroke 5.2 years, median Brunnström 
stage 4) were recruited. QMUS images were obtained bilaterally from 2 arm and 
4 leg muscles. Corrected echogenicity (muscle ultrasound grayvalue) and muscle 
thickness were compared to reference values obtained from healthy subjects. 
Correlations of muscle changes with demographic, clinical and neurophysiological 
characteristics were explored. 
Results: Out of 6 muscles, a significant increase in mean echogenicity was found 
in 4 paretic and 3 non-paretic side muscles. Significant decreases in mean muscle 
thickness were found in 2 paretic side muscles and 1 non-paretic side muscle. 
Echogenicity of the medial gastrocnemius correlated moderately with walking 
speed (inversely) and time since stroke. 
Conclusions: This study showed that QMUS is a feasible technique to investigate 
architectural changes in skeletal muscles in the chronic phase of stroke and that 
abnormalities can be found in muscles on both the hemiparetic and non-paretic 
side. 
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Introduction
Stroke is primarily regarded as a central nervous system (CNS) disorder, but post- 
stroke structural changes in skeletal muscles have been described. Imaging techniques 
such as Dual Energy X-ray Absorptiometry (DEXA) and Computed Tomography (CT) 
have revealed atrophy in several paretic side muscles of stroke survivors [53, 54]. 
In addition to atrophy, increased intramuscular fat has been found in hemiparetic 
muscles of post-stroke patients [50-52]. These changes of muscle composition 
after stroke show similarities to the adaptations seen in aging [49, 136-138] and in 
neuromuscular disorders (NMD) [139]. Disuse is often reported as a primary cause 
of the structural changes, especially of muscle atrophy, following stroke [50, 53, 54, 
140]. However, it is increasingly proposed that post-stroke alterations of the lower 
motor neuron (LMN) might be involved in the structural changes of paretic side 
muscles [49, 54]. 
 Changes of the LMN and, consequently, of the muscle architecture that 
emerge following a stroke may occur through a phenomenon called transsynaptic 
degeneration [49, 54, 141-144]. Reduced input of the upper motor neuron causes 
transsynaptic degeneration of the motor nerves, resulting in (partial) denervation of 
the muscle. Support for this theory has been found through electromyography 
(EMG) in a variety of muscles. Shortly after stroke onset a rapid drop in functional 
motor units of paretic side muscles has been observed [45, 48]. Particularly high 
threshold motor units are affected, which points towards a specific loss of type II 
muscle fibers [145]. Weeks to months after the onset of stroke, motor unit loss and 
spontaneous muscle activity have been found in the hemiparetic side muscles 
suggesting LMN dysfunction [45-47]. Muscle fibers of dysfunctional motor units 
may eventually be reinnervated by the remaining motor nerve fibers, typically 
favoring type I fiber clusters [49]. Type I muscle fibers show a relatively high 
intramuscular fat content. Besides, it is well known that denervation of muscles 
results in infiltration of fibrous tissue and fat.  
 Following stroke, muscle architectural changes and LMN degeneration have 
mostly been studied separately and often these changes were studied by assessing 
inter-limb differences. Importantly, by focusing on inter-limb differences, bilateral 
changes might be missed, which results in an underestimation of the impact of 
stroke on the muscles. Quantitative muscle ultrasound (QMUS) can be a suitable 
technique to systematically investigate bilateral changes in muscle architecture. 
Changes in muscle morphology as a result of NMD have been studied successfully 
with QMUS [146]. In CNS disorders this method has only been used in patients with 
amyotrophic lateral sclerosis [147] focused on LMN involvement, but not yet in 
people with stroke. Grayscale analysis, i.e. quantifying ultrasonographically the 
amount of interspersion of muscle fibers with fibrous tissue and fat, is a robust, 
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patient-friendly, non-invasive clinical technique with a high inter-observer agreement 
that has good clinical validity in detecting neuromuscular pathology [148]. QMUS 
allows comparison of both the paretic side and non-paretic side muscles with 
reference values, corrected for sex, age and weight, obtained from healthy subjects 
[136, 149]. 
 With this study we wanted to determine the utility of QMUS in stroke and assess 
whether it can detect structural changes in skeletal muscles in the chronic phase. 
We expected to see decreased muscle thickness and increased echogenicity, i.e. 
increased mean grayscale values, in the paretic side limb compared to the 
non-paretic side muscles as well as abnormalities of both sides compared to 
reference values. We also explored possible correlations of QMUS findings with 
clinical (time post stroke, body mass index, walking speed, physical activity) and 
neurophysiological (compound motor action potentials) characteristics. If QMUS is 
able to detect muscle adaptations in the chronic phase of stroke, it might be a pa-
tient-friendly biomarker for muscle function and muscular integrity and a way to 
monitor recovery and effects of therapy. 
Methods
Patients
All patients who were enrolled in a study evaluating the effects of implanted functional 
electrical stimulation (FES) on ambulation and for whom QMUS measurements 
were available at baseline were eligible for this cross-sectional study. This group of 
participants will be referred to as ‘FES group’. Only baseline, preoperative, data of 
the FES group was used in this study. Additional participants were recruited from 
those who visited the outpatient rehabilitation department of our hospital for gait 
problems after stroke. Inclusion criteria were: (1) having sustained a supratentorial 
stroke at least six months ago, and (2) the ability to walk at least 10 meters with or 
without walking aid(s). Subjects were excluded if: (1) they had a history of (poly-)
neuropathy or (poly-)radiculopathy, or (2) they were morbidly obese (body mass 
index >40), as the latter can preclude reliable QMUS measurements by attenuation 
of the ultrasound beam. Patients gave their informed consent and the study was 
approved by the local medical ethics committee.
Measurements
Quantitative muscle ultrasound
The mean ultrasound grayvalue of a certain tissue is determined by the amount and 
amplitude of the sound wave reflection and is called echogenicity. Interspersion of 
muscle fibers with fat and fibrous tissue as a result of disease or aging is responsible 
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for an increase in echogenicity [137, 138, 150, 151], resulting in a whiter appearance 
of the muscles on the screen (see figure 1 for an example). Using a fixed scanning 
protocol, all measurements were performed with a Philips IU 22 ultrasound machine 
(Philips Healthcare Systems, Best, The Netherlands) and a broadband linear 5 to 
17 MHz transducer. The system was set at: gain 70dB, compression 55, time gain in 
neutral position and focal zone of 1.0 to 2.5 cm depth. System settings were kept 
constant throughout all measurements and no additional image enhancements 
were applied. Muscles investigated were biceps brachii, forearm flexors, rectus 
femoris, medial head of the gastrocnemius, tibialis anterior and extensor digitorum 
brevis. All muscles were assessed bilaterally. Muscle ultrasound was measured at a 
predefined site for each muscle corresponding to the maximum muscle belly 
thickness, as has been previously described [152]. Muscle ultrasound was obtained 
three times for each muscle, while pressure on the skin was avoided and relaxation 
of the muscles was assured as well as possible. Digital images were stored off-line 
as DICOM files for further analysis. Mean echogenicity and thickness of separate 
muscles on the paretic and non-paretic side were calculated using proprietary 
Qumia software [153-156]. This software also compares grayscale values to reference 
values corrected for age, sex, and weight, which differences are expressed as z-scores 
(i.e. the number of standard deviations (SD) from the mean). Thus, a positive z-score 
for echogenicity is considered worsening of muscle quality, whereas a positive 
z-score in muscle thickness is considered improvement of muscle trophic status. 
Reference values are specific for a system and its system settings. The reference 
values used in this study were obtained from the previously mentioned studies 
(Arts et al. , 2010, Verhulst et al. , 2011).
Figure 1  Example of paretic side (left panel) and non-paretic side (right panel) tibialis anterior. 
Echogenicity of the paretic side tibialis anterior muscle appears whiter (more echodense) on 
the screen, indicating interspersion of intramuscular fat and fibrous tissue.
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Demographic and clinical characteristics
Age, sex, time since stroke, body mass index, lower extremity Motricity Index [157], 
Brunnström stage [158, 159], comfortable walking speed, and physical activity were 
obtained at inclusion. The body mass index was calculated by dividing body mass 
(kg) by the square of body length (m). Comfortable walking speed was assessed on 
a 10 meter walkway by a physician using a stopwatch. Physical activity was registered 
by means of a Digi-Walker SW-650 pedometer (Yamax Corporation, Tokyo, Japan) 
counting the amount of daily steps averaged over a period of 7 days. This last 
measure was only available for the participants of the FES group. Only baseline, 
preoperative, data of the FES group was used in this study.
Neurophysiological characteristics
For the evaluation of peripheral motor nerve function the compound motor action 
potentials (CMAPs) from the tibialis anterior muscles were bilaterally obtained by 
stimulation of the common peroneal nerve, dorsal to the head of the fibula. This 
measure was only available for the participants of the FES group as part of a 
longitudinal study. In this group of participants neurophysiological data was 
available only for the common peroneal nerve, as this was the (stimulated) nerve 
under evaluation. Surface EMG electrodes (1 cm diameter) were placed on the 
muscle belly and muscle tendon of the tibialis anterior muscle. Ground electrodes 
were placed between the head of the fibula and the muscle belly electrode. 
Peak-to-peak CMAP amplitude as well as area under the curve after rectification of 
the raw signal were extracted from data using Matlab 2010b (The Mathworks Inc. 
Natick, Massachusetts). Only baseline, preoperative, data of the FES group was 
used in this study.
Statistical analysis
To test whether group means of echogenicity and muscle thickness were different 
from normal values, a one sample t-test (test value: µ=0) was performed. Whether 
muscle characteristics of the paretic side differed from the non-paretic side was 
assessed using a two-sample paired t-test. Level of significance was set at p ≤ 0.05. 
In addition, echogenicity and thickness of individual muscles were calculated and 
considered abnormal if the z-score exceeded 2.0 or -2.0. 
 Associations of echogenicity of the lower extremity muscles with time since stroke, 
body mass index, comfortable walking speed, physical activity and tibialis anterior 
CMAPs were tested using Pearson’s correlation coefficient (p<0.05). All statistical 
analyses were performed with SPSS for Windows 19.0 (SPSS, Inc., Chicago, Illinois).
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Twenty-eight participants were included in this cross-sectional study of which 13 
belonged to the FES group. Group characteristics are presented in table 1.
Outcomes
Echogenicity
Echogenicity was normally distributed in all of the assessed muscles except the 
biceps brachii on the non-paretic side. At group level the mean echogenicity of all 
the assessed muscles was significantly different from the reference values, except 
for the medial gastrocnemius (92%, table 2) on the non-paretic side. Echogenicity 
was bilaterally increased in the biceps brachii, forearm flexors, and in the tibialis 
anterior. In addition, the medial head of the paretic side gastrocnemius showed 
increased echogenicity. An average decrease in echogenicity was found for the 
rectus femoris and extensor digitorum brevis on both the hemiparetic and the 
non-paretic side.
 At an individual level, 31 of 166 paretic side muscles (19%) exceeded a z-score 
of 2.0. These abnormally high scores for echogenicity were mostly found for the 
paretic side forearm flexors (46% of the participants), biceps brachii (29% of the 
participants) and medial head of the gastrocnemius (29% of the participants). Eight 
out of 166 paretic side muscles (5%) exceeded the z-score of -2.0. These abnormally 
low scores for echogenicity were found particularly for the paretic side rectus 
femoris (25% of the participants).




N 28 13 15
Age;  mean yrs (SD) 58.7 (10) 56.1 (10.2) 61 (9.6)
Sex; male/female 20/8 10/3 10/5
Affected side; left/right 15/13 8/5 7/8
Type of stroke; ischaemic/ haemorrhagic/ unknown 22/5/1 9/4/0 13/1/1
Years after stroke; mean yrs (SD) 5.2 (4.4) 5.3 (4.3) 5.1 (4.7)
BMI; mean kg/m2(SD) 27.2 (4) 26.4 (3.4) 27.8 (4.4)
Brunnström stage (1-6); median score (range) 4 (3-5) 5 (4-5) 4 (3-5)
Motricity Index (0-100): median score (range) 67 (33-91) 72 (42–91) 64 (33-75)
Step count; number of steps daily (SD) 5349 (2558) -
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 On the non-paretic side 12 of 166 individual muscles (7%) exceeded a z-score 
of 2.0. These abnormally echodense muscles were mostly forearm flexors (25% of 
the participants). Sixteen out of 166 non-paretic side muscles (10%) exceeded the 
z-score of -2.0. These abnormally echolucent muscles were mostly rectus femoris 
muscles (46% of the participants).
 Compared to the non-paretic side, mean echogenicity was significantly higher 
on the paretic side in 4 of the 6 muscles (67%): biceps brachii, forearm flexors, 
medial head of gastrocnemius and extensor digitorum brevis. The largest mean 
difference between paretic side and non-paretic side echogenicity was found for 
the medial head of the gastrocnemius (mean z-score 1.56 on the paretic side vs. 
0.09 on the non-paretic side). Figure 2 depicts an overview of the significant 
differences in mean echogenicity of the paretic side muscles compared to reference 
values as well as to non-paretic side muscles. 
Figure 2  Mean echogenicity of 6 muscles expressed in z-scores. NP = Non-paretic side, 
P = Paretic side. Left panel: Colored muscles are significantly different from reference values. 
Right panel: Colored muscles are significantly different between paretic and non-paretic side. 













A   P and NP vs reference values B   ∆ P vs NP




Muscle thickness was normally distributed in all of the assessed muscles except the 
biceps brachii and the forearm flexors on the paretic side. At group level the mean 
muscle thickness was significantly different from reference values in 5 of the 12 
tested muscles (42%, table 3). On the paretic side muscle thickness was significantly 
smaller for the medial head of the gastrocnemius and the extensor digitorum 
brevis. On the non-paretic side the extensor digitorum brevis was also found to be 
smaller, whereas the forearm flexors and the biceps brachii showed an average 
increase in muscle thickness.
 At an individual level, 27 of 166 paretic side muscles (16%) exceeded the z-score 
of -2.0. These atrophied muscles were mostly the medial head of the gastrocnemius 
(36% of the participants), rectus femoris (18% of the participants), extensor digitorum 
brevis (15% of the participants) and the forearm flexors (14% of the participants). 
Figure 3: Mean muscle thickness of 6 muscles expressed in z-scores. NP = Non-paretic side, 
P = Paretic side. Left panel: Colored muscles are significantly different from reference values. 
Right panel: Colored muscles are significantly different between paretic and non-paretic side. 
Note: negative z-scores indicate muscle atrophy.
A   P and NP vs reference values                                   B   ∆ P vs NP
































































































































































































































































































































































































































































































































































































































































































































































Three out of 166 paretic side muscles (2%) exceeded the z-score of 2.0. On the 
non-paretic side 11 individual muscles (7%) exceeded the z-score of -2.0. Most of 
these atrophied muscles were the medial gastrocnemius (18% of the participants) 
and the extensor digitorum brevis (12% of the participants). Fifteen out of 166 paretic 
side muscles (9%) exceeded the z-score of 2.0. These hypertrophic muscles were 
mostly the forearm flexors (25% of the participants), the biceps brachii (11% of the 
participants) and the rectus femoris (11% of the participants). 
 Compared to the non-paretic side, mean muscle thickness on the paretic side 
was significantly decreased in 4 of the 6 muscles (67%): biceps brachii, forearm 
flexors, rectus femoris and the medial gastrocnemius. The largest difference between 
the paretic side and non-paretic side was found for the forearm flexors (mean 
z-score -0.24 on the paretic side vs. 1.24 on the non-paretic side). Figure 3 depicts 
an overview of the significant differences in mean muscle thickness of the paretic 
side muscles compared to reference values as well as to non-paretic side muscles.
Table 4   Correlations (Pearson’s r) of echogenicity of lower limb muscles with 

































































RF, rectus femoris. GM, medial head of the gastrocnemius. TA, tibialis anterior. EDB, extensor digitorum 
brevis. Significant correlations are indicated in bold.
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Associations
Correlations between echogenicity of lower limb muscles with clinical and neuro-
physiological characteristics are presented in table 4. We found two significant, 
moderate correlations, both for the medial head of the gastrocnemius. Time since 
stroke was positively correlated with the paretic side gastrocnemius (r=0.57, p<0.01) 
and comfortable walking speed was negatively correlated with the non-paretic side 
gastrocnemius (r=-0.40, p=0.04).
Discussion
QMUS is a suitable method for investigation of skeletal muscle thickness and 
echogenicity in people with stroke since it is a portable, patient friendly method 
that has been validated for neuromuscular abnormalities. Furthermore, our results 
indicate that QMUS provides additional information on architectural changes after 
a stroke, compared to studies that merely assessed inter-limb differences. Recently, 
Picelli et al. used muscle ultrasound to examine echogenicity of the gastrocnemius 
muscle in people with stroke [160]. These investigators, however, used visual 
grayscale analysis although it is known that quantitative grayscale analysis is a more 
sensitive method and more appropriate for multi-muscle assessment [148]. Our 
results confirm the findings obtained with computed tomography that muscles on 
the paretic side show more atrophy, fatty infiltration and fibrous tissue compared to 
the non-paretic side [50-54]. More importantly, we found that changes in muscle 
architecture are not solely restricted to the muscles on the paretic side. When 
compared to reference values obtained from healthy people, both paretic and 
non-paretic side muscles showed deviations at a group level. Four out of 6 paretic 
side muscles showed an increased echogenicity at group level: biceps brachii, 
forearm flexors, tibialis anterior and medial gastrocnemius. Individual analysis 
indicated that for 3 of these 4 muscles (biceps brachii, forearm flexors, and medial 
gastrocnemius) the percentages of abnormally high echogenicity were larger than 
25%, which is well above chance. Remarkably, at group level, mean echogenicity 
was increased also in 3 non-paretic side muscles (biceps brachii, forearm flexors 
and tibialis anterior). At an individual level, the non-paretic side forearm flexors were 
the only muscle group showing abnormally increased echogenicity well above 
chance level (25%). In contrast, compared to reference values, the rectus femoris 
and extensor digitorum brevis muscles showed a significant decrease in echo - 
genicity on both the paretic and non-paretic side, but individual analysis yielded 
that this decrease was only well above chance for the rectus femoris (25% and 
46%, respectively). A decrease in echogenicity of the extensor digitorum brevis and 
rectus femoris could theoretically be due to compensatory hypertrophy, however, 
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since muscle thickness did not increase for these muscles we do not have an 
explanation for this finding. In general, abnormal muscle thickness was less prominent 
than abnormalities in echogenicity. Mainly the medial gastrocnemius on the paretic 
side showed clear atrophy compared to reference values at group level (and in 36% 
of the individual cases), whereas the non-paretic side forearm flexors showed 
substantial hypertrophy at group level (and in 25% of the cases).
 It is well known that infiltration of fat and fibrous tissue in skeletal muscle 
increases with age, weight [136], disuse [50] and denervation [161]. It is unlikely that 
the increases in mean echogenicity seen in this study are due to age or obesity, 
since the calculated echogenicity was corrected for age and weight. Disuse atrophy 
is often regarded as an underlying cause for increased fatty infiltration in muscles 
of people with stroke. However, decrease in muscle thickness was not consistently 
related to increase in muscle echogenicity. Where on the paretic side increased 
echogenicity of the medial gastrocnemius coincided with muscle atrophy, echo - 
density of the forearm flexors on the non-paretic side was accompanied by muscle 
hypertrophy. As hypertrophy of the non-paretic side forearm flexors is most likely 
caused by compensatory overuse of the non-paretic upper limb, the observed 
increase in echogenicity cannot be explained by disuse. With regard to the paretic 
side, besides LMN involvement, disuse may still play a role in the causation of 
increased echogenicity, despite absence of significant muscle atrophy in the biceps 
brachii and forearm flexors. Indeed, muscle volume is not the only criterion for 
muscle (dis)use, particularly with regard to spastic muscles that are often activated 
involuntarily. In addition, the medial gastrocnemius did show a combination of 
muscle atrophy and echodensity, which is coherent with the notion that a substantial 
proportion of our patients (38%) did not pass the 5000 steps per day upper limit of 
a sedentary lifestyle according to Tudor-Locke [162]. Moreover, echogenicity of the 
non-paretic side gastrocnemius muscle showed a significant, negative correlation 
with comfortable walking speed, suggesting some relationship with physical inactivity. 
However, given the multiple associations tested in this study, this correlation should 
be interpreted with caution. 
 While transsynaptic degeneration of lower motor neurons on the paretic side 
can readily be understood based on the predominance of crossed corticospinal 
neurons innervating the extremities, it is much harder to understand that it may 
explain LMN degeneration on the non-paretic side. Indeed, merely about 10% of 
the direct corticospinal connections to the motorneurons in the spinal cord remain 
uncrossed, of which the majority innervate the trunk and shoulder/pelvic girdle 
muscles situated close to the long axis of the body [163]. Consistent with this notion, 
so far, electrophysiological investigations of LMN function did not reveal denervation 
on the ipsilesional body side following stroke [48, 143]. Hence, other factors might 
play a role in the increased echogenicity of ipsilesional forearm flexors as observed 
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in this study, such as nutrition [164], use of medication [165] and the possibility that 
our subjects may already have had an abnormally high echogenicity in some 
skeletal muscles prior to their stroke due to metabolic disorder. Interestingly, a 
trend towards increased level of tumor necrosis factor-alpha (TNFα) has been found 
in the non-paretic thigh after stroke [166]. This raises the possibility that more 
diffuse inflammatory pathway activation is present following stroke, causing 
bilateral changes of muscle architecture. Unlike Picelli et al., we were unable to find 
a significant correlation between reduced CMAPs and increased echogenicity 
[160]. Apart from the limited number of subjects, the absence of a significant 
association in our study might be caused by the fact that we tested the participants 
rather late (minimally 6 months) after stroke. Reduced CMAPs in the acute phase 
have been found to normalize in the chronic phase after stroke [47], because of 
collateral sprouting with full reinnervation of the muscle by the remaining motor 
axons. 
Study limitations
In this study a limited number of muscles were tested in a relatively small and 
specific group of patients after stroke who were physically active, but who had a 
reduced ambulatory capacity. Thus, our findings cannot be generalized to the 
entire stroke population. We excluded participants with a known peripheral nerve 
deficit because of its effect on echogenicity. Furthermore, participants with obesity 
were excluded since increased subcutaneous fat might hamper reliable ultrasound 
measurement. Since patients with stroke are often obese and inactive, our results 
may not be representative for a larger group of stroke survivors. Our data, however, 
illustrates that even in relatively active patients after stroke (bilateral) changes in 
muscle architecture are present.The limited number of subjects also precludes the 
possibility of finding clinically meaningful associations of changes in muscle 
architecture with clinical or neurophysiological characteristics. In this study, we 
used a statistical criterion to identify abnormal muscles at an individual level. Future 
studies should aim at identifying cut-off criteria for relevant changes in both 
echogenicity and muscle thickness on clinical grounds. In addition, future research 
should use a longitudinal design in larger and broader groups of patients throughout 
the acute, subacute and chronic phases of stroke to identify relationships of 
abnormal muscle architecture with neurophysiological and clinical characteristics. 
Such studies should also investigate a larger set of muscles, including agonist- 
antagonist couples, to provide a more complete overview of the changes in skeletal 




This study shows that abnormalities can be found in muscles on the paretic as well 
as on the non-paretic side after stroke when compared to reference values obtained 
from healthy control subjects. It also demonstrates that quantitative muscle ultra - 
sound is a feasible technique to investigate architectural changes in skeletal muscles 
in the chronic phase of stroke. This technique, therefore, may be a  patient-friendly 
biomarker for muscle function and muscular integrity and a way to monitor recovery 
and effects of therapy after stroke. 
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Background: Peripheral changes to muscle and motor nerves occur following 
stroke, which may further impair functional capacity. We investigated whether a 
year-long use of an implanted peroneal FES system reverses stroke-related changes 
in muscles and motor nerves in people with foot drop in the chronic phase after 
supratentorial stroke.
Methods: Thirteen persons with a chronic stroke (mean age 56.1 years, median 
Fugl-Meyer Assessment leg score 71%) were included and received an implanted 
peroneal FES system (ActiGait®). Quantitative muscle ultrasound (QMUS) images 
were obtained bilaterally from three leg muscles (i.e. tibialis anterior, rectus femoris, 
gastrocnemius). Echogenicity (muscle ultrasound gray value) and muscle thickness 
were assessed over a one-year follow-up and compared to age-, sex-, height- and 
weight-corrected reference values. Compound motor action potentials (CMAPs) 
and motor evoked potentials (MEPs) were obtained from the tibialis anterior muscle. 
Generalized estimated equation modeling was used to assess changes in QMUS, 
CMAPs and MEPs outcomes over the follow-up period.
Results: Echogenicity of the tibialis anterior decreased significantly during the 
follow-up on the paretic side. Z-scores changed from 0.88 at baseline to -0.15 after 
52 weeks. This was accompanied by a significant increase in muscle thickness on 
the paretic side, where z-scores changed from -0.32 at baseline to 0.48 after 52 
weeks. Echogenicity of the rectus femoris normalized on both the paretic and 
non-paretic side (z-scores changed from -1.09 and -1.51 to 0.14 and -0.49, 
respectively). Amplitudes of CMAP and MEP (normalized to CMAP) were reduced 
during follow-up, particularly on the paretic side (ΔCMAP=20% and ΔMEP=14%).
Conclusions: We show that the structural changes to muscles following stroke are 
reversible with FES and that these changes might not be limited to electrically 
stimulated muscles. No evidence for improvement of the motor nerves was found. 
123
EFFECTS OF IMPLANTED FES ON MUSCLE AND NERVE
8
Introduction
Stroke is typically defined as a lesion of the upper motor neuron (UMN). However, 
it is known that secondary to this UMN lesion peripheral changes occur after a 
stroke [167, 168]. Following the loss of central activation, lower motor neurons 
(LMN) may become functionally depressed or may even undergo ‘transsynaptic 
degeneration’ leading to denervation of muscle fibers [46, 47, 169]. Since 
denervation of muscle fibers induces muscle atrophy and infiltration of fibrous 
tissue and fat, this process of denervation after stroke also has an effect on the 
structure of skeletal muscles. Indeed, muscle atrophy and infiltration of fibrous 
tissue and fat are often reported in paretic muscles after stroke [53-55]. Recently we 
have shown that structural changes to muscles after stroke are not restricted to the 
paretic side alone and that the changes in muscle structure cannot be explained 
solely by disuse [170]. These changes to skeletal muscle structure are believed to 
further impair functional capacity of people with stroke [55]. Therefore, interventions 
preventing or mitigating this undesirable involvement of the peripheral nerve 
system and muscles after stroke are needed. 
 Functional electrical stimulation (FES) of paretic muscles is a commonly applied 
method to compensate for severe muscle weakness after stroke. One of the most 
widely used applications of FES in people with stroke is the activation of the 
peroneal nerve to reduce foot drop [171]. With peroneal FES, paretic dorsiflexor 
muscles are electrically activated during the swing phase and early stance of the 
gait cycle, resulting in an ‘active’ foot elevation [30]. It has been theorized that such 
electrically induced contractions combined with voluntary contractions can 
strengthen spinal synapses and induce cortical changes [172]. Indeed, increased 
excitability, metabolism and reorganization of the motor cortex have been reported 
after prolonged peroneal FES use in people with a neurological disease, including 
people with stroke [34, 56-58]. These plastic changes after long-term FES use 
indicate central motor recovery, which raises the question whether stroke-related 
changes to skeletal muscles and lower motor neurons can also be reversed with 
prolonged FES use. 
 In this study we aimed to investigate whether a year-long use of an implanted 
peroneal FES system (ActiGait®, Neurodan, Denmark, Otto Bock Group, 2006) 
reverses stroke-related changes in skeletal muscles and their motor innervation in 
people with persistent foot drop in the chronic phase after a supratentorial stroke. 
Bilateral leg muscle thickness and echogenicity were monitored over time using 
quantitative muscle ultrasound (QMUS), which is valid method for objective 
assessment of muscle architecture [147, 173, 174] and has been used in various 
patient populations with neuromuscular and central nervous system disorders [146, 
170, 175]. Muscle thickness provides an indication of the presence of muscle 
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atrophy (or hypertrophy), whereas echogenicity (i.e. how white or black the image 
looks on the screen) is a measure of how (ab-)normal the tissue architecture is. 
Infiltration of muscle fibers with fat and fibrous tissue following denervation increases 
muscle echogenicity, making the muscle appear more white on the screen (see 
figure 1 for an example). Furthermore, whether long-term FES stimulation of ankle 
dorsiflexor muscles changes functioning of the lower motor neurons and alters 
corticospinal integrity was tested by obtaining compound motor action potentials 
(CMAPs) and motor evoked potentials (MEPs) from the primary ankle dorsiflexor 
muscle (i.e. tibialis anterior muscle). 
 We hypothesized that, following a year-long period of implanted peroneal FES 
use, muscle architecture would be restored in the electrically stimulated ankle 
dorsiflexor muscles, but not in other muscles on the paretic or non-paretic side. 
In addition, as long-term use of FES has been found to induce cortical changes, 
we hypothesized that MEPs would be increased after a year of FES use. The results 
of this study will lead to a better insight into the reversibility of architectural changes 
of muscles and motor nerves after stroke using long-term FES.
Figure 1 Example of paretic side (A) and non-paretic side (B) tibialis anterior. The paretic 
tibialis anterior muscle appears whiter on the screen (i.e. a higher echogenicity), indicating 
infiltration of intramuscular fat and fibrous tissue. Echogenicity z-scores were z=1.45 and 
z=0.29 for the paretic and non-paretic side, respectively.
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All participants were recruited from the outpatient clinic of the department of 
Rehabilitation at the Radboud university medical center in Nijmegen and were 
enrolled in a study evaluating the effects of implanted functional electrical 
stimulation (FES) on ambulation [116]. Inclusion criteria were: (1) having sustained a 
supratentorial stroke, i.e. a lesion in one of the cerebral hemispheres, at least six 
months before inclusion, (2) paresis including unilateral foot dorsiflexion weakness 
(Medical Research Council scale < 5), (3) the ability to walk at least 10 meters 
without a walking aid (except for the use of an ankle-foot orthosis which was 
allowed) and (4) a positive response to surface-based peroneal nerve stimulation 
(NESS L300, Bioness inc, Valencia, California) defined as the ability to make initial 
heel contact during gait with stimulation. Subjects were excluded if: (1) they had a 
history of (poly-) neuropathy or (poly-) radiculopathy, or (2) were morbidly obese 
(body mass index >40), as this can preclude reliable QMUS measurements by 
attenuation of the ultrasound beam, or (3) reported contraindications for transcranial 
magnetic stimulation (TMS) (e.g. active epilepsy or the presence of an implanted 
pacemaker, neurostimulator or cochlear implant). All patients gave their informed 
consent. The study was approved by the local medical ethics committee and 
conducted in accordance with the World Medical Association Declaration of 
Helsinki [176].
Demographic and clinical characteristics
Age, sex, time since stroke, type of stroke, body mass index, leg motor strength 
(Motricity Index [157]) and leg motor selectivity (Fugl-Meyer Assessment [159]) were 
obtained by the same rehabilitation physician (ACG) at inclusion. In addition, preferred 
walking speed [177] at baseline and after 52 weeks of implanted FES use was assessed 
on a 10-meter walkway using a stopwatch. Physical activity at baseline and after 
52 weeks of FES use was registered by means of a Digi-Walker SW-650 pedometer 
(Yamax Corporation, Tokyo, Japan) counting the amount of daily steps averaged 
over a period of 7 days.
ActiGait® implanted FES system
The ActiGait® system is an implantable 4-channel peroneal nerve stimulator (figure 2). 
The implant consists of an electrode cuff at the distal end and a stimulator body at 
the proximal end connected by a lead wire. The electrode cuff has 4 separate 
electrodes, which are selectively controlled by the stimulator body, allowing 
differential activation of nerve fibers to the tibialis anterior, peroneus longus/brevis, 
and toe extensor muscles. The system is operated through external parts: a heel 
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switch (placed under the heel and attached to the shoe or a special sock) and a 
control unit, worn at the pelvis, which is connected to an antenna on the skin 
directly over the stimulator body. The control unit enables users to switch the 
stimulation on and off and to make adjustments in stimulation intensity. The heel 
switch wirelessly communicates with the control unit to provide information for 
onset and offset of stimulation. 
 ActiGait® implantation was performed by a trained neurosurgeon at the Radboud 
university medical center in Nijmegen. The implant was activated three weeks after 
surgery. Use of the Acitgait® system was then built up gradually in 3 weeks from 
15-60 minutes per day in the first week up to minimally 6 hours per day in the third 
week. The procedure of ActiGait® implantation and system activation has previously 
been described in detail [32, 74, 75] and can be found in the appendix of this thesis.
Figure 2  The ActiGait® system. The implanted part of the ActiGait® consists of a stimulator 
body (A) and an electrode cuff (B), the latter placed around the common peroneal nerve. 
The implant is controlled by a control unit (C), which activates the implant through an antenna 
placed on the thigh (D). The timing of activation is determined by a heel switch (E), which 
communicates wirelessly with the control unit.
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Study design
A within-subjects repeated-measures design was used for the follow-up of one 
year after implantation. QMUS measurements were performed at inclusion (T0) as 
well as 26 weeks (T3) and 52 weeks (T4) after activation of the ActiGait® system. 
Neurophysiologic assessments were performed at inclusion (T0) and 2 weeks (T1), 
8 weeks (T2), 26 weeks (T3) and 52 weeks (T4) after activation of the ActiGait® 
system. The effects of long-term implanted FES use on walking capacity have been 
published elsewhere [75, 116]. 
Measurements
Quantitative muscle ultrasound
We used QMUS, a method with high interrater reliability [148, 178, 179], to assess 
the primary ankle dorsiflexor muscle (i.e., the tibialis anterior muscle), its antagonist 
(i.e., the medial head of the gastrocnemius muscle) and the rectus femoris muscle, 
a biarticular upper leg muscle, all being key muscles for locomotion. Muscle 
ultrasound images of the tibialis anterior, medial head of the gastrocnemius, and 
rectus femoris muscles were obtained bilaterally with a Philips IU 22 ultrasound 
machine (Philips Healthcare Systems, Best, The Netherlands) and a broadband 
linear 5-17 MHz transducer. A dedicated musculoskeletal preset was used for all 
scanning, with fixed system parameters set to: gain 70dB, compression 55, time 
gain in neutral position, and focal range of 1.0 to 2.5 cm depth. To ensure reproduc-
ibility, automatic image optimizing software was turned off as much as possible. 
System settings remained unchanged throughout all measurements [180]. Muscle 
ultrasound images were taken at predefined sites corresponding to the maximum 
muscle thickness of each muscle, following the description of Scholten et al. [152]. 
At each assessment, three separate muscle ultrasound images were taken from 
each muscle, all the while ensuring there was no pressure on the skin or the muscle 
and with the participant in a relaxed, supine position. The digital images were stored 
as DICOM files for offline analysis. In each image a region of interest (ROI) was 
selected. Using an image histogram analysis tool, the mean gray value and thickness 
over the ROIs of separate muscles were calculated with the help of a custom 
software program (“QUMIA”, [147, 154-156, 170]). This software then compared the 
muscle thickness and gray values to age-, sex-, height- and weight-corrected 
reference values [136, 149]. The difference found was expressed as a z-score, i.e. 
the number of standard deviations (SD) from the mean. Positive z-scores for 
echogenicity (i.e. muscles looking relatively white on the screen) were considered 
indicative of poorer muscle architecture with more infiltration of fibrous tissue and 




Surface EMG signals were recorded from the tibialis anterior muscle on both the 
paretic and non-paretic side. Adhesive electrodes (1 cm diameter) were placed on 
the muscle belly and muscle tendon of the tibialis anterior muscle. Ground 
electrodes were placed between the stimulus and recording site. EMG recordings 
were performed using a multichannel biomedical amplifier (Neurotop MME 3132, 
Nihon Kohden, Tokyo, Japan). 
Peripheral motor nerve stimulation
Peripheral motor nerve function was evaluated by measuring the CMAPs from the 
tibialis anterior muscle. Assessment of CMAPs from the tibialis anterior muscle has 
been shown to have good test-retest reliability [181]. CMAPs were obtained, for the 
paretic and non-paretic side separately, by stimulation of the common peroneal 
nerve, dorsal to the fibular head. Stimulation intensity was increased gradually until 
an increase in intensity did not further increase the motor-wave (M-wave) amplitude 
(i.e. supramaximal stimulation). The results of five consecutive stimulations were 
then recorded and used for analysis. After rectification of the raw signal, the 
maximum peak-to-peak amplitude and the largest area under the curve (AUC) of 
these five contractions were extracted offline, using a custom Matlab script (Matlab 
20141b, The Mathworks Inc. Natick, Massachusetts). 
Transcranial magnetic stimulation
For assessment of the corticospinal connections to the tibialis anterior, MEPs were 
obtained using TMS. The motor cortex was stimulated three times at the vertex with 
a double-cone coil at maximal stimulator output using a transcranial magnetic 
stimulator (Magstim 200, Magstim, Whitland, UK). The MEPs were recorded when 
participants performed a slight voluntary ankle dorsiflexion to enlarge the MEP 
response. From the three stimuli obtained in each assessment, participants’ 
maximum peak-to-peak amplitude as well as the largest AUC after rectification of 
the raw signal were extracted offline using a custom Matlab script (Matlab 2041b, 
The Mathworks Inc. Natick, Massachusetts). Since MEP output is limited by 
functioning of the lower motor neuron, MEP peak-to-peak amplitude and AUC 
were also normalized to CMAP amplitude and AUC, for instance: (MEPamplitude/
CMAPamplitude)*100%.
Statistical analysis
To test whether group means of echogenicity and muscle thickness at baseline 
were different from normal values, a one sample t-test (test value: µ= 0) was 
performed. Baseline differences in echogenicity and muscle thickness between 
the paretic and non-paretic side were tested using paired samples t-tests. 
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Generalized estimated equation modeling (GEE), with time (T0-T4) and side (paretic 
and non-paretic) as the independent variables, was used to assess changes over 
the follow-up period in the dependent variables: muscle echogenicity, muscle 
thickness, CMAP amplitude and AUC and (normalized) MEP amplitude and AUC. 
Since we expected that assessments obtained shortly after each other (e.g. T1 and 
T2) would be correlated stronger than assessments with a longer time interval (e.g. 
T2 and T3), we selected an autoregressive structure as the working correlation 
structure of the GEE model. In the case of a significant interaction of side by time, 
additional GEE analyses of time effects were performed for the paretic and 
non-paretic side, separately. These additional analyses of time per body side were 
corrected for multiple comparisons using Bonferroni correction. To assess changes 
in walking activity and capacity (steps per day and comfortable walking speed) 
Wilcoxon signed-rank tests were performed. We used SPSS (SPSS 15.0, SPSS Inc, 
Chicago, Illinois) for all statistical analyses. The level of significance was set at 
p<0.05.
Results
The characteristics of the included participants are presented in table 1. One 
participant died before the first follow-up measurement, the cause of death being 
unrelated to the study; data of this participant was removed from the analysis. In 
one participant the FES system failed after 26 weeks. Since sufficient follow-up data 
were obtained, this participant was included in the final analysis. Hence, data of a 
total of 12 participants were used for final analysis. After one year of FES use the 
number of steps per day (6248 ± 3019, p=0.59) and comfortable walking speed 
(1.02 ± 0.2 m/s, p=0.09) were not significantly different from baseline values (5794 
± 2671 and 0.97 ± 0.2, respectively). 
Quantitative muscle ultrasound
Tibialis anterior
At baseline, the mean echogenicity of the tibialis anterior muscle was significantly 
higher on both the paretic and non-paretic side (z=0.88, p=0.001, and z=0.65, 
p=0.008, respectively), meaning that the muscles looked more white and hence 
more structurally abnormal on the screen compared to reference values. Baseline 
echogenicity was not found to be significantly different between the paretic and 
non-paretic side. Over the follow-up period we found a decrease in tibialis anterior 
echogenicity which was most profound on the paretic side, as reflected by a 
significant interaction effect of time by side (p<0.001). Echogenicity z-scores on the 
paretic side were significantly different from baseline at T3 (p<0.001) and T4 
130
CHAPTER 8
(p<0.001) and decreased on average by 1.03 SD, indicating that muscle architecture 
improved over time. Remarkably, the echogenicity of the paretic side became 
lower than that of the non-paretic side at T4 (see figure 3A). We also found a 
significantly decreased echogenicity on the non-paretic side at T4 compared to T0, 
however, this finding was driven by imputation of two missing values at T4 by the 
GEE model. Additional parametric t-tests did not reveal a significant difference in 
echogenicity between baseline and T4 on the non-paretic side (p=0.180). 
 At baseline, no significant differences compared to reference values or between 
the paretic and non-paretic side were found for muscle thickness of the tibialis 
anterior. Muscle thickness of the tibialis anterior on the paretic side increased over 
the follow-up period, being significantly different from baseline at T3 (p<0.001) and 
T4 (p=0.001; average increase of 0.80 SD, see figure 3D), whereas the muscle 
thickness on the non-paretic side did not (interaction time by side, p<0.001).
Medial head of gastrocnemius
At baseline, the mean echogenicity of the medial head of the gastrocnemius 
muscle was significantly higher on the paretic side compared to reference values 
(p=0.019) and compared to the non-paretic side (p=0.007). The mean echogenicity 
did not change over time for either the paretic or non-paretic side. Overall, mean 
z-scores for echogenicity of the paretic and non-paretic side were 1.59 and -0.13, 
respectively (see figure 3B). 
 Similar to the echogenicity pattern of the gastrocnemius, the paretic side muscle 
thickness at baseline was significantly smaller than reference values (p=0.002) and 
compared to the non-paretic side (p=0.006). Over the follow-up period muscle 
thickness remained significantly different between the paretic and non-paretic side 
Table 1  Baseline group characteristics
N=13
Age; mean yrs (SD) 56.1 (10.2)
Sex; male/female 10/3
Affected side; left/right 8/5
Type of stroke; ischaemic/ haemorrhagic 9/4
Years after stroke; mean yrs (SD) 5.2 (4.5)
Body Mass Index; mean kg/m2(SD) 26.7 (3.4)
Fugl-Meyer Assessment – leg score (0-100%); median score (range) 71 (53-85)
Motricity Index – leg score (0-100%); median score (range) 72 (42–91)
Walking speed; mean m/s (SD) 0.97 (0.2)
Step count; mean steps/day (SD) 5794 (2671)
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(mean muscle thickness z-scores -2.56 and -0.81, respectively, p<0.001), indicating 
that both sides showed reduced muscle thickness at a group level. Similar to the 
echogenicity, no significant changes in muscle thickness were found over time 
during FES use (see figure 3E).
Rectus femoris
At baseline, the mean echogenicity of the rectus femoris muscle was significantly 
lower than reference values on both the paretic side and non-paretic side (z=-1.09, 
p=0.014, and z=-1.51, p=0.002, respectively). Baseline echogenicity was not 
significantly different between the paretic and non-paretic side. During the follow-up 
period we found a significant change in echogenicity for both the paretic and 
non-paretic side at 52 weeks (T4) compared to T0 (p=0.021). On average, echogenicity 
z-scores increased by 1.24 and 1.01 for the paretic and non-paretic side, respectively. 
Thus, after one year of FES use, mean echogenicity values for both the paretic and 
non-paretic side returned within one SD of the reference values (see figure 3C).
 At baseline, mean rectus femoris muscle thickness on the paretic and non- 
paretic side were not significantly different from reference values. Paretic side muscle 
thickness was significantly smaller compared to the non-paretic side (p=0.009), 
which was maintained over the follow-up period (p=0.001). On average, paretic 
and non-paretic z-scores were -0.58 and 0.08, respectively, indicating that only the 
paretic side showed reduced muscle thickness. No significant changes in rectus 
femoris thickness on either side could be detected over time (see figure 3F).  
Electrophysiologic assessment
Compound motor action potentials
The CMAP AUC and amplitudes of the tibialis anterior muscle were generally lower 
on the paretic side compared to the non-paretic side (p<0.001). Following FES 
implantation, differences in CMAP AUC between the paretic and non-paretic side 
became larger (interaction time by side p<0.002). This significant interaction of 
time by side was driven by a significant reduction in CMAP AUC on the paretic side 
(see figure 4A). It decreased from 58.7mVms (T0) to 46.0mVms (T4), and was found 
to be significantly different from baseline values during the entire follow-up period 
(p<0.004). Similarly, an interaction of time by side was found for CMAP amplitudes 
(p<0.005). Again, this interaction was driven by significant changes on the paretic 
side (see figure 4B). CMAP amplitudes on the paretic side decreased from 8.0mV 
(T0) to 6.4mV (T2, p<0.001).
 Subsequent analysis of the CMAP AUC and amplitudes showed no further 
changes from T1 or T2 to T4, indicating that the bilateral loss of CMAP amplitude/
AUC after the surgical intervention was not fully reversed during the 1-year follow-up 
period.
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MEP AUC and amplitudes of the tibialis anterior muscle were generally lower on the 
paretic side compared to the non-paretic side (p< 0.036). Similar to the CMAP AUC 
and amplitudes, the differences in MEP AUC between the paretic and non-paretic 
side became larger during the follow-up period, as was reflected by a significant 
interaction of time by side (p=0.005). Also for MEP AUC, this significant interaction 
of time by side was due to a decrease on the paretic side, which was significantly 
different from baseline at T2 (p<0.001). Between baseline and T2, mean MEP AUC 
decreased from 47.9mVms to 33.1mVms on the paretic side (see figure 4C). 
 MEP amplitudes on the paretic and non-paretic side decreased from 4.2 to 
3.1 mV and from 6.6 to 6.0 mV, respectively. Although the average decrease in MEP 
amplitudes on the paretic side was nearly twofold the change on the non-paretic 
side, no significant interaction of time by side was found (p=0.119 at T2, see figure 
4D). In general, MEP amplitudes were significantly different from baseline during 
the entire follow-up, T1-T4 (p<0.046).  
 To assess whether changes over time in MEPs were due to changes in CMAPs 
we tested the effects of time and side on normalized MEPs. In contrast to MEP AUC, 
no significant interaction of time by side was found. Overall, normalized MEP AUC 
was significantly reduced, only at T2 (p<0.001). With normalization of MEP amplitudes 
part of the time effects for MEP amplitudes, reported above, disappeared. With 
normalized MEP amplitudes significant differences in time were found only at T2 
(p<0.001) and T4 (p=0.038). 
Discussion
Our study confirms that structural changes in skeletal muscle after a supratentorial 
stroke, reported here and elsewhere [50-52, 160, 170, 182], appear to be reversible 
with long-term FES use. Echogenicity of the tibialis anterior muscle decreased 
during the follow-up on the paretic side, which was accompanied by an increase in 
muscle size. Because of the chronic condition of the participants, it is unlikely that 
these changes are attributable to spontaneous recovery.
Quantitative muscle ultrasound 
In agreement with our hypothesis, the year-long use of an implanted peroneal FES 
stimulator successfully reversed the maladaptive changes to muscle structure in 
the tibialis anterior muscle. Previous studies have shown that FES can be successful 
in stopping or counteracting muscle atrophy, but this was done in other groups 
of patients (e.g., spinal cord injury) and through a resistance training program 
specifically aimed at muscle mass gain using surface-based FES stimulation[183-
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185]. The reduction in echogenicity on the paretic side of 1.03 SD comes down to 
a change in absolute echogenicity of approximately 20%[136], which is well over 
the 10% variation that could be expected between measurements[178]. Reduced 
echogenicity in the tibialis anterior muscle may have (partly) been caused by an 
increase in muscle mass [186], something we observed on the paretic side. 
However, the changes in echogenicity on the paretic side exceeded the changes in 
muscle thickness, which makes it unlikely that the observed decrease in echogenicity 
would be merely due to activity-induced muscle hypertrophy. 
 Since the implanted FES stimulator acts on the ankle dorsiflexor muscles, we 
hypothesized that no significant changes would occur in the medial gastrocnemius 
or rectus femoris muscle during one year of FES use. Although this was true for 
the medial head of the gastrocnemius, we did find changes in rectus femoris 
echogenicity during the follow-up period. Unexpectedly, and unlike the other 
muscles, the average echogenicity of the rectus femoris muscle was bilaterally 
lower than the reference values at baseline. This finding contrasts with the recent 
work by Akazawa et al. who reported increased echogenicity in the paretic rectus 
femoris muscles of sedentary and active people with stroke [182]. However, in the 
study by Akazawa et al., echogenicity was not corrected for age, sex, height or 
weight, as we did in the current study. As a result, direct comparison of the two 
studies is not possible. We have no explanation for the relatively low echogenicity 
of both rectus femoris muscles as observed in our study, however, our results 
indicate that this echogenicity was normalized after one-year of FES use. The 
normalization of echogenicity might point at a changed activity of the rectus 
femoris muscles as a result of FES use, at least on the paretic side, but this post-hoc 
explanation needs further investigation. 
Neurophysiologic assessment
Our results indicate that the CMAPs from the tibialis anterior muscle of the 
stimulated leg decreased after implantation of the FES system, a finding which we 
did not expect. The marked decline of the CMAP amplitudes on the paretic side (i.e. 
a loss of about 20%) could theoretically result from a reduction of functionally 
active motor units (e.g. due to nerve damage upon implantation) or from a lower 
excitability of motor unit components (i.e. axons, neuromuscular junctions and/or 
muscle fibers). Given the invasive character of the intervention, it is possible that the 
common peroneal nerve might have been damaged during surgery. However, if 
this would have been the case, we would have expected problems stimulating the 
tibialis anterior muscles and we would have expected signs of denervation of this 
muscle (i.e., increase in echogenicity and decrease in muscle size), which we did 
not find. We therefore believe that it is most likely that the excitability of the common 
peroneal nerve changed following implantation and, particularly, following activation of 
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the FES stimulator. Indeed, axonal excitability can change under various conditions 
including overuse and fatigue [187, 188], and rapidly fatiguing muscles are a well- 
known problem in the application of FES [189]. Although participants were instructed 
to build up their daily FES use slowly and gradually, it might be that the paretic 
neuromuscular complex needed more time or was unable to adjust to the suddenly 
increased activation. Signs of fatigue were commonly reported by the participants, 
especially during the first weeks of follow-up. Additionally, it might be that the 
nature of FES provides a very different stimulation context for the motor axons than 
physiologic activation does, with concomitant changes in axonal resting and firing 
thresholds that may lead to a decrease in single-stimulus CMAP parameters. 
 In a number of studies, the use of FES has been shown to induce plastic 
changes on a cortical level [34, 56-58]. Like in our study, Everaert et al. used MEPs 
to assess the effects of FES on cortical plasticity. In contrast to their work, we did 
not find signs of cortical plasticity after a year-long FES use. Instead, in our study, 
MEP amplitudes from the tibialis anterior muscle were even slightly reduced during 
the follow-up period. However, direct comparison of the results derived from both 
studies should be done with caution, given an important difference in measurement 
protocol. Where we used a fixed position of the magnetic stimulator for eliciting 
MEPs throughout the follow-up period, Everaert et al. aimed for the localization of 
‘hot spots’ to achieve the best MEP response. 
Study limitations and recommendations
We assessed changes in three muscles in a relatively small and specific group of 
chronic stroke patients. The participants in our sample showed reduced ambulatory 
capacity, but were relatively active compared to the stroke community at large. The 
group in our study walked on average about 5800 steps per day, which is well 
above the number of steps reported in other studies [10]. To assure reliable imaging 
of muscles with muscle ultrasound, stroke survivors who were morbidly obese 
were excluded from the study. Since people with stroke are often obese and 
inactive, our results may therefore not be representative for the entire group of 
stroke survivors. However, our data show that even in active people with stroke 
structural changes in muscle architecture can be reversed, in our case by applying 
peroneal FES. Although we compared muscle characteristics to height-, weight-, 
sex- and age-corrected reference values, it is still uncertain whether the changes 
obtained in our study are clinically relevant. Future studies should aim at identifying 
cut-off criteria for relevant changes in both echogenicity and muscle thickness in 
this study population. In addition, other factors might influence muscle ultrasound 
characteristics in people with stroke, such as their hydration status that can change 
with the use of diuretics. The effects of such variables should be investigated in 
future research. Finally, this study focused on reversing the structural changes to 
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muscle and nerves in people with chronic stroke (>6 months post onset). It might 
be interesting to investigate whether FES could also be used to prevent such 
structural changes in the first months after a stroke. 
Conclusion
We have shown that the structural changes to muscles following supratentorial 
stroke are reversible with implanted peroneal FES and that these findings are not 
restricted to the stimulated ankle dorsiflexor muscles alone. We could not identify 
improvement of lower motor neuron functioning or cortical plasticity. The findings 
in this study add to the evidence that peroneal FES may have an added value over 
the use of an ankle-foot orthosis in people with unilateral drop foot after stroke.
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Summary 
Functional electrical stimulation (FES) of the common peroneal nerve can serve as 
a method to prevent foot drop in people with stroke. With implantable FES, problems 
encountered with surface-based FES systems such as skin irritation and allergic skin 
reactions are avoided. In addition, with implanted electrodes the motor nerve is 
stimulated directly, offering a more precise activation of the foot elevators, both 
spatially and temporally. The aim of this thesis was to investigate the long-term 
effects of implanted FES of the common peroneal nerve in people with drop foot 
after stroke. In the first part, the focus was on the orthotic benefits of implanted FES 
compared to conventional aids, such as an ankle-foot orthosis (AFO). Differences 
between implanted FES and conventional aids were assessed during steady state 
walking as well as during more challenging tasks that require gait adaptability. In the 
2nd part, the effects of long-term FES use on muscle and nerve characteristics were 
investigated. After a summary of this thesis, the main findings are addressed in a 
broader context in terms of their clinical meaning and implications for future 
research (general discussion). 
Part 1:  Surplus value of implanted peroneal FES over conventional 
drop foot treatment 
Objective and subjective advantages of implanted FES during regular 
(overground) walking
The first 1-channel implantable FES systems were developed in the nineties. These 
systems failed to provide a selective and balanced stimulation of the foot and were 
not suitable for management of drop foot. To provide a more selective stimulation 
of the peroneal nerve implantable 2-channel-systems were developed, which 
showed promising improvements in gait speed and temporal characteristics of the 
stance phase. More recently, a 4-channel implantable drop foot stimulator 
(ActiGait®, Neurodan, Denmark, Otto Bock Group, 2006) received approval for 
hemiplegia following stroke and was released onto the market. In Chapter 2, 
indications and clinical results of this implanted 4-channel peroneal FES system 
with regard to the management of drop foot following stroke were addressed. Four 
studies tested the orthotic effects of implanted 4-channel FES use in people with 
drop foot after stroke. Generally, participants were included if they 1) were at least 
six months post stroke onset, 2) suffered ankle dorsiflexor weakness (MRC score < 
5), 3) had a passive range of ankle motion of at least 30 degrees with at least 0 
degrees of dorsiflexion while standing, 4) had an independent walking capacity of 
10 minutes, and 5) showed a positive response to surface-based FES. Three out of 
142
CHAPTER 9
the four studies compared walking with FES (ON) to walking without stimulation 
(OFF) and reported increases in gait speed and walking distance with stimulation. 
Two studies tested the differences between implanted FES and AFO and found no 
differences in gait speed or walking distance. Interestingly, both studies did report 
benefits of implanted FES over AFO on ankle kinematics in the stance phase of gait. 
Patient satisfaction with the ActiGait® system was generally good, based on two 
studies. Hence, the first studies on the effects of implanted 4-channel FES use in 
people with drop foot show promising results, but scientific evidence for a surplus 
value of implantable FES over AFO is still scarce. Therefore, it was concluded that 
there is a need for studies that identify the underlying mechanisms of orthotic and/
or therapeutic (both neural and neuromuscular) effects of long-term FES use in 
people with drop foot after stroke. 
 Since people with a drop foot after a stroke commonly receive an AFO to 
improve walking capacity, comparison between AFO and implanted FES is of 
utmost clinical importance. AFOs are usually successful in counteracting drop foot 
during the swing phase of gait, but may at the same time obstruct normal ankle roll 
off during the stance phase of gait. Depending on their stiffness, most AFOs hamper 
passive ankle motion for dynamic balance and roll off, and limit the use of residual 
active ankle plantarflexion during the late stance phase of gait. Hence, it was 
hypothesized that replacing AFO with implanted FES would lead to a more normal 
paretic ankle rocker resulting in a metabolically more efficient gait pattern. In 
Chapter 3, the differences between implanted FES versus AFO with respect to the 
energy costs of walking and gait quality were assessed over a follow-up period of 
26 weeks in ten community walkers with a drop foot after stroke. Gait quality, 
assessed with 3D gait analysis on a 10-meter walkway, revealed improved paretic 
ankle kinematics and kinetics in the late stance phase of the gait cycle with 
implanted FES. Peak paretic ankle plantarflexion was larger with FES (mean 
difference from AFO 4.7°), which was accompanied by a 49% higher paretic peak 
ankle power and a 6.6% reduction of step-length asymmetry. Despite these 
improvements in gait quality, no significant differences in metabolic energy cost of 
walking were found in a six-minute walking task, which could be explained by the 
absence of a significant difference between the two devices on gait speed. 
Generally participants preferred the use of implanted FES over their conventional 
AFO. The implanted FES system was particularly appreciated for its comfort, 
appearance and the functional benefits in walking up and down the stairs.
 Interestingly, the improvements in gait quality reported above were found 
during the stance phase of gait, when the peroneal nerve stimulation was inactive. 
This may very well be explained by FES interfering less with ankle motion compared 
to AFO. Such interference with paretic ankle motion could extend to other joints 
and affect other aspects of the gait cycle. For instance, obstruction of tibial 
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progression during the 2nd rocker could induce knee instability towards knee 
extension and a limitation of active plantarflexion during the 3rd rocker could 
reduce propulsion and leg swing initiation. Therefore, the effects of replacing AFO 
by implantable FES on paretic stance stability, propulsion, and swing initiation were 
extensively investigated in Chapter 4. The differences between AFO and implanted 
FES were assessed in 22 participants over follow-up periods of 26 or 52 weeks after 
activation. Gait quality was assessed through 3D gait analysis on a 10-meter 
walkway. With implanted FES the paretic peak knee extension velocity in stance 
was lower (on average 18.1°/s), indicating better knee stability compared to AFO. 
Again, paretic ankle push-off during late stance was found superior with implanted 
FES as was reflected by higher paretic peak ankle plantarflexion velocity (mean 
difference 29.2°/s) and higher paretic peak ankle power (mean difference 0.2 W/
Kg.). With implanted FES, the ground reaction force (GRF) vector at the instant of 
paretic peak ankle power was oriented more anteriorly (mean difference 1.1°) and 
the horizontal GRF (mean difference 0.8% body mass) was higher, indicating better 
propulsion with implanted FES. Although no significant differences between 
implanted FES and AFO were found for paretic knee or hip kinematics during swing 
, individual improvements in late stance kinematics and kinetics were significantly 
associated with maximum paretic hip flexion velocity during swing, which may 
point towards some type of functional coupling between these phenomena as a 
result of peroneal stimulation.
STIMULATING STATEMENT:
Despite being particularly active during the swing phase of gait, the benefits of 
implanted peroneal FES, relative to an AFO, are found in the stance phase of the 
gait cycle. Unobstructed paretic ankle motion with FES allows better utilization 
of residual paretic ankle plantarflexion leading to increased push-off power 
and forward propulsion in people with drop foot after stroke.
Mimicking daily life walking environments: differences in gait adaptability 
between implanted FES and conventional drop foot treatment
In spite of the superiority of implanted FES over AFO with regard to the quality of 
gait in people with a drop foot after stroke and the patient preference for implanted 
FES, scientific evidence for a surplus value of FES with regard to mobility in everyday 
life is still limited. The efficacy of FES on functional outcomes has been tested, but 
usually during regular overground walking tasks. Typically, most FES users are 
community walkers (comfortable walking speed > 0.4 m/s) for whom daily-life 
walking requires continual adaptation to environmental challenges, such as uneven 
or slippery ground surfaces, (un)expected obstacles and traffic. The benefits of 
implanted FES use for gait quality might, therefore, particularly be exploited in 
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challenging walking environments that require adaptation of the gait pattern to 
external disturbances. Therefore, gait adaptability was tested in Chapter 5, where 
we compared the capacity to avoid sudden obstacles during treadmill walking 
between implanted FES and AFO in people with drop foot after stroke. Gait 
adaptability assessments were repeatedly performed in 22 participants up to 26 
weeks or 52 weeks after FES-system activation. At all assessments, 30 trials in which 
obstacles were suddenly dropped onto the treadmill in front of the paretic leg were 
recorded with each assistive device. Trials were stratified by available response 
times (ART) and success rates were calculated. Obstacle avoidance appeared to be 
superior with implanted FES, as success rates across all ARTs were on average 4.7% 
higher compared to AFO. In trials with the longest ARTs (i.e. 450 to 600ms), an 
average difference in success rate of 15% was found between FES and AFO. 
Interestingly, a moderate but significant correlation between motor impairment 
and individual difference in success rate (implanted FES-AFO) showed that 
participants with relatively poor leg motor control benefited most from implanted 
FES. The findings in this chapter closely match the results of a previous study that 
investigated the capacity to avoid suddenly dropped obstacles while people with 
drop foot after stroke used a surface-based FES system. 
 Besides adaptation to single stepping constraints (as when avoiding a sudden 
obstacle), real-life walking often involves adaptation of the gait pattern to multiple 
and consecutive environmental constraints, for instance when walking along a 
forest trail or on cluttered terrain. People with stroke have profound impairments in 
gait adaptability, as step adjustments are usually delayed and foot placement is 
inaccurate. In stroke survivors with relatively good paretic leg motor recovery, these 
deficits in gait adaptability may especially be revealed by tasks that require multiple 
consecutive step adjustments. In the same vein, benefits from implanted FES use 
for gait adaptability may be higher when walking requires multiple consecutive 
stepping constraints (cf. to a single stepping constraint). Therefore, performance of 
a stepping task with irregularly spaced targets on a self-paced treadmill was tested 
in Chapter 6. Continual step adaptation capacity was tested in 12 participants with 
chronic stroke who had received implanted FES. During a single-day visit, 
participants performed a target stepping task with both implanted FES and their 
conventional device. Stepping stones were projected onto a self-paced treadmill 
and served as targets for the participants to step on. The positions of the targets 
were based on the participant’s own gait characteristics and were varied randomly, 
both mediolaterally and anteroposteriorly. Performance on the target stepping task 
was assessed by calculation of the total error - a combined measure of constant 
error and variable error - of the foot placement relative to the center of the projected 
targets. Step adaptation is known to impose a considerable attentional demand on 
people with stroke, as reflected by substantial dual-task costs when a secondary 
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cognitive task needs to be performed concurrently. Therefore, the target stepping 
task was performed both with and without a cognitive task (i.e. an auditory Stroop 
task). Responses to the cognitive task were recorded and success rates were 
calculated. With implanted FES participants showed less total error during the target 
stepping task, albeit only statistically significant in the frontal plane. On average, 
differences in total error between implanted FES and conventional care were 1.0 
cm and 2.3 cm in favor of FES in the frontal and sagittal planes, respectively. There 
was no significant association between better step accuracy and the degree of leg 
motor impairment. Total error in the frontal plane tended to increase when a 
cognitive task was performed simultaneously (albeit only bordering significance). 
The addition of a cognitive task neither enlarged the difference in step accuracy 
between devices, nor were there significant differences in Stroop task performance. 
Median success rates during the dual task were 88.2% with implantable FES and 
73.6% with conventional care.
 Together, Chapters 5 and 6 support the idea that differences between implanted 
FES and a conventional care, such as an AFO, with respect to gait capacity become 
particularly apparent in complex walking environments, demanding quick gait 
adaptations to environmental challenges, albeit that the observed effects were 
moderate. These findings underline the importance of using gait assessments that 
require interaction with the environment, besides assessment of stationary walking, 
especially in community ambulators.
CHALLENGING CONCLUSION:
Benefits of FES use for functional gait capacity may be missed if gait is assessed 
solely by means of clinical gait assessments. If a person is a community walker, 
the capacity to walk in challenging gait environments should be tested as well.
Part 2:  Pathophysiological changes of muscle and nerve and  
the effects of long-term implanted peroneal FES use
It has frequently been reported that changes to peripheral structures, such as 
skeletal muscle and peripheral motor nerve, may occur following stroke. Following 
a loss of central activation, lower motor neurons may become functionally 
depressed or may even undergo ‘transsynaptic degeneration’ leading to denervation 
of muscle fibers. Since denervation of muscle fibers induces muscle atrophy and 
infiltration of fibrous tissue and fat, this process of denervation after stroke also has 
an effect on the structure of skeletal muscles. Such peripheral changes are believed 
to further impair functional capacity of people with stroke. Alterations in muscle 
tissue after stroke, for instance assessed with ultrasound, are commonly assessed 
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by investigating inter-limb differences. As a result of such intra-person comparisons, 
bilateral changes of muscle architecture following stroke might be missed and 
deviations from the healthy population might be underestimated. Quantitative 
muscle ultrasound (QMUS) is a method that objectively detects muscle abnormalities 
in people with neuromuscular disorders. It has also been used in people with 
central nervous system disorders, e.g. amyotrophic lateral sclerosis, but not yet in 
people with stroke. Therefore, in Chapter 7, we investigated whether bilateral 
architectural changes in skeletal muscles can be detected in chronic, physically 
active patients. Twenty-eight stroke survivors were recruited. QMUS images were 
obtained bilaterally from 2 arm and 4 leg muscles, i.e. biceps brachii, forearm 
flexors, rectus femoris, medial head of the gastrocnemius, tibialis anterior and 
extensor digitorum brevis. Echogenicity and muscle thickness were corrected for 
age, sex, height and weight and expressed as z-scores. Positive z-scores for 
echogenicity (i.e. muscles looking relatively white on the screen) were considered 
indicative of poorer muscle architecture with more infiltration of fibrous tissue and 
fat. Negative z-scores for muscle thickness indicated loss of muscle mass. Significant 
elevation of mean echogenicity was found in 4 paretic and 3 non-paretic side 
muscles. Forearm flexors showed the largest increases in echogenicity (z=2.22 and 
1.07 for the paretic and non-paretic side, respectively). Significant decreases in 
mean muscle thickness were found in 2 paretic side muscles and 1 non-paretic side 
muscle. Mean muscle thickness of the paretic gastrocnemius was reduced most 
(z=-1.78). Muscle architecture of just one muscle was significantly associated with 
clinical characteristics. Echogenicity of the medial gastrocnemius moderately 
(inversely) correlated with walking speed and time since stroke. This study showed 
that abnormalities can be found in muscles on both the hemiparetic and non-paretic 
side of active people with stroke. QMUS appeared to be a suitable technique for 
investigation of architectural changes in skeletal muscles in the chronic phase of 
stroke. It may, thus, be a patient-friendly biomarker for muscular integrity and a way 
to monitor functional recovery and effects of therapy after stroke.
 Implanted FES constitutes an active aid to reduce foot drop after stroke. By 
stimulating the common peroneal nerve the ankle dorsiflexors are activated, which 
may potentially lead to a reversal of the functional and structural changes that 
occur in peripheral motor nerves and muscles due to stroke. In chapter 8 we 
investigated whether a year-long use of an implanted FES system reverses stroke- 
related changes in muscles and motor nerves in people with foot drop. Thirteen 
participants in the chronic phase after stroke were included and followed-up over 
a period of 52 weeks after FES-system activation. QMUS images were obtained 
bilaterally from three leg muscles (i.e. tibialis anterior, rectus femoris, gastrocnemius). 
Echogenicity (muscle ultrasound gray value) and muscle thickness were assessed, 
corrected for age, sex, height and weight, and expressed as z-scores. Peripheral 
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motor nerve function was evaluated by measuring the compound motor action 
potentials (CMAPs) from the tibialis anterior muscle. For assessment of the 
corticospinal connections to the tibialis anterior muscle, motor evoked potentials 
(MEPs) were obtained using transcranial magnetic stimulation (TMS). Echogenicity 
of the paretic tibialis anterior significantly decreased during the follow-up. The 
average z-score changed from 0.88 at baseline to -0.15 after 52 weeks. This was 
accompanied by a significant increase in muscle thickness on the paretic side, 
where z-scores changed from -0.32 at baseline to 0.48 after 52 weeks. Echogenicity 
of the rectus femoris normalized on both the paretic and non-paretic side (z-scores 
changed from -1.09 to 0.14 and from -1.51 to -0.49, respectively). Interestingly, 
during follow-up, amplitudes of CMAP and MEP (normalized to CMAP) on the 
paretic side (tibialis anterior) decreased by 20% and 14%, respectively. This reduction 
in CMAP and MEP amplitudes on the paretic side might be indicative of chronic 
muscle fatigue resulting from a year-long implanted FES use. Overall, we showed 
that the structural changes to muscles following stroke are reversible with FES and 
that these changes might not be limited to electrically stimulated muscles. No 
evidence for improved function of the motor nerves was found.
PARETIC AND NON-PARETIC MUSCULAR PLASTICITY 
After stroke, bilateral changes of muscle thickness and echogenicity may occur 
in both upper and lower extremity muscles, albeit that the strongest changes 
are observed on the paretic side. These structural changes can partly be reversed 




From here, the results of this thesis will be placed in a broader context with regard 
to the applicability of functional electrical stimulation (FES) of the common 
peroneal nerve for the treatment of drop foot in people with stroke. This general 
discussion is organized along the following six questions: 
• What are the benefits of implanted peroneal FES compared to surface-based FES?
• What are the orthotic effects of peroneal FES?
• What are the therapeutic effects of peroneal FES?
• Which subjects are likely to benefit most from peroneal FES?
• What are the risks and costs of (implanted) peroneal FES?
• What are the future perspectives regarding peroneal FES? 
What are the benefits of implanted peroneal FES compared to 
surface-based FES?
Direct comparison of implanted versus surface-based peroneal FES is difficult, 
since differences in effects between the two types of systems have never been 
tested directly in a controlled study. Multiple RCTs have shown improvements in 
functional outcomes (e.g. gait speed, physiologic cost index, walking endurance) 
with the use of surface-based FES systems [171]. Compared to walking without 
stimulation, increases in gait speed have been found ranging from 0.1 to 0.2 m/s 
[38, 40, 85, 190, 191], whereas distance walked in a 6-minute endurance task increased 
by 40m with surface-based FES [40]. Unfortunately, no RCTs have been conducted 
yet on the effect of implanted FES in people with drop foot after stroke. However, 
when looking at the results of uncontrolled studies on the differences between 
walking with implanted FES versus walking without stimulation, increases in gait 
speed (0.1-0.2 m/s) and distance walked (24-60m) were similar to changes reported 
for surface-based systems [32, 71, 74]. The notion that implanted FES does not 
provide superior functional outcomes over transcutaneous FES is supported by this 
thesis, as the obstacle avoidance success rate with implanted FES was almost 
equivalent to the success rate for surface-based FES (55.4% vs 52.6%, respectively). 
Thus, it can be concluded that, despite benefits in usability (e.g. no skin irritation, no 
daily electrode placement, better system reliability) implanted FES does not have a 
clear functional advantage over surface-based peroneal FES. Therefore, in the remainder 
of this discussion, no distinction will be made between studies conducted with 
implantable FES systems versus those using surface-based FES systems.
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What are the orthotic effects of peroneal FES? 
A key difference in mechanism of action between peroneal FES and AFO is that FES 
mainly acts during the swing phase of gait and is therefore expected not to interfere 
with ankle motion during the stance phase. Indeed, improved kinematics and 
spatiotemporal gait parameters have been reported when AFO is replaced by FES [36, 
39, 74]. Probably the most impactful restriction of AFO on ankle motion is during late 
stance, when the ankle joint is accelerated towards plantarflexion through contraction 
of the calf muscles. This ankle plantarflexion facilitates a push-off which is known to 
aid propulsion [92, 104, 106, 107], leg swing initiation [105], and balance regulation in 
the frontal and sagittal plane [192]. By allowing full freedom of motion at the ankle 
joint, patients would be able to use residual calf muscle strength for generating ankle 
plantarflexion power and propulsion during push-off. This thesis supported this 
theory as it showed that - with peroneal FES - patients are better able to utilize residual 
calf muscle strength for generating ankle plantarflexion power and propulsion during 
push-off, which may also optimize step-length symmetry in asymmetric patients. 
Since the advantages with FES were mostly found in a phase of the gait cycle where 
the peroneal nerve is not stimulated, one might suggest that the reported benefits 
from FES were merely the result from removal of a too restrictive AFO. Restrictions on 
ankle motion by AFO may become smaller in the future given recent developments 
of (actuated) articulated AFOs. The use of articulated AFOs was shown to be beneficial 
over unarticulated AFOs in terms of stance phase kinematics and gait speed [28, 95, 
193, 194]. However, improvements in paretic side propulsion, reflected by changes in 
peak ankle plantarflexion power or anteriorly directed ground reaction force, have 
not been reported for articulated AFOs [28]. In contrast, actuated AFOs have shown 
the potential for generating paretic side propulsion [195-198]. Regrettably, such 
actuated AFOs are not yet available for daily clinical practice. 
 Despite the benefits of FES on gait kinematics and kinetics, no superiority has 
been found with regard to functional outcomes such as walking speed and energy 
expenditure [43, 124]. Interestingly, the larger propulsion with FES reported in this 
thesis was not accompanied by a clinically meaningful increase in gait speed. 
Possibly, the gain in paretic propulsion allowed for a reduction of compensation 
elsewhere (e.g. reduced ipsilateral hip flexion moment or contralateral ankle 
plantarflexion moment). Although information on comfortable walking speed is 
very valuable, important aspects of walking ability might be missed when focusing 
solely on gait speed. Clinically, gait speed is usually assessed over 5 or 10 meter on 
a perfectly even pathway without any environmental constraints and distractions. 
In such settings, patients may be able to fully utilize compensation strategies, 
leading to overestimation of their walking ability. This is believed to be particularly 
true for people with walking speeds below 0.8 m/s [199], which therefore may 
apply to a significant number of participants in this thesis. 
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For community ambulators the ability to modify walking to environmental demands 
is key, especially for people who frequently walk outside. Assessment of gait 
adaptability brings people closer to their absolute limit of walking ability and might 
provide a better estimate of true walking capacity [200]. Gait adaptability has been 
tested in various settings including overground obstacle courses [201, 202], 
time-critical obstacle avoidance tasks [22, 125], and target stepping tasks [203, 204]. 
Typically, gait adaptability is impaired in people with stroke, as responses to 
environmental challenges are usually too slow and/or too small, leading to increases 
in stepping errors and a longer time to return to steady state walking [22, 125, 126]. 
 Despite the important role of gait adaptability in daily life, few studies have 
tested the effects of FES on gait adaptability in people with stroke. Two groups have 
investigated the differences between peroneal FES and AFO on the modified Emory 
Functional Ambulation Profile (mEFAP), a clinical test consisting of 5 walking tasks 
including a short obstacle course [37, 205]. The RCT by Bethoux et al yielded faster 
obstacle course completion times with FES than AFO at long-term follow-up, 
indicating better functional capacity with FES [37]. In contrast, Sheffler et al reported 
no immediate surplus effects of FES on completion times of the short obstacle 
course, which may suggests that FES users need some adaptation time before FES 
benefits outweigh the orthotic effects of AFO on functional capacity[205]. 
 Using an obstacle avoidance paradigm, a moderately larger capacity to avoid 
suddenly dropped obstacles on a treadmill was demonstrated for surface-based 
peroneal FES compared to AFO by van Swigchem et al.[44]. With the obstacle 
avoidance paradigm, available time to respond to the suddenly dropped obstacle 
can be controlled, allowing stratification and analysis by level of difficulty. The same 
obstacle avoidance task was used for this thesis and, in agreement with van 
Swigchem et al [44], moderately higher success rates were found for implanted FES 
compared to AFO. Interestingly, superiority of FES with regard to obstacle avoidance 
success rates was particularly found in trials where the available response time was 
relatively long. People commonly lengthen their crossing stride to place the foot 
behind the obstacle if the response time is relatively long. This strategy of ‘stride 
lengthening’ may have been facilitated by the increased capacity for paretic ankle 
push-off, discussed above. 
 Limited dynamic ankle control with an AFO impairs compensatory stepping 
responses after a perturbation, thereby decreasing dynamic stability [206]. Since FES 
does not restrict ankle motion, it allows unrestricted stabilizing ankle movements, 
which may particularly be exploited in situations that pose a continuous threat to 
dynamic stability. Support for this notion was provided in chapter 8, where a target 
stepping task imposed continual stepping adjustments. With FES, stepping adjustments 
were found to be more accurate in the frontal plane for both the paretic and 
non-paretic leg compared to conventional care (such as an AFO). Better accuracy 
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of mediolateral foot placement with FES most likely indicates better dynamic 
balance control, because proper foot placement is crucial in maintaining a stable 
gait pattern during perturbed and unperturbed gait [207]. Therefore, the effects of 
implanted FES on bilateral foot positioning could very well be clinically meaningful. 
 The superior gait quality and functional benefits with FES compared to AFO are 
in agreement with the subjective benefits reported by FES users. For instance, FES 
users have stated that they experience better quality of gait, better stability during 
gait, and a reduced effort of walking with FES compared to AFO[31]. As a result, 
satisfaction with FES is consistently high [26, 31], whereas people who use an AFO 
are often unsatisfied with their device, leading to limited use or even rejection [29].
What are the therapeutic effects of peroneal FES 
Ever since the first published peroneal FES study [30], therapeutic effects of FES use 
have been in the searchlight of the scientific community. Being an ‘active’ orthotic 
device, peroneal FES is believed to induce structural changes to motor neurons and 
muscle. Ultimately these structural changes may result in better walking capacity. 
 Primarily, stroke causes damage to the upper motor neuron, leading to impaired 
motor control. FES may be used to induce plastic changes at a cortical level, 
thereby restoring motor function. Repetitive stimulation of peripheral motor nerves 
has shown the potential to alter (short-term) cortical excitability [172, 208, 209]. 
Besides short-term effects, peroneal FES use could result in sustainable motor 
learning through Hebbian-like plasticity [210]. Prerequisite for such plasticity after 
peroneal FES use would be that foot elevation is planned and the electrically elicited 
movement of the foot is executed with concurrent volitional intention, causing the 
movement to be perceived as self-generated [211]. Indeed, structural changes at a 
cortical level have been found with prolonged use of (orthotic) peroneal FES [34, 
56-58]. Interestingly, in the study of Merkel et al., it was shown that therapeutic 
effects on walking capacity did not occur in people with persistent bilateral 
sensorimotor cortex recruitment [58]. The outcomes of the electrophysiologic 
assessments presented in this thesis (i.e. significantly reduced MEPs after a year-long 
FES use) are in contrast to the hypothesis and previous reported findings on cortical 
changes after FES use. Potentially, the participants in this thesis did not perceive the 
stimulation as self-generated, or participants were still more reliant on bilateral 
sensorimotor cortex activity. Alternatively, plastic changes in the motor cortex may 
have been missed in our study because we applied TMS at a fixed point (i.e. the 
vertex), whereas it has been shown that plastic changes after FES use included a 
shift in organization of the sensorimotor cortex [56, 58]. Support for improved 
motor control after FES use has also been reported with electromyographic (EMG) 
assessments of maximal voluntary contractions (MVC). Increased MVCs have been 
found for both the paretic side tibialis anterior muscle and paretic gastrocnemius 
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muscle after 3 to 12 months use of a surface-based FES system [56, 65], but 
interestingly, significant changes in MVC did not translate into significant changes 
in EMG parameters during walking [65].
 As a secondary consequence of stroke, changes may also occur in peripheral 
structures, such as skeletal muscle and peripheral motor nerve. Such peripheral 
changes are likely to further impair functional capacity. Stimulation of the peripheral 
motor nerve may serve as a method to reverse secondary consequences of stroke 
on muscle and nerve. At a muscular level, increased oxidative capacity as well as 
the number of microcapillaries are believed to increase following repetitive muscle 
activation, while the muscle fiber type of the stimulated muscles are thought to 
shift towards type 2 muscle fiber types [212, 213]. In this thesis it was shown that 
stroke-induced changes to muscle thickness and echogenicity can be turned 
around with daily peroneal FES use. The increase in the paretic tibialis anterior 
muscle thickness and the decrease in its muscle echogenicity may very well benefit 
paretic muscle strength, as muscle strength is known to be dependent on muscle 
mass and composition [214, 215]. If this increased muscle mass can be used 
voluntarily, this could indeed result in a better control of dorsiflexion during walking 
or other activities. Furthermore, the electric impulses applied to the motor nerve 
do not only conduct distally towards the neuromuscular junctions, but also 
proximally (i.e. in antidromic direction) towards the soma in the anterior horn cells 
of the spinal cord. These antidromic impulses are believed to strengthen anterior 
horn synapses at the spinal level [216]. The outcomes of electrophysiologic 
assessments in this thesis did, however, not support the hypothesis that long-term 
FES strengthens neural (spinal) synapsis. The lower CMAP from the paretic tibialis 
anterior muscle were likely due to changes in the excitability of the common 
peroneal nerve following implantation and FES use. With decreased excitability of 
common peroneal motor nerve it may become harder to activate the paretic tibialis 
anterior muscle. This raises the question whether we have successfully fulfilled the 
therapeutic potential of implanted FES use and whether a different stimulation 
regime would be preferable in daily practice. 
 Overall, long-term FES use is believed to have a positive effect on primary and 
secondary neurophysiologic deficits after stroke. Hence, the structural changes to 
the muscle and upper motor neuron are likely to outweigh the possible adverse 
effects on the lower motor neuron. This notion seems to be supported by FES 
users who often report improved walking ability when the system is turned off, for 
instance when going to the bathroom at night. Remarkably, equal therapeutic 
effects on gait capacity, in terms of walking speed, have been reported for FES and 
AFO [217]. Possibly, however, these therapeutic effects of FES and AFO use on gait 
speed are achieved through different underlying mechanisms. Where the 
application of FES may induce therapeutic effects through restitution of impaired 
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neuromuscular functions, the therapeutic effects following AFO use may be related 
to learning adaptative motor strategies. Whether the therapeutic effects of FES and 
AFO translate differently into everyday-life mobility remains to be investigated.
Which subjects are likely to benefit most from peroneal FES?
Not all stroke survivors with a drop foot will benefit equally from peroneal FES. 
Therefore, a proper guideline or decision tree for patient selection is needed for 
good clinical decision making. First of all, it is important to notice that multiple 
stroke-related deficits can be associated with a ‘drop foot’. Primarily, drop foot after 
stroke arises from the inability to selectively activate ankle dorsiflexor muscles. 
However, spasticity of ankle plantarflexors as well as ankle plantarflexor contractures 
may significantly add to this inability to elevate the forefoot during the swing phase 
of gait. In the case of (relevant) contracture or (relevant) spasticity of the calf or 
other lower leg muscles (e.g. tibialis posterior, toe flexors), these problems need te 
be addressed first before a decision can be made for selecting peroneal FES instead 
of an AFO [218]. Following this line of reasoning, people with at least 0 degrees 
dorsiflexion in stance and mild to moderate ankle plantarflexor tone (modified 
Ashworth Scale score ≤2) seem to be eligible for peroneal FES. 
 Few studies have tried to identify the clinical characteristics that could predict 
for whom FES has added value over AFO [39, 44]. Based on these studies and the 
work in this thesis, it seems that the largest difference between FES and AFO may 
be expected in people who have relatively severe leg motor impairment after 
stroke. More severe muscle weakness has been associated with a surplus value of 
FES on walking speed, step length [39], and the ability to avoid obstacles (chapter 5 
and [44]). In addition, in chapter 4 it was shown that people with more step length 
asymmetry at baseline had the largest improvement in step length asymmetry with 
FES. Sheffler et al. argued that people with higher levels of leg motor impairment 
may be more dependent on stance phase proprioceptive input (e.g. joint position 
sense, footsole sensation), which might be compromised by an AFO [39]. In 
contrast, electrical stimulation may induce extra sensory input from the lower leg. 
Indeed, sensory stimulation of the paretic foot has been found to improve step 
precision in people with stroke [219]. In addition, the electronic burst of FES to the 
motor nerve and the subsequent contraction possibly acts as a trigger for activation 
of other paretic muscles involved in paretic leg swing initiation. 
 The fact that people with greater leg motor impairment show the largest 
functional benefit from peroneal FES somewhat contradicts the notion that the 
biggest asset of peroneal FES is that it enables active ankle push-off for people that 
have residual plantarflexion control. Partly, this contradiction may arise from the 
misconception that residual plantarflexion control is linked to the clinical motor 
recovery state. Indeed, additional analysis of data from Chapter 4 showed no significant 
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correlation between changes in peak ankle push-off power (AFO vs FES) and the 
level of motor recovery as assessed with the Motricity Index—Leg score (rs = 0.07, 
p=0.78). One explanation may be that calf muscle strength is not part of this 
frequently used clinical score. Another explanation may be that not all people with 
good motor recovery, including calf muscle strength, fully exploit the benefits of 
free ankle range of motion. Unfortunately, the sample sizes in this thesis were too 
small to associate residual ankle plantarflexion strength or power with gait 
adaptability (obstacle avoidance or target stepping). Nevertheless, since ankle 
push-off power during the late stance phase of gait is strongly dependent on ankle 
plantarflexor strength it seems reasonable to include good calf muscle strength in 
the selection criteria for peroneal FES.
 Free ankle mobility is required in many daily life activities other than walking 
(e.g. kneeling, squatting, cycling), which may be important especially for those 
people with relatively mild leg motor impairment. Hence, people with stroke who 
often perform such activities during their work (e.g. carpenters) or hobby (e.g. 
gardening) will likely prefer peroneal FES over AFO. In addition, with FES there is 
almost no limitation to the type of footwear, as long as a proper heel contact and 
heel rise are possible. The possibility to switch between shoes may be very valuable, 
and is often reported to be one of greater assets of FES use. Carefully listening to a 
patient’s desires and goals in daily life is, therefore, of utmost importance when 
selecting a proper device for drop foot management. 
 The timing of FES or AFO application is another interesting issue. In this thesis, 
participants were included in the chronic phase after stroke. Since peroneal FES 
may enhance neuromuscular plasticity and most of the motor recovery after stroke 
occurs in the subacute phase, it may be interesting to start with FES already in the 
early phase after stroke. Yet, the effect of subacute FES use on (the recovery) of 
walking capacity has hardly been investigated [220-224]. The use of implanted FES 
in subacute stroke does not seem feasible, since implanted FES is meant as a 
permanent intervention, whereas spontaneous leg motor recovery might still take 
place. Furthermore, the recovery time needed after surgery would interfere too 
much with the primary rehabilitation during the subacute phase after stroke.
What are the risks and costs of peroneal FES?
Application of peroneal FES may come with certain risks that need to be addressed. 
Some of these problems are specific to implanted systems or surface-based 
systems, whereas other issues appear in both types of systems. In general, all FES 
systems depend on a proper connection between several different electric 
components, which makes peroneal FES susceptible to failure. For instance, timing 
of the electrical stimulation is often determined by a pressure sensor worn under 
the heel. This registration is delicate and can be influenced by shoes/soles and by 
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the way of stepping (e.g. making a shorter step or a turn will affect foot contact with 
the floor). As a result, FES users have reported that the FES system sometimes 
missed a step. In addition, dealing with the various components (e.g. wired control 
units) can be somewhat awkward, especially for people with stroke who function 
single-handedly. The ability to handle these components independently should 
therefore be assessed before selecting FES in hemiparetic patients. 
 Problems with surface-based FES systems often involve the use of electrode 
pads. In systems that use adhesive electrodes, for example the ODFS® system 
(Odstock Medical ltd, Salisbury, United Kingdom), accurate placement of the 
electrodes can be an iterative process, which is time consuming and frustrating. 
Other systems, for example the NESS L300 (Bioness Inc, Valencia, California), use a 
leg cuff with integrated electrodes to facilitate reproducible electrode positioning. 
Regardless of the system used, skin irritation and even allergic reactions have been 
reported with prolonged use of surface-based FES systems. Hence, especially for 
people who show a positive response to surface-based peroneal FES but for whom 
daily use is limited because of skin irritation, implantable FES systems should be 
considered.
 Clearly, implantable FES requires a surgical intervention. With the surgical procedure 
comes a risk of complications, for example nerve damage or wound infections. 
Altogether, the number of complications related to the surgical procedure reported 
in our studies and by other groups is fairly low: there were 13 reported complications 
related to surgery in 174 operated persons [32, 57, 73, 74, 135, 225]. Improvements 
to the surgical procedure and the pre-operative (e.g. MRI) and post-operative 
management have already reduced the risk of surgical complications (e.g., direct 
surgical damage to the peroneal nerve, or indirect nerve damage due to excessive 
tension on the lead wire). It is, therefore, likely that the rate of complications will 
drop as surgical and rehabilitation teams will become more familiar with the 
procedure. The expected durability of the implanted peroneal FES system is ten 
years, however, we have encountered problems with (partial failure) of implanted 
parts (e.g. a loss of one or two stimulation channels) already well before this term. 
This could jeopardize the efficacy of the stimulation, depending in which channels 
are lost. In the case of an entirely failing implant, a new surgical intervention with a 
new implant might be needed, which is costly and time consuming.
 Besides risks, the costs of medical-technical innovations may also be barrier 
for clinical applicability. One group has assessed cost-effectiveness of long-term 
peroneal FES use in people with foot drop after neurological disease (e.g. stroke 
and multiple sclerosis) [69]. Taylor et al. assessed the cost-effectiveness of the 
ODFS® surface-based FES system (Odstock Medical Ltd, Salisbury, United Kingdom) 
by calculating cost per Quality Adjusted Life Year (QALY). QALY is a generic measure 
of disease burden, including both the quality and the quantity of the life lived. A gain 
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in QALY, based on changes in walking speed and on the number FES users who 
reported skin irritation, was found with long-term FES use and it was concluded 
that the cost per QALY was well within the ‘willingness to pay’ threshold of £20,000 
per QALY, as set by National Institute for Health and Clinical Excellence, making 
peroneal FES a cost-effective intervention [69].
 So far, no studies have compared the cost-effectiveness of peroneal FES 
relative to usual care (i.e. AFO). Therefore, a fair appraisal of the cost-effectiveness 
of FES is difficult. If we consider the effects of AFO and peroneal FES on walking 
capacity in people with drop foot after stroke to be more or less equal, we can 
simply compare the differences in costs of peroneal FES and AFO. At the moment, 
healthcare insurers in the Netherlands usually do not reimburse the costs of 
peroneal FES. Depending on the system, initial costs of a surface-based FES system 
are between €750 and €5,000. Annual cost for disposable materials (e.g. electrode 
pads) comes down to approximately €50 per year. In contrast, people with a foot 
drop after a stroke are entitled to reimbursement of costs for a new AFO 
approximately every two years. Costs of unarticulated (‘off the shelf’) AFOs are 
often fairly low (between €300 and €400), compared to surface-based FES systems, 
but the costs of custom-made (often articulated) AFOs may amount to €1500-2000 
every two years. With an estimated durability of 5 years for most surface-based FES 
systems, this would imply more or less equal costs for FES and custom-made AFOs 
in the long term. 
 Obviously, costs of implantable FES systems are much higher than for surface- 
based systems. For instance, the ActiGait® (Neurodan, Denmark, Otto Bock Group, 
2006) system used in our study costed an initial €17,000, excluding the expenses 
associated with hospital admission, MRI, surgery, and post-surgical care. As the 
costs of this device (both implant and external parts) are not covered by healthcare 
insurers, such systems are hardly available to people with drop foot after stroke. 
Indeed, the limited sales of the ActiGait system (inter)nationally was the major 
reason why the manufacturer discontinued its production in the year 2016. 
Technological advancements leading to lower production costs and an upscale of 
the production could lower the costs for implanted FES systems in the future, 
however, it is uncertain whether such cost reductions are feasible under the 
international rules and regulations for active implants. 
What are the future perspectives regarding peroneal FES
Peroneal FES is a quite simple form of electrical stimulation: a single sensor (i.e. the 
heel switch) determines the onset and ending of stimulation (i.e. either ON or OFF) 
of a single muscle group (i.e. the ankle dorsiflexors and evertors). Over the past two 
decades, several developments in FES application have been presented to the 
scientific community. If these developments would be successfully translated to 
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clinical practice, walking capacity of people with stroke may even be more improved 
in the near future. 
 Weakness of the ankle dorsiflexor muscles is often just one of several motor 
impairments after hemiparetic stroke. Like for the paretic dorsiflexor muscles, FES 
could be used to compensate for weakness of other paretic muscles (e.g. the hip 
flexors, hip extensors, or ankle plantarflexors) while walking. Even more importantly, 
combinations of paretic muscles could be stimulated during the gait cycle. Using 
multichannel FES systems, stimulation of paretic ankle dorsiflexor muscles (during 
the swing phase) and hip abductor muscles (during the stance phase) was found to 
be superior over stimulation of dorsiflexor muscles alone in terms of gait speed 
[226]. Likewise, a combination of paretic ankle dorsiflexor and plantarflexor muscle 
stimulation showed to improve stance phase kinetics and knee kinematics during 
swing in people with stroke [227, 228]. Ultimately, all muscles contributing to impaired 
walking ability in people with stroke could be stimulated. So far, a maximum of eight 
separately stimulated paretic muscles has been reported in people with stroke [229]. 
Daly et al, successfully used implanted multichannel stimulation to assist motor 
practice in a 12-week gait training program. They reported improved coordinated 
gait (by means of the Gait Assessment and Intervention Tool) after multichannel 
FES gait training compared to training without FES, which persisted at 6-month 
follow-up [229].
 One of the problems encountered with, especially multichannel, FES application is 
the timing of muscle activation and the type stimulation pattern used (i.e. rectangular 
or trapezoid patterns). Sequential stimulation of muscles requires delicate timing 
of separate onsets or otherwise it may result in undesired outcomes [227]. First- 
generation FES systems often use simple sensors (e.g. heel switches, tilt sensors) to 
determine when stimulation should be on or off. Such simple setups are suitable for 
highly predictable and repetitive (cyclic) movement patterns, but may fall short if 
behavioral output requires any form of flexibility. To provide a more natural 
stimulation pattern, EMG activity patterns derived from healthy subjects or from the 
stroke survivors themselves have been used as input for stimulation patterns [230, 
231]. The main disadvantage with these EMG derived stimulation patterns is that 
they are optimized to the setting in which the data are obtained. Therefore, these 
stimulation patterns still need manual adjustment to the actual need of the FES 
user (e.g. when walking on different terrains or when muscles become fatigued). 
Continuous automatic adjustment of stimulation parameters could be achieved 
using closed-loop dynamically controlled FES systems [232]. Muller et al. developed 
such a learning system, which was shown to be effective in people with spinal cord 
injury [233]. 
 Even though closed-loop dynamically controlled FES systems may be able to 
optimize stimulation patterns to the current need of the FES user, they may not be 
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entirely able to avoid muscle fatigue. With voluntary muscle contraction, motor 
units are recruited progressively from small, typically slow motor units to larger, 
typically fast motor units [234]. Electrical stimulation is believed to reverse this order 
or to recruit in a non-specific pattern, causing rapid muscle fatigue [235]. In 
paraplegia, hybrid systems using FES and robotics are used to deal with FES-induced 
muscle fatigue. With such hybrid systems the robotically controlled movements 
lower the demand on FES evoked muscle power and vice versa, resulting in lighter 
robotic systems and delay of muscle fatigue [236]. However it seems unlikely that 
such cumbersome devices fit the desires of community walkers after stroke. 
Dealing with muscles fatigue following prolonged FES use remains one of the main 
challenges in the near future. 
 So far, use of multichannel FES and dynamically controlled systems has been 
restricted to therapeutic training programs in scientific studies. It would be very 
interesting to see whether such multichannel FES systems can become feasible for 
daily ‘orthotic’ use, and how long-term daily use of such multichannel FES systems 
would affect walking capacity in people with stroke. Ideally such effects should be 
tested in larger randomized controlled trials including functional assessments that 
reflect complex daily life ambulatory capacity and performance. Moreover, larger 
cohorts are needed for proper identification of responders and non-responders to 
(multichannel) FES use in people with stroke. If the next generation of FES systems 
would combine multichannel stimulation with dynamically controlled activation 
patterns and if these systems would be developed with the cosmetic and practical 
needs of the users in mind, the future for FES application in people with leg motor 
impairment after a stroke would be bright.
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Een van de meest voorkomende loopstoornissen bij mensen die een beroerte 
hebben gehad is de zogeheten sleepvoet. Een sleepvoet na een beroerte ontstaat 
voornamelijk door problemen in de aansturing van de voetheffers waardoor de 
voet tijdens de zwaaifase niet goed (genoeg) van de grond komt. Een sleepvoet kan 
worden opgeheven met behulp van functionele elektrostimulatie (FES) van de 
motorische zenuw die de voetheffers aanstuurt: de peroneus zenuw. Oppervlakte 
stimulatie, een veelgebruikte methode waarbij de motorische zenuw wordt 
gestimuleerd via plakelektrodes op de huid, zorgt vaak voor problemen zoals huid - 
irritatie en allergische huidreacties. Dat kan worden vermeden door gebruik te maken 
van een implanteerbaar FES-systeem. Bijkomend voordeel van een geïmplanteerd 
FES-systeem is dat de motorische zenuw direct wordt gestimuleerd, waardoor de 
voetheffers preciezer kunnen worden aangestuurd. Het doel van dit proefschrift 
was het onderzoeken van de langetermijneffecten van geïmplanteerde FES bij 
mensen met een sleepvoet na een beroerte. Dit hoofdstuk geeft een beknopte 
Nederlandse samenvatting van dit proefschrift. Een uitgebreide (Engelstalige) samen - 
vatting en discussie is te vinden in Hoofdstuk 9 ‘Summary and General Discussion’ 
Deel 1:  Meerwaarde van geïmplanteerde peroneale FES ten opzichte 
van conventionele sleepvoet behandeling 
In het eerste deel van de het proefschrift lag de focus op de voordelen van 
geïmplanteerde FES op de loopfunctie ten opzichte van conventionele hulp -
middelen, zoals een enkel-voetorthese (EVO). Verschillen tussen geïmplanteerde 
FES en conventionele hulpmiddelen werden beoordeeld tijdens het comfortabele 
lopen en tijdens meer uitdagende taken waarbij het looppatroon moest worden 
aangepast aan de omgeving. 
Objectieve en subjectieve voordelen van geïmplanteerde FES tijdens het 
comfortabele lopen.
De eerste, 1-kanaals, implanteerbare FES-systemen zijn in de jaren negentig 
ontwikkeld. Echter, stimulatie met deze systemen was niet selectief en gebalanceerd 
genoeg voor een goede correctie van een sleepvoet. Om de peroneus zenuw 
selectiever te kunnen stimuleren zijn implanteerbare 2-kanaalssystemen ontwikkeld, 
welke veelbelovende verbeteringen in de loopsnelheid en loopkwaliteit lieten zien. 
Aan het begin van dit millennium werd een 4-kanaalssysteem (ActiGait®, Neurodan, 
Denemarken, Otto Bock Group, 2006) goedgekeurd en op de markt gebracht voor 
gebruik bij mensen met een sleepvoet na een beroerte. In hoofdstuk 2 zijn de 
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indicaties voor gebruik en eerste klinische resultaten van dit geïmplanteerde 
4-kanaals FES-systeem besproken. Vier studies onderzochten de effecten van het 
geïmplanteerde 4-kanaals FES-systeem op het lopen bij mensen met een sleepvoet 
na een beroerte. Over het algemeen werden deelnemers geschikt bevonden voor 
deelname aan de studies als 1) de beroerte tenminste 6 maanden geleden had 
plaats gevonden , 2) er spierzwakte van de voetheffers aanwezig was, 3) de enkel 
tenminste 30 graden passieve bewegingsuitslag had waarbij de enkel op zijn minst 
in neutrale stand kon tijdens het staan, 4) de deelnemers in staat waren 10 minuten 
zelfstandig te kunnen lopen en 5) oppervlakte stimulatie een positief effect liet zien 
op het lopen. Drie van de vier studies vergeleken lopen met FES (AAN) met het 
lopen zonder stimulatie (UIT) en rapporteerden toenames in loopsnelheid en 
loopafstand wanneer de stimulatie aan stond. Twee studies testten de verschillen 
tussen geïmplanteerde FES en EVO en vonden geen verschillen in loopsnelheid of 
loopafstand. Interessant daarbij is dat beide onderzoeken wel voordelen van 
geïmplanteerde FES ten opzichte van EVO op enkel kinematica (d.w.z. de beweging 
van het enkelgewricht) in de standfase van het lopen rapporteerden. Twee onder - 
zoeken onderzochten de tevredenheid gebruikers van het ActiGait®-systeem en 
vonden dat patiënttevredenheid over het algemeen goed was. Concluderend: de 
eerste studies naar de effecten van gebruik van een geïmplanteerd 4-kanaals FES- 
systeem bij mensen met een sleepvoet laten veelbelovend resultaten zien. Echter, 
wetenschappelijk bewijs voor een meerwaarde van implanteerbare FES ten opzichte 
van EVO is nog steeds schaars. Daarom werd geconcludeerd dat er behoefte is aan 
wetenschappelijke studies die de onderliggende mechanismen onderzoeken van 
orthotische en/of therapeutische effecten van langdurig geïmplanteerd FES-gebruik 
bij mensen met een sleepvoet na beroerte.
Aangezien de meeste mensen met een sleepvoet na een beroerte een EVO 
aangemeten krijgen om de loopcapaciteit te verbeteren, is het van klinisch belang 
om de effecten van geïmplanteerde FES op de loopcapaciteit te vergelijken met die 
van EVO. Een EVO is meestal succesvol in het tegengaan van een sleepvoet tijdens 
de zwaaifase van het lopen, maar tegelijkertijd kan een EVO normale afwikkeling 
van de voet belemmeren tijdens de standfase van het lopen. Afhankelijk van de 
stijfheid, belemmeren de meeste EVO’s normale enkelbewegingen welke nood - 
zakelijk zijn voor dynamische balans en voetafwikkeling, en beperken ze de 
mogelijkheid om resterende kuitkracht in te zetten tijdens de late standfase van het 
lopen. Daarom werd verondersteld dat vervanging van EVO door geïmplanteerde 
FES zou leiden tot een normalere enkel beweging aan de aangedane zijde, hetgeen 
zou resulteren in een metabolisch efficiënter looppatroon. In hoofdstuk 3 zijn de 
verschillen tussen geïmplanteerde FES en EVO met betrekking tot de energiekosten 




weken na activatie van het geïmplanteerde FES-systeem bij tien mensen met een 
sleepvoet na beroerte. Kwaliteit van lopen, beoordeeld met 3D-gangbeeldanalyse 
op een 10 meter pad, verbeterde met geïmplanteerde FES de enkel kinematica en 
kinetiek van het aangedane been in de late stand fase van de loopcyclus. De 
maximale plantairflexie (strekking van het enkel gewricht) aan de aangedane zijde 
was groter met FES (gemiddeld verschil met EVO 4.7°), wat gepaard ging met een 
49% hogere piekkracht van de enkel en een vermindering van de staplengte 
asymmetrie van 6.6%. Ondanks deze verbeteringen in de loopkwaliteit, werden er 
geen significante verschillen in metabole energiekosten van het lopen gevonden 
tijdens een zes minuten wandeltest, wat verklaard zou kunnen worden door het 
ontbreken van een significant verschil tussen FES en EVO op loopsnelheid. Over 
het algemeen gaven deelnemers de voorkeur aan het gebruik van geïmplanteerde 
FES boven hun conventionele EVO. Het geïmplanteerde FES-systeem werd vooral 
gewaardeerd om zijn comfort, uiterlijk en de functionele voordelen bij het op- en 
aflopen van de trap.
Interessant genoeg werden de hierboven beschreven verbeteringen in de kwaliteit 
van het lopen gevonden tijdens de standfase loopcyclus, wanneer het geïmplanteerde 
FES-systeem inactief was. Dit kan goed worden verklaard doordat FES minder 
interfereert met de enkelbeweging in vergelijking met EVO. Verhindering van de 
normale enkelbeweging aan de aangedane zijde tijdens de standfase kan zijn 
weerslag hebben op andere gewrichten en kan andere aspecten van de loopcyclus 
beïnvloeden. Tegenwerking van het voorover kantelen van de tibia (het scheenbeen) 
tijdens de standfase kan bijvoorbeeld knie-instabiliteit veroorzaken in de richting 
van de knie-extensie (kniestrekking) en een beperking van actieve plantairflexie 
tijdens de late standfase kan de voortstuwing en de inzet van de beenzwaai ver - 
minderen. Daarom zijn de effecten van het vervangen van EVO door implanteerbare 
FES op de kniestabiliteit, voortstuwing en beenzwaai uitgebreid onderzocht in 
hoofdstuk 4. De verschillen tussen EVO en geïmplanteerde FES werden beoordeeld 
bij 22 deelnemers gedurende 26 of 52 weken na activatie van het FES-systeem. De 
loopkwaliteit werd beoordeeld door middel van 3D-gangbeeldanalyse op een 10 
meter pad. Bij geïmplanteerde FES was de piekrotatiesnelheid van de knie-extensie 
van het aangedane been tijdens de standsfase lager (gemiddeld 18.1°/s), wat wijst 
op een betere knie-stabiliteit in vergelijking met EVO. Wederom werd een betere 
afzet tijdens late standfase gevonden met geïmplanteerde FES, wat tot uiting kwam 
in een hogere piek plantairflexiesnelheid (gemiddeld verschil 29.2°/s) en een hogere 
piek enkelkracht (gemiddeld verschil 0.2 W/kg) aan de aangedane zijde. Met 
geïmplanteerde FES was de richting van de grondreactie kracht (GRK) op het moment 
van de piekkracht van de enkel meer naar voren gericht (gemiddeld verschil 1.1°) en 
de horizontale GRK (gemiddeld verschil 0.8% lichaamsgewicht) was hoger, wat 
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wijst op een betere voortstuwing met geïmplanteerde FES. Hoewel er geen 
significante groepsverschillen tussen geïmplanteerde FES en EVO werden gevonden 
voor knie- of heupkinematica tijdens de zwaaifase van de loopcyclus, correleerde 
individuele verbeteringen in enkelkinematica en kinetiek tijdens de late standfases 
significant met maximale heupflexiesnelheid aan de aangedane zijnde tijdens de 
zwaaifase, wat kan wijzen op een functionele koppeling tussen deze verschijnselen 
als gevolg van peroneale stimulatie.
Nagebootste dagelijkse wandelomgevingen: verschillen in  
het aanpassingsvermogen van het lopen tussen geïmplanteerde FES 
en conventionele sleepvoet behandeling
Ondanks de betere loopkwaliteit met geïmplanteerde FES ten opzichte van EVO én 
de voorkeur van de patiënt voor geïmplanteerde FES, is wetenschappelijk bewijs 
voor een meerwaarde van FES op de dagelijks loopfunctie van mensen met 
een sleepvoet na een beroerte nog steeds beperkt. De effecten van FES-gebruik 
op functionele uitkomsten is weliswaar getest, maar meestal tijdens simpele en 
ongestoorde wandeltaken. De meeste FES-gebruikers zijn echter zelfstandig 
wonende onafhankelijke wandelaars (comfortabele loopsnelheid > 0.4 m/s) bij 
wie het looppatroon in het dagelijks leven voortdurend moet worden aangepast 
aan uitdagingen in de omgeving, denk hierbij bijvoorbeeld aan oneffen of gladde 
grond oppervlakken, (on)verwachte obstakels en verkeer. De voordelen van 
geïmplanteerde FES op loopkwaliteit worden dus mogelijk met name benut in 
uitdagende omgevingen die aanpassing van het looppatroon vereisen. Daarom is 
het vermogen om het lopen aan te kunnen passen getest in hoofdstuk 5, waar we 
de capaciteit om plotselinge obstakels te vermijden tijdens het lopen op een 
loopband vergeleken tussen geïmplanteerde FES en EVO. Tweeëntwintig proef -
personen voerden de obstakeltaak uit zowel met FES als met EVO. De obstakeltaak 
werd herhaaldelijk uitgevoerd tot 26 weken of 52 weken na activering van het 
FES-systeem. Bij de obstakeltaak viel er 30 maal plotseling, en in verschillende fases 
van het looppatroon, een obstakel op de loopband die de deelnemers moesten 
zien te vermijden met hun aangedane been. De obstakels werden geordend naar 
beschikbare reactietijden (BRT) in drie categorieën (450-600 ms, 300-450 ms en 
150,300), het aantal maal dat een obstakel succesvol werd vermeden werd 
uitgedrukt in succespercentages. Het vermogen om plotselinge obstakels te 
vermijden bleek groter met geïmplanteerde FES dan met EVO, met een gemiddeld 
verschil in succespercentages over alle BRT’s van 4.7%. Het voordeel van FES ten 
opzichte van EVO was het grootst wanneer proefpersonen relatief veel beschikbare 
reactietijd hadden (450-600 ms), met een gemiddeld verschil in succespercentage 
van liefst 15%. Interessant genoeg vonden we een matige maar significante 




(geïmplanteerde FES-EVO), waarbij deelnemers met een relatief slechte been 
functie het meeste baat bleken te hebben bij geïmplanteerde FES. De bevindingen 
zoals beschreven in dit hoofdstuk komen nauwkeurig overeen met de resultaten 
van een eerdere studie waarin de effecten van het gebruik van oppervlakte 
stimulatie bij mensen met een sleepvoet na een beroerte werd getest op dezelfde 
obstakeltaak.
Naast aanpassingen van het lopen aan enkelvoudige omgevingsbeperkingen (zoals 
bij het vermijden van één obstakel), moet het lopen in het dagelijkse leven vaak 
worden aangepast aan meerdere en opeenvolgende omgevingsbeperkingen, 
bijvoorbeeld wanneer gelopen wordt over een bospad of in een rommelige ruimte. 
Mensen met een beroerte hebben over het algemeen problemen met het 
aanpassings vermogen van het lopen, omdat aanpassingen van het looppatroon 
meestal vertraagd zijn en de plaatsing van de voet onnauwkeurig is. Bij mensen die 
relatief goed hersteld zijn van een beroerte kunnen deze tekortkomingen in het 
aanpassingsvermogen van het lopen vooral aan het licht komen bij looptaken die 
meerdere opeenvolgende stapaanpassingen vereisen. In dezelfde geest kunnen 
de voordelen van geïmplanteerd FES-gebruik op het vermogen om het lopen aan 
te passen duidelijker naar voren komen wanneer meerdere opeenvolgende stap-
beperkingen worden opgelegd. Om dit te testen is de uitvoering van een stappen - 
taak met onregelmatig verdeelde staptegels getest in hoofdstuk 6. Het vermogen 
om opeenvolgende stapaanpassingen te maken werd getest bij 12 deelnemers met 
een beroerte bij wie in voorgaande studies een FES-systeem werd geïmplanteerd. 
Tijdens een eendaags bezoek voerden de deelnemers een stappentaak uit met 
zowel geïmplanteerde FES als met hun conventionele hulpmiddel. Staptegels 
werden geprojecteerd op een feedbackgestuurde loopband, een loopband waarop 
proefpersonen op hun gewenste snelheid kunnen lopen, en dienden als doelwit 
voor de deelnemers om op te stappen. De posities van de staptegels waren 
gebaseerd op het eigen looppatroon van de deelnemer en werden willekeurig 
gevarieerd, zowel in zij-, voor- en achterwaartse richting. Prestaties op de stappen - 
taak werden beoordeeld door berekening van de totale fout, een gecombineerde 
maat van constante fout en variabele fout, van de voetplaatsing ten opzichte van 
het midden van de geprojecteerde staptegels. Het is bekend dat het maken van 
stapaanpassingen relatief veel aandacht kost bij mensen met een beroerte, wat tot 
uiting komt in de aandachtskosten bij het uitvoeren van dubbeltaken wanneer 
gelijktijdig een secundaire cognitieve taak moet worden uitgevoerd. Daarom werd 
de stappentaak zowel met als zonder een cognitieve taak uitgevoerd. Een auditieve 
Stroop-taak werd gebruikt als cognitieve taak waarbij de deelnemers moesten 
beantwoorden of de woorden “hoog” en “laag” in een hoge of een lage toonhoogte 
werden uitgesproken. Reacties op de cognitieve taak werden opgenomen en het 
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aantal correcte reacties werd uitgedrukt succespercentages. De totale fout op de 
stappentaak was minder groot met geïmplanteerde FES ten opzichte van 
conventionele hulpmiddelen, zij het alleen statistisch significant op de zijwaartse 
totale stapfout. Gemiddeld was de totale fout met geïmplanteerde FES 1.0cm en 
2.3cm kleiner in respectievelijk de zijwaartse en voor-achterwaartse stapfout. In 
tegenstelling tot het vorige hoofdstuk werd er dit maal geen significant verband 
gevonden tussen betere stapnauwkeurigheid en been functie. Toevoeging van de 
cognitieve taak aan de stappentaak leidde tot een toename in de totale zijwaartse 
fout, al was deze toename slechts grenzend aan een statistisch significant verschil. 
De toevoeging van een cognitieve taak aan de stappentaak resulteerde niet in een 
groter verschil tussen FES en conventionele hulp op het verschil in stapnauw-
keurigheid, ook waren er geen significante verschillen in succespercentages op de 
auditieve Stroop-taak. 
 De hoofdstukken 5 en 6 ondersteunen de gedachte dat verschillen tussen 
geïmplanteerde FES en conventionele hulpmiddelen, zoals een EVO, op de loop - 
functie vooral duidelijk worden in complexe loopomgevingen die snelle aanpassingen 
van het lopen aan omgeving eisen. De verschillen tussen geïmplanteerde FES en 
conventionele hulpmiddelen bleven echter wel bescheiden. De bevindingen in 
deze hoofdstukken ondersteunen het belang van het testen van loopfunctie in 
uitdagende situaties die interactie met de omgeving vereisen, naast het testen van 
gangbare stationaire looptaken, met name bij mensen die in het dagelijkse leven 
buiten lopen.
Deel 2:  Veranderingen in spieren en zenuwen na een beroerte en 
effecten van langdurig geïmplanteerd peroneus FES-gebruik
In het tweede deel van het proefschrift werden de effecten van langdurig 
FES-gebruik op spier en zenuw onderzocht. Veranderingen in perifere structuren 
na een beroerte, zoals in skeletspieren en perifere motorische zenuwen, zijn 
veelvuldig beschreven in de literatuur. Na een verlies van centrale activering vanuit 
de hersenen kunnen lager gelegen motor neuronen functioneel inactief worden 
of zelfs ‘transsynaptische degeneratie’ ondergaan, wat leidt tot denervatie van 
spiervezels. Omdat denervatie van spiervezels leidt tot afname van spiermassa en 
infiltratie van spiervezels met bindweefsel en vet, heeft dit proces van denervatie na 
een beroerte ook een effect op de structuur van skeletspieren. Het is aannemelijk 
dat dergelijke perifere veranderingen in de spieren en zenuwen de functionele 
capaciteit van mensen met een beroerte verder beperken. Veranderingen in 
spierweefsel na een beroerte worden doorgaans onderzocht aan de hand van 




alleen naar deze verschillen te kijken worden eventuele veranderingen aan de 
niet-aangedane zijde gemist en kunnen afwijkingen ten opzichte van de gezonde 
populatie worden onderschat. Kwantitatieve spierechografie wordt als methode 
gebruikt om objectieve spierafwijkingen te detecteren bij mensen met neuromus-
culaire aandoeningen. Deze methode is recentelijk ook gebruikt bij mensen met 
aandoeningen van het centrale zenuwstelsel, b.v. amyotrofische laterale sclerose, 
maar nog niet bij mensen met een beroerte. Daarom hebben we in hoofdstuk 7 
onderzocht of tweezijdige architecturale veranderingen in skeletspieren kunnen 
worden gedetecteerd bij fysiek actieve mensen in de chronische fase na een 
beroerte. Achtentwintig mensen met een beroerte werden gerekruteerd voor de 
studie. Kwantitatieve spierechografie beelden werden tweezijdig afgenomen van 
twee arm- en vier beenspieren; biceps brachii, flexoren van de onderarm, rectus 
femoris, mediale kop van de gastrocnemius, tibialis anterior en extensor digitorum 
brevis. Echogeniciteit en spierdikte werden gecorrigeerd voor leeftijd, geslacht, 
lengte en gewicht en als z-scores uitgedrukt. De z-score geeft aan hoeveel stan-
daarddeviaties een score van de normaalwaarde af zit en is daarmee een statistische 
maat voor hoe (ab)normaal weefsel is. Positieve z-scores voor echogeniciteit (d.w.z. 
spieren die er relatief wit uitzien op het scherm) werden beschouwd als een 
indicatie voor slechtere spierarchitectuur met meer infiltratie van bindweefsel en 
vet. Negatieve z-scores voor spierdikte duidden op verlies van spiermassa. Een 
significante verhoging van de gemiddelde echogeniciteit werd gevonden in vier 
spieren aan de aangedane zijde en in drie spieren aan de niet-aangedane zijde. De 
flexoren van de onderarm vertoonden de grootste toenames in echogeniciteit (z = 
2.22 en 1.07 voor respectievelijk de aangedane zijde en niet-aangedane zijde). 
Significante afnames van de gemiddelde spierdikte werden gevonden in twee 
spieren aan de aangedane zijde en in éen spier aan de niet-aangedane zijde. De 
gemiddelde spierdikte van de gastrocnemius aan de aangedane zijde was het 
meest verminderd (z = -1.78). Echogeniciteit van de mediale gastrocnemius 
vertoonde een matige negatieve correlatie met loopsnelheid en tijd sinds een CVA. 
Geen andere correlaties werden waargenomen tussen spierarchitectuur en pa-
tiëntkarakteristieken. Deze studie toonde aan dat er afwijkingen kunnen worden 
gevonden in spieren aan zowel de aangedane zijde als aan de niet-aangedane zijde 
van actieve mensen met een beroerte. Kwantitatieve spierechografie bleek een 
geschikte techniek te zijn voor het onderzoeken van architectonische veranderingen 
in skeletspieren in de chronische fase van een beroerte. Kwantitatieve spierecho-
grafie kan een patiëntvriendelijke biomarker zijn voor spierintegriteit en kan 
daarmee dienen als methode om functioneel herstel en de effecten van therapie 
na een beroerte te monitoren.
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Geïmplanteerde FES kan gezien worden als een actief hulpmiddel om een sleepvoet 
na een beroerte op te heffen. Door het stimuleren van de peroneus communis 
zenuw worden de voetheffers geactiveerd, wat mogelijk kan leiden tot een 
omkering van de perifere veranderingen die optreden in motorische zenuwen en 
spieren als gevolg van een beroerte. In hoofdstuk 8 hebben we onderzocht of een 
jaar lang geimplanteerd FES-gebruik de beroerte-gerelateerde veranderingen in 
spieren en motorische zenuwen bij mensen met een sleepvoet kan terugdraaien. 
Dertien deelnemers in de chronische fase na een beroerte werden gedurende een 
periode van 52 weken na activeren van het FES-systeem gevolgd. Kwantitatieve 
spierechografie beelden werden tweezijdig afgenomen van drie beenspieren 
(d.w.z. tibialis anterior, rectus femoris, gastrocnemius). Echogeniciteit en spierdikte 
werden beoordeeld, gecorrigeerd voor leeftijd, geslacht, lengte en gewicht, en 
uitgedrukt als z-scores. Om veranderingen in het functioneren van de perifere 
motorische zenuw te evalueren werd de perifere motorische zenuw gestimuleerd 
en werd de compound motor action potential(CMAP) van de tibials anterior spier 
gemeten. Om veranderingen in de motorische schors in de hersenen en de 
corticospinale banen te meten werd de motorische hersenschors gestimuleerd 
middels transcraniele magnetische stimulatie. Verandering van deze verbindingen 
werd bepaald aan de hand van motor evoked potentials (MEP) gemeten aan de 
tibialis anterior spier. De echogeniciteit van de tibialis anterior aan de aangedane 
zijde nam significant af tijdens de opvolgperiode. De gemiddelde z-score veranderde 
van 0.88 bij aanvang naar -0.15 na 52 weken. Deze vermindering in witheid van de 
spier ging gepaard met een significante toename in spierdikte aan de aangedane 
zijde, waar de z-scores veranderden van -0.32 bij aanvang naar 0.48 na 52 weken. 
Echogeniciteit van de rectus femoris normaliseerde aan zowel de aangedane als 
de niet-aangedane zijde (z-scores veranderden van respectievelijk -1.09 naar 0.14 
en van -1.51 naar -0.49). Interessant is dat tijdens de opvolgperiode de pieken 
van CMAP en MEP (genormaliseerd naar CMAP) aan de aangedane zijde met 
 respectievelijk 20% en 14% afnamen. Deze afname in CMAP- en MEP-pieken aan de 
aangedane zijde kunnen een aanwijzing zijn voor chronische spiervermoeid - heid als 
gevolg van een geïmplanteerd FES-gebruik. Deze studie toont aan dat de structurele 
veranderingen in spieren na een beroerte omkeerbaar zijn met FES en dat deze 
veranderingen mogelijk niet beperkt blijven tot elektrisch gestimuleerde spieren. 






















Het begon in 2013  met een brief die zichzelf liet schrijven. Ik had net een weten-
schappelijke stage afgerond naar de effecten van elektrostimulatie bij mensen met 
een dwarslaesie en had voor mezelf bepaald dat ik me wat meer wilde gaan 
verdiepen in het lopen, liefst bij mensen na CVA. Alsof het zo had moeten zijn 
kwam de vacature op het Radboudumc voorbij.
 Ondanks dat ik beretrots ben dat mijn naam op de voorkant van het proefschrift 
staat voelt het zeker niet als een solo prestatie. Niets in dit proefschrift zou bestaan 
zonder steun van collega’s, vrienden, familie en anderen. Met het dankwoord kan 
ik daar eindelijk uitgebreid bij stilstaan. Uiteraard zal het mij niet zijn gelukt om 
iedereen bij naam te kunnen noemen of wellicht ben ik domweg iemand vergeten 
(“PhD Brain dd 23-7-2020”), mocht je naam niet in het dankwoord voorbij komen 
maar ben je toch op een of andere manier betrokken geweest bij het proces: weet 
dat ik je dankbaar ben!  
Tijdens mijn Nijmeegse periode heb ik het geluk gehad met veel goede en fijne 
mensen te mogen samenwerken. Allereerst heb ik het dan over mijn promotieteam: 
Sander, Vivian en Nens.
 First and foremost, Sander. “Ha Frank, ga maar vast zitten, ik type nog even dit 
mailtje af en dan kom ik er aan”. Zo begon 90% van de overleggen die we hebben 
gehad de afgelopen 7 jaar. Wat ik altijd zeker wist: zodra het bewuste mailtje (met 
twee vingers getypt) was verstuurd heb ik direct je volle attentie, hoeveel er op de 
achtergrond ook bij je mocht spelen. Vanaf meet af aan ben je scherp. Met ogen-
schijnlijke gemak beschrijf je in twee zinnen perfect, waar ik in tien zinnen nog niet 
toe in staat ben. Tevens bezit je een bizar scherp oog voor detail. Memorabel 
voorbeeld daarvan is dat jij mijn volledige manuscript nog even doornam met de 
snelheid van het licht (ongeveer 3 pagina’s per seconde) en er op het blote oog nog 
doodleuk een paar keer inconsequent hoofdlettergebruik, missende punten en 
dubbele spaties tussenuit vist. Maar meer nog dan al je technische en punctuele 
kwaliteiten waardeer ik je interesse en persoonlijke benadering. De afgelopen jaren 
hebben we het veel over de inhoud gehad, maar minstens net zo vaak over zaken 
uit ‘het echte leven’. Ik heb me in hele moeilijke tijden altijd bijzonder gesteund 
gevoeld door je en daar wil ik je enorm voor bedanken.
 Vivian, in de eerste jaren was je vooral op de achtergrond aanwezig maar toen 
mijn project meer en meer de richting opging van ‘gait adaptability’ kwam ik 
logischerwijs meer en meer op jou kamer terecht. Je kennis op het gebied van 
lopen en balans is ongeëvenaard. Dat je een voorname rol speelt op het mondiale 
podium van loop- en balansonderzoek kwam tweejaarlijks duidelijk naar voren op 
de ISPGR congressen. Het maakte me iedere keer weer trots om daar als een van 
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je ‘Radboud kuikens’ rond te mogen lopen. In mijn leerproces duurde het soms een 
tijdje voordat ik mijn ontvanger op jouw zendfrequentie kreeg afgestemd. Maar als 
me dat eenmaal lukte viel er veel van je te leren. Wat mij tijdens het schrijfproces 
altijd is opgevallen is jouw topsportmentaliteit. Je gaat vol voor ieder procent 
verbetering, waarbij tijdsinvestering geen issue lijkt, hoeveel er ook op je bureau 
ligt. De kracht om iedere keer weer tot het uiterste te kunnen gaan is bewonderens-
waardig. Vivian, dank voor je steun en geduld. 
 Nens, halverwege het project werd je pas toegevoegd aan het promtieteam 
maar met jouw specifieke expertise was je een onmisbare schakel op het project. 
Klinische neurofysiologie was voor mij nog onontgonnen gebied, en dat er 
desondanks 2 mooie papers zijn verschenen in gerenommeerde tijdschriften mag 
grotendeels op jouw conto worden geschreven. Je feedback rondes op de papers 
waren altijd snel (“ik zit op een congres en heb maar even naar je stuk gekeken…”) 
en kleurrijk (véél rood, maar ook met véél droge humor). In overleggen was je altijd 
een fijne sparringpartner en toonde je veel geduld, ook als ik voor de tiende keer 
moest vragen waarom echogeniciteit van een spier nou kan verbeteren zonder dat 
de massa van een spier toeneemt. Nens, ik wil je bedanken voor de bijzonder 
prettige samenwerking. 
Toen ik begon aan de klus in Nijmegen was dat met een contract voor slechts 2 
jaar, dat ik uiteindelijk de tijd heb gekregen om een mooi en volledig proefschrift te 
maken is grotendeels te danken aan stichting Toegepast Wetenschappelijk Instituut 
voor Neuromodulatie (TWIN). Het was bijzonder fijn om een stichting achter me te 
hebben staan die niet alleen financiële steun bood maar bovenal welgemeende 
interesse in het onderwerp toonde en actief meedacht bij het opzetten van nieuw 
onderzoek. Een blik op de website van stichting TWIN leert dat mede door hen 
prachtig impactvol onderzoek worden uitgevoerd, een heel knap en mooi resultaat 
voor een relatief kleine subsidieverstrekker. In het bijzonder wil ik Professor Gerrit 
Zilvold voor bedanken voor uw steun en de fijne gesprekken die we in de loop van 
de jaren op diverse congressen en bijeenkomsten hebben gevoerd. 
De ActiGait is een product uit de Ottobock-stal. Ottobock heeft het onderzoek 
ondersteund met middelen (levering van systemen) en technische ondersteuning. 
De verpersoonlijking van die steun van Ottobock is Jean-Pierre Lust. JP, ik wil u 
graag bedanken voor uw onvoorwaardelijke steun tijdens het project. Ik hoefde 
maar te mailen of te bellen en u stond klaar. Door het directe en warme contact dat 
ik met u had voelde het grote Ottobock toch aan als een klein, en persoonlijk 
betrokken bedrijf. Ik weet hoeveel u zich heeft ingezet om de ActiGait tot een 




Ook wil én moet ik de deelnemers aan de diverse studies natuurlijk bedanken. 
Geen onderzoek komt van de grond zonder de welwillendheid van mensen om 
een deel van hun tijd op te geven voor deelname aan wetenschappelijk onderzoek. 
Ik heb de afgelopen jaren veel mooie persoonlijke gesprekken gevoerd met diverse 
deelnemers en dat maakte dat ieder datapunt op mijn beeldscherm veel meer voor 
me betekende dan een alleen proefpersoonsnummer. Ik heb veel van jullie geleerd 
over het leven na een CVA, lessen die ik mijn huidige baan nog dagelijks meeneem. 
Hartelijk dank voor jullie inzet! Hartelijk dank voor de gesprekken!
Ik dank de leden van de manuscriptcommissie: Prof. dr. R.H.M.A Bartels, Prof. dr. ir. 
N. Verdonschot, Prof. dr. J.S. Rietman voor het kritisch lezen en goedkeuren van het 
manuscript. Ik kijk er erg naar uit om jullie bevindingen over het proefschrift live aan 
te horen en met jullie in discussie te gaan. 
Ieder paper is een teamprestatie, daarvoor wil ik ook de co-auteurs uiteraard 
hartelijk bedanken. 
 Allereerst de gaat mijn dank uit naar de mensen van het AMC Amsterdam: 
Frans, Anita, Pepijn en Sven. Ondanks de fysieke afstand tussen de twee UMC’s 
voelde jullie toch altijd dichtbij. Zonder jullie specifieke kennis was het nooit tot drie 
prachtige papers gekomen. Sven, het was bijzonder prettig om aan het begin van 
mijn wetenschappelijke carrière mee te mogen kijken over jouw schouder. Ik heb 
er veel van geleerd!   
 Joost, met name in de eerste fase van het onderzoek heb ik veel met je te 
maken gehad. De operatie die ik heb mogen bijwonen zal ik nooit vergeten. Ik heb 
ongelooflijk veel respect gekregen voor het prachtige maar moeilijke vak dat je 
beoefend.
 Michaela Pinter, thank you for inviting us to co-author on the book chapter. 
Hopefully the findings in this thesis will someday lead to an update of the chapter!
 Anne-Marieke, dank voor je werk op het eerste spierecho paper. De opdracht 
leek bij aanvang zo simpel maar bleek uiteindelijk toch een lastige puzzel. Mede 
door jouw nieuwsgierigheid en volharding is er een bijzonder interessant paper 
uitgekomen.  
 Jasper, je bent veel belangrijker geweest voor dit onderzoek dan de enkele 
keer dat je staat vernoemd als co-auteur doet vermoeden. Het is lastig iemand te 
vinden die enthousiaster is over FES dan jij. Gedurende mijn hele periode in 
Nijmegen ben je dan ook een belangrijke steunpilaar en sparringpartner geweest. 
Maar even waardevol vind ik de keren dat je gezellig mee ging naar de SMALLL 
congressen met als hoogtepunt een onvergetelijke nachtelijke rondleiding door 
‘ jouw’ Leuven. Ik hoop je nog vaak te treffen op congressen, al zorg ik de volgende 
keer voor de zekerheid even voor een stadsplattegrond.
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 Noel, op het laatste paper verdedig jij de eer van de Maartenskliniek. Tijdens 
overleggen, labmeetings en journal clubs heb ik je leren kennen als een bijzonder 
prettige collega met een klinisch relevante blik. Met name je vermogen om even 
een stap terug te nemen en logisch na te denken heb ik daarin erg gewaardeerd. 
Dat je een drukke wetenschappelijke baan weet te combineren met (semi)topsport 
vind ik ongelooflijk knap.
 Roos, zonder al jouw werk in de jaren voorafgaand aan mijn tijd in Nijmegen 
was er nooit sprake geweest van dit proefschrift. Dat ik het stuur van een rijdende 
auto heb kunnen overnemen 7 jaar geleden is voor de volle 100% aan jou te danken. 
Nog steeds maak ik dankbaar gebruik van de goede structuur die je destijds hebt 
neergezet. Ik vind het bijzonder fijn dat je de afgelopen jaren hebt meegeschreven 
aan verschillende artikelen. Dat je tijdens mijn verdediging gaat plaatsnemen in de 
oppositie maakt het cirkeltje wat mij betreft rond! 
In de loop van de jaren heb ik gebruik mogen maken van diverse bewegingslabs 
verspreid over het land (maar met name verspreid over Nijmegen). Op het Radboud 
heb ik altijd de technische en emotionele steun gehad van Roland en later van 
Geert. Ik heb geen idee hoe vaak ik jullie heb moeten bellen met technische 
problemen, altijd lukte het jullie om de boel weer draaiende te krijgen. Geert, naast 
je technische ondersteuning ben je ook nog een tijd mijn vaste meetassistent 
geweest, dank voor al je hulp! 
 Bij MotekMedical heb ik mijn eerste stapjes mogen zetten op de GRAIL. Zonder 
de steun van Frans, Johannes en Sanne was het nooit tot een werkend protocol 
gekomen, laat staan tot een paper. Het contact met jullie is altijd zeer prettig geweest. 
Bezoekjes aan jullie hoofdkwartier in Amsterdam waren altijd gezellig maar bovenal 
heel erg inspirerend. Dank voor al jullie tijd en energie. 
 Metingen doen op de GRAIL, bij de Sint Maartenskliniek is altijd een feestje 
geweest. Dat ik op zaterdagen ontspannen de berg op en af kon voor mijn metingen 
is te danken aan de inzet van Bart, Lise en Lysanne. Dank voor jullie hulp bij het 
opzetten van de metingen. 
Oneindige dank aan alle Radboudianen, in eerste instantie aan de mensen die het 
het zwaarst te verduren hebben gehad, de RadboudRoomies: Hanneke, Lars, 
Janine, Rifka, Jolanda, Milou, Renee, Marian, Mitch, Wouter, Vera en Digna. Ik houd 
jullie allen mede verantwoordelijk voor de uitloop van mijn PhD. Want wat kon het 
gezellig zijn tussen de lastige (onderzoeks)tijden door. Praatjes over trouwerijen, 
praatjes over gestrande relaties (in temptation island), praatjes over katten, praatjes 
over wie het beste was in een dom online spelletje, noem het maar op! Alle zin en 




 Overige collega onderzoekers: Sjoerd, Jorik, Arjen, Noortje, Claudia, Mariska, 
Merel, Marielle, Laura, Rosanne, Rosemarie en Teo. Onbetaalbaar is jullie steun 
geweest in diverse overleggen, onvergetelijk waren de uitjes, de carréloop, so you 
think you can calibrate wedstrijden, Laaf borrels en andere activiteiten. Dank, danke, 
gracias por todo! 
 Dank aan behandelaren en staf van de afdeling revalidatie, met in het bijzonder 
het duo Laurien en Dorien van het stafsecretariaat. Steevast begon mijn dag bij 
jullie, even bijkletsen en weer door. Ik mis het nog elke dag!
 Dank aan de stagiairs, Elise en Daniëlle. Dank voor jullie hulp in de opzet en 
uitvoer van de GRAIL studie. Ik hoop dat jullie net zo veel van mij hebben kunnen 
leren als ik van jullie!
Ik ben er bijzonder trots op dat ik zulke leuke en goede mensen heb leren kennen 
in mijn Radboud tijd, sprekend voorbeeld daarvan zijn de drie paranimfen die ik aan 
mijn zijde heb tijdens de verdediging. Lotte, you came in like a wrecking ball! Of het 
door je Achterhoekse roots komt of gewoon omdat je een bijzondere plezierig 
persoon ben, vanaf het eerste moment hadden we een goede band. Vanaf het 
eerste moment ben je altijd mijn buurvrouw geweest op de onderzoekerskamer en 
dat heeft tot heel wat leuke (SYTYCC) avonturen geleid. Je hebt geleerd je eigen 
koers te varen en maakt moedige keuzes, ik ben er trots op om je achter me te 
hebben staan tijdens de verdediging.  
 Joyce, over een wrecking bal gesproken... Muurtjes optrekken heeft geen zin 
bij jou, je knalt er dwars door heen. Afgelopen jaren heb je me vaak een spiegel 
voorgehouden tijdens talloze gesprekken in onze daily commute vanuit Utrecht. 
Mede daardoor ben ik veel opener gaan kijken naar mezelf en de rest van de wereld. 
Naast deze eerlijke gesprekken was er bovenal altijd ruimte voor gezelligheid: “Ee’m 
bakkie doen?” Je bent een topwijf, enig gewoonweg. 
 Bastiaan, met jou kan ik echt over van alles praten: statistiek, schrijfprocessen, 
politiek. Maar uiteindelijk gaat het toch eigenlijk alleen maar over vrouwen en 
dumpertfilmpjes. Wat hebben we een goede tijd gehad op kantoor, op stok in het 
Kippenhok, op SMALLL congressen en natuurlijk als klapper in Miami. Ik vind het 
prachtig dat we nog meerdere keren per jaar even afspreken om onder het genot 
van een aardige barrekening de stand van zaken door te spreken. Dat jij met je 
verdediging, vijf dagen eerder dan de mijne, als een doorgewinterde wielerprof je 
voorwiel net voor het mijne over de streep heb weten te duwen nadat je jarenlang 
in mijn wiel heb zitten profiteren doet daar niets aan af ;)
Ik bedank ook graag mij nieuwe collega’s van Reade, met in het bijzonder de 
teamgenootjes van Team 2. Het plekkie aan de Overtoom voelt al zo vertrouwd dat 
ik het idee heb dat ik er al jaren werk. Dat ik dagelijks kan rondlopen met een grote 
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glimlach is te danken aan de ontspannen werksfeer en de professionaliteit van het 
team. De persoonlijke interesse en de betrokkenheid van een groot aantal collega’s 
bij de afronding van mijn manuscript was hartverwarmend. Hopelijk kan ik de 
energie die nu vrij komt na deze “bevalling” volledig inzetten op mijn werk in 
Amsterdam. Jullie zijn nog niet van me af!
Ik blijf even in Amsterdam, voor de belangrijkste bijzaak in het leven: voetbal. Ik wil 
graag de Amsterdamsche Football Club Ajax bedanken, met in het bijzonder de 
selecties van 2016 -2017 en 2018-2019. De afgelopen jaren hebben jullie laten zien 
dat er prachtige dingen kunnen gebeuren als je dicht bij je kernwaarden blijft maar 
tegelijkertijd groots durft te dromen. Ik hoop het op mijn kleine bescheiden manier 
ook te kunnen toepassen in mijn eigen leven. Dank voor de inspiratie en voor de 
afleiding.
 Van ons aller Ajax is het slechts een kleine stap terug naar Sokkie. Kaalvoet 
vrienden, wat is het heerlijk om tweewekelijks het gele tenue aan te mogen trekken, 
de zaal in te lopen, die jongen gasten bij Olympos er van langs geven (althans toen 
onze conditie dat nog toeliet) en de kantine in te kruipen voor een paar uurtjes aan 
slappe verhalen. Al het slappe geklets op en buiten het veld biedt in ieder geval een 
prima tegenwicht aan de diepgang en complexiteit die de rest van het leven met 
zich mee neemt. Het eerstvolgende kannetje + teamschaal bruinfruit is voor mij!
Zonder vrienden kan ik niet. Nicole, Sam, Sjoerd, Oscar, Marleen, Lajla, Fred, Maya, 
Arjan, Chiel, Erik en natuurlijk alle lieve partners. Dank voor alle etentjes, spelavonden, 
wieleravonden, hardloopwedstrijden, vrijgezellenfeesten, bruiloften, babybezoekjes, 
weekendjes, vakanties en noem maar op. Ik voel me heel rijk met een grote diverse 
groep vrienden. Dank voor alle steun die ik impliciet en expliciet heb mogen 
ontvangen de afgelopen jaren. 
 Thijs en Sanne, ik zou jullie onder meerdere categorieën in dit hoofdstuk 
kunnen plaatsen maar graag licht ik jullie er even apart uit. Jullie hebben de 
afgelopen 7 jaar meer interesse getoond in mijn PhD dan ik zelf. Support met talloze 
kaartjes, lieve berichtjes, cadeautjes, belletjes en tegenwoordig FaceTime vanuit 
Ethiopië, het houdt maar niet op. Talloze keren heb ik jullie moeten afzeggen omdat 
ik een deadline had of gewoon nog veel moest doen, nooit viel er een onvertogen 
woord van jullie kant. Jullie strooien met zoveel liefde, ik kan het nooit terugbetalen. 





Via Chrisje heb ik er een leuk stel vrienden bij gekregen: Anne-Sophie, Mark, Giselle, 
Xander, Malou, Ilja, Bram, Jelger en Lisette. De afgelopen jaren heb ik met enige 
regelmaat lieve opbeurende appjes en kaartjes van jullie ontvangen die me telkens 
weer motiveerde om door te gaan! Dank lieverds!
Uiteraard krijg je niet alleen een set vrienden cadeau als je aan relatie begint, ook 
een schoonfamilie hoort bij het totaalpakket. Ik mag me gelukkig prijzen met een 
hele hechte en lieve schoonfamilie. Wouter en Joline, jullie voelen als eigen familie 
en tegelijkertijd als goede vrienden. Onze levens verlopen in grote lijnen parallel en 
mede daarom lijken jullie altijd feilloos aan te voelen waar we behoefte aan hebben. 
Bert, ik denk oprecht dat er niemand anders op de wereld rondloopt die al mijn 
artikelen heeft gelezen. Ik waardeer je moed en doorzettingsvermogen om de 
papers te doorgronden. Sterkjes, dank voor de steun en interesse de afgelopen 
jaren.
Dan naar de mensen uit mijn eigen Achterhoekse nest. De Hellekampjes (Vincent, 
Sabine, Jesse, Wietse en Lynn), De Garvelinkkampjes (Marc, Annet, Lotte en Else) en 
De Brommetjes (Desiree, Rik, Lieke en Sophie). Wat zijn we uitgedijd de afgelopen 
jaren. Ik geniet iedere keer weer als ik de malle oom mag spelen of gewoon het 
warrige vreemde broertje mag zijn. De afgelopen jaren was ik vaker dan me lief is 
afwezig bij familiebijeenkomsten en zaten spontane bezoekjes er amper in. Nooit 
namen jullie het me kwalijk. Hopelijk kan ik de komende jaren wat meer tijd en 
ruimte vrijmaken voor jullie.
 Pa en Ma, in het gezellig volle nestje aan de Berkenlaan hadden we nooit veel, 
maar er was altijd genoeg. Ik was een lastige nakomeling die nogal verschilde van 
de kuikens voor mij, maar gelukkig hebben jullie mij nooit een bijzondere 
behandeling gegeven (al zullen broers en zus daar soms anders over denken). 
Vanuit huis kreeg ik mee: “doe maar normaal dan doe je al gek genoeg”. Ik vrees dat 
het me niet volledig is gelukt om me daar aan te houden, maar het feit dat ik over 
het algemeen vrij nuchter in het leven sta  komt volgens mij voor een groot gedeelte 
voort uit die opvatting. Opgroeien in een groot, liefdevol en stabiel gezin, het leek 
altijd heel erg vanzelfsprekend voor me. Maar met de jaren ben ik gaan beseffen 
hoe bijzonder dat eigenlijk is en wat jullie daar allemaal voor hebben gedaan (en 
gelaten). Lieve Pa en Ma, ik zeg niet het niet vaak genoeg: ik houd van jullie en ben 
jullie enorm dankbaar!
Joopie. Je bent klein van stuk, maar zeker niet minder belangrijk. Op thuiswerkdagen 
heb jij mijn spanningsboog menig keer onderuit gehaald door me even te bezoeken. 
Je hebt inmiddels zo vaak over mijn toetsenbord gewandeld dat ik er mijn hand niet 
meer voor in het vuur durf te steken of jij iets hebt ‘bijgedragen’ aan de matlab 
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scripts of aan artikelen. Voor het gemak houd ik je daarom maar verantwoordelijk 
voor iedere spel- of typefout in dit proefschrift. Dank voor je mediterende werking, 
het heeft me geholpen het proefschrift af te ronden. Maar zoals het een echte kat 
betaamd geef je er waarschijnlijk niet veel om...
Tot slot, Chrisje, natuurlijk Chrisje. Er bevinden zich niet genoeg letters in mijn 
toetsenbord om te kunnen beschrijven hoe dankbaar ik je ben. Zonder jou had ik 
m’n maffe zelf niet teruggevonden, zonder jou had ik niet durven kijken voorbij de 
vensters van mijn eigen comfort bubble. Je laat me zien hoeveel er uit het leven te 
halen valt als je er maar voor gaat. Het feit dat er nu een gedrukt proefschrift klaar 
ligt, met het design van jouw hand, is daar een mooi tastbaar bewijs van. 
 De afgelopen 7 jaar hebben we bijna non-stop tegenwind gekend, desondanks 
zijn we hechter dan ooit. Je gaat altijd voorop in de strijd op weg naar betere tijden. 
Met een prachtig huisje, ons eerste kindje op komst en veel meer tijd en aandacht 
van mij lijkt er dan eindelijk wat plain sailing weather aan te komen. Voor altijd 





Surgical procedure and system activation
Surgical procedure
Surgery was performed by a neurosurgeon under general anaesthesia at either 
Academic Medical Center Amsterdam (AMC) or Radboud University Medical Center 
(Radboudumc). After linear skin incision (starting caudal at the knee joint, length 
7cm, 1cm dorsal from the biceps tendon) the cuff electrode was placed around the 
common peroneal nerve just below the branch of the lateral sural nerve and just 
behind the distal tendon of the biceps femoris muscle, approximately 6-10 cm 
above the knee joint. Optimal location and surgical approach was determined 
pre-operatively by an MRI scan of the leg. The stimulator body was implanted 
through a separate skin incision at the lateral side of the thigh approximately 10 cm 
below the trochanter major and attached to the superficial fascia. The lead wire 
was pulled through and positioned in the subcutaneous fat layer without longitudinal 
tension. Directly after placement of the internal parts, the system was tested 
per-operatively to make sure that adequate foot dorsiflexion and eversion could be 
obtained. After closing the wounds, X-ray images of the implant were taken with 
the knee in a flexed and extended position to check the placement and stability of 
the implants. Participants were admitted to the neurosurgery ward for one or two 
days to ensure adequate post-operative care and guidance.
System activation
In order for the wounds to heal and the implants to ‘settle down’, system activation 
was postponed until 3 weeks after surgery. Prior to system implantation as well as 
before its first activation, an integrity check of the common peroneal nerve was 
performed using electromyography (EMG). Both sensory and motor nerve 
conduction times of the superficial and deep peroneal nerve branches were tested 
and needle EMG of tibialis anterior, extensor digitorum brevis, and peroneal longus 
muscles was performed. If post-operative EMG was comparable to pre-operative 
results, a 3-step activation of the ActiGait® system was performed at one of the 
participating centres by a trained physiotherapist and a trained movement scientist. 
During the first step, movement direction, motor threshold and maximum tolerated 
stimulation intensity were established for each of the four channels with participants 
lying in supine position. During the second step, the clinically most useful channels 
and appropriate intensities were identified. During the third step, participants walked 
on a 10m walkway and adjustments of stimulation intensity were made to the initial 
settings based on professional gait observation and subjective experience by the 
participant to ensure optimal foot dorsiflexion during the swing phase, heel contact 
during initial contact, and controlled plantarflexion during the loading response. 
During this latter step, parameters such as reaction time of the heel switch, and 
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ramp-up and ramp-down of the neurostimulation were individually adjusted. After 
the 3-step activation, the participants gradually built up the use of the ActiGait® 
during a 3-week familiarisation period from 15-60 minutes per day in the first week 
up to minimally 6 hours per day at the end of the third week. In the case of activation 
problems or other practical issues, they were supported by follow-up telephone 
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GRAIL).
 Accessible: All data will be available on request by contacting the staff secretary 
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